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ABSTRACT OF DISSERTATION 
PPAP2B EXPRESSION LIMITS THE DEVELOPMENT OF LESION 
FORMATION IN MURINE MODELS OF ATHEROSCLEROSIS 
Coronary artery disease (CAD) is the leading cause of death in both men and women 
worldwide and is defined as a narrowing of the coronary arteries due to accumulation of 
atherosclerotic plaques. Genome-wide association studies have identified risk loci within 
the gene PPAP2B that confers increased risk of developing CAD. Evidence suggests 
these aforementioned SNPs are regulating PPAP2B expression in a cis-manner through 
the interruption of transcription factor binding sites. PPAP2B encodes the lipid phosphate 
phosphatase 3 enzyme that plays a key role in degrading bioactive lysophosphatidic acid 
(LPA). LPA has a plethora of effects on vascular tissue and is implicated in increasing 
inflammation and exacerbating the development of atherosclerotic lesions in mice. 
Interestingly, PPAP2B expression is increased in murine models of atherosclerosis and 
both global and smooth muscle cell-specific deletion increases the development of lesions 
compared to control mice. LPP3-deficient mice with increased atherosclerosis show 
significant increases in LPA accumulation in their proximal aorta as well as increased 
expression of inflammatory markers and positive staining for leukocyte marker CD68. 
Globally deficient mice also show substantial increases in ICAM-1 staining in their aortic 
root lesions relative to controls. Preliminary evidence also suggests that total LPA content, 
and specifically unsaturated LPA species, increase in the atherogenic LDL-C fractions of 
plasma in hyperlipidemic mice prone to developing atherosclerosis. Taken together, these 
data suggest that as CAD develops, LPA accumulates in atherosclerotic plaques, and the 
intrinsic mechanism of defense is to upregulate LPP3 through transcription factor-
mediated effects on PPAP2B; however, individuals harboring the previously mentioned 
risk alleles are unable to increase PPAP2B expression and thus experience unchecked 
inflammation and exacerbated development of atherosclerosis. 
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Chapter 1: Introduction 
Since 1921 cardiovascular disease (CVD) is the leading cause of death of both men and 
women worldwide. From 2003 to 2013 death rates attributable to CVD declined 28.8% 
with the actual number of deaths per year dropping 11.7% in the United States[1]. These 
declines in death rates and total death toll are a display of progress, but it is important to 
note that in 2013 30.8% of all 2,596,993 deaths in the United States are still attributed to 
CVD [2]. Needless to say, in spite of declining rates of disease, CVD remains a significant 
burden on the United States and accounts for an estimated $316.6 billion burden annually 
[2]. With an estimated 15.5 million Americans over the age of 20 that suffer from CAD [3] 
there has been a focus on understanding not only the vascular pathophysiology, but also 
the factors that predispose an individual to an increased risk of disease. Bioactive lipids 
have taken a spotlight in the regulation and modulation of vascular pathophysiology. This 
chapter will discuss one such bioactive lipid, Lysophosphatidic acid (LPA), and its role in 
regulating vascular pathology. LPA, and its regulators autotaxin (ATX) and lipid phosphate 
phosphatase 3 (LPP3), play integral roles in components of vascular physiology and 
pathophysiology that are key steps in the development and progression of CAD. This 
chapter will discuss in detail the burden and specific mechanisms of CAD pathology and 
break down tissue-specific contributions to disease progression. Identifying risk factors 
contributing to CAD is essential to its prevention and treatment; as such, advances in 
genome-wide sequencing to identify genomic loci conferring risk of disease has become 
a rapidly developing field. Genome-wide association studies (GWAS) will be described in 
addition to a specific locus in the gene PPAP2B which confers increased risk of disease 
[4]. PPAP2B encodes the LPA-degrading protein LPP3 which has been implicated in both 
embryonic development and vascular disease. LPP3 structure and function will also be 
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described in detail. The aim herein is to illustrate a role for LPA and its regulators in the 
pathophysiology of CAD.    
Lysophosphatidic Acid1 
LPA is a bioactive lysophospholipid composed of a phosphate molecule bound to a 
glycerol backbone, which bears a variable length fatty acid chain (Figure 1.1). LPA is found 
in all eukaryotic tissues in low concentrations and its activity is dependent on its binding 
to one of six known extracellular G protein-coupled receptors (GPCRs) termed LPA 
receptor 1 – 6 (LPA1 – LPA6) which are differentially expressed throughout various tissues 
and cells [5-9]. Any given LPA receptor is capable of activating at least 2 of the 4 known 
g-protein complexes eliciting a variety of cell responses ranging from cytoskeletal 
rearrangement, migration, proliferation, survival and mild platelet activation [10-15]. In fact, 
the lysophospholipid was first identified in 1963 as a regulator of blood pressure mediating 
effects through smooth muscle cell function [16, 17]. LPA can be generated via two 
pathways: 1) lysophospholipase D activity of ATX hydrolysis of lysophosphotidylcholine 
and 2) phospholipase A2-mediated deacylation of phosphatidic acid leads to LPA 
production [18]. Pathways for production will be described in section “LPA Biosynthesis”. 
Degradation of LPA can occur through the actions of a family of membrane-bound proteins 
termed lipid phosphate phosphatases (LPPs), which are discussed in more detail in 
section “PPAP2B Encodes Lipid Phosphate Phosphatase 3”. 
 
 
                                               
1  Portions of this section were taken from Mueller et al. [15]. Some additions and 
modifications to the text and figures have been made for clarity of information. 
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LPA Receptor Signaling 
The receptors for LPA are widely distributed on blood and vascular cells. In preclinical 
animal models, targeting the LPA receptors genetically and pharmacologically suggest 
that they may contribute to vascular injury and inflammatory responses, as well as 
endothelial barrier function and vascular stability. Single and multiple deletions of LPA 
receptors in mice produce differing vascular phenotypes. Deficiency of Lpar1, which 
results in 50% neonatal lethality, gives rise to the development of spontaneous frontal lobe 
hematomas [19]. This suggests a role for LPA1 in stabilization of vessels, as no defect in 
hemostasis has been observed in these animals. In experimental arterial injury models, 
LPA1 regulates the development of intimal hyperplasia, a complex response involving 
inflammation and smooth muscle cell proliferation and migration. LPA1 may influence the 
vascular remodeling response via the Gα12/Gα13 pathway that couples to RhoGEF to 
activate RhoA, given the similarities in development on intimal hyperplasia after injury in 
the Lpar1-/- mice [10] and those lacking the Gα12/Gα13 and Rho pathways [20] in smooth 
muscle cells. The lack of LPA1 disrupts the endothelial barrier and results in increased 
vascular permeability in response to inflammatory stimuli in the lung [21] and the skin [22]. 
Conversely, LPA1 antagonists prevent inflammation in response to peritoneal injection of 
lipopolysaccharide [23]. Whether either a defect in smooth muscle or endothelial cell 
function accounts for the bleeding observed in the Lpar1-/- mice remains unknown. 
Knockout of both Lpa1 and Lpa2 increases the incidence of prefrontal hematomas [24], 
impairs the response to vascular injury [10], and results in the development of pulmonary 
hypertension with age [25]; the latter phenotype is not observed in mice with deficiency of 
either of the receptors alone. Together, these results suggest some redundancy or overlap 
between the 2 receptor systems. Likewise, LPA1 and LPA3 antagonists, Ki16425, reduce 
arterial remodeling elicited by denudation injury [11] in mice, perhaps due to attenuated 
signaling through both Gα12/Gα13 and Gq/G11 signaling pathways, which appear to 
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regulate vascular remodeling antagonistically. Lpar4-deficient mice display a genetic 
background-dependent defect in formation of vasculature. On the C57Bl/6 background, 
the mice develop hemorrhage and edema due to a maturation defect from lack of smooth 
muscle cell and pericyte recruitment to vessels [26]. Additionally, LPA signaling through 
RAGE may also affect SMC function [27]. As described in more detail below, studies in 
zebrafish also support a role for several of the canonical LPA receptors in blood vessel 
formation 
LPA Biosynthesis 
LPA is present in many biologic fluids, including plasma, ascites, and bronchoalveolar 
lavage fluid. In the circulation, LPA turns over rapidly [28] and therefore must be 
maintained by constant production. Certain conditions, such as acute coronary syndromes 
[29, 30] and chronic liver disease [31] are associated with higher levels of plasma LPA. 
Whether this is due to increased production or reduced clearance or both is currently not 
known. As mentioned before there are several pathways that can generate LPA. The 
secreted lysophospholipase D ATX generates extracellular LPA by hydrolysis of 
lysophosphatidylcholine (LPC) [32-34]. ATX is an ecto-nucleotide 
pyrophosphatase/phospho-diesterase family member (encoded by ENPP2 in humans and 
Enpp2 in mice) that is synthesized as a pre-proenzyme and undergoes sequential signal 
peptide removal and proprotein convertase cleavage before being secreted from cells. Of 
five functional isoforms (ATXα, ATXβ, ATXγ, ATXδ, and ATXε) generated through 
alternative splicing, ATXβ is the most abundant and appears to account for most of the 
lysophospholipase D activity in plasma. The cellular source(s) of plasma ATX are 
incompletely understood, however, adipocytes likely secrete a substantial portion [35]. 
ATX is also stored in platelets and released during their activation [34, 36]. Circulating 
ATX is rapidly taken up by scavenger receptors of liver sinusoidal endothelial cells, the 
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same class of receptors capable of clearing formylated and maleyted BSA, and then 
degraded in the liver [37]. Thus, much like hormones, including insulin, ATX is largely 
removed from the circulation during first passage through the liver. While ATX is normally 
a major source of plasma LPA levels [28, 38], other minor pathways may contribute to 
increases in LPA in certain situations, such as in the setting of acute myocardial infarction 
[29, 30, 39].  
Autotaxin’s Role in Vascular Development 
Studies of organisms that lack or express catalytically-inactive ATX have shed light on its 
role, and by inference, the role of LPA signaling, in vascular biology. ATX expression is 
required for normal vascular development in mice. Enpp2-deficient mice [40, 41] die 
between embryonic days 9.5–10.5 with blood vessel formation defects in the yolk sac and 
embryo. In the absence of ATX, initial blood vessel formation appears normal, but vessels 
fail to mature, suggesting that ATX is critical for extension and stabilization of blood 
vessels but perhaps not for the initial endothelial cell differentiation and migration. The 
phenotype of Enpp2-/- mice resembles that observed in Gα13 knockout embryos, which 
would be consistent with ATX-generated LPA signaling through Gα13-coupled receptors. 
To date, no single or multiple LPA receptor knock-out mice have fully recapitulated the 
phenotype observed in embryos lacking ATX or Gα13. However, mice expressing a 
functionally inactive ATX (T210A) also die embryonically [42], indicating that the catalytic 
activity of ATX, and likely LPA synthesis, is essential for vascular development. Enpp2-
heterozygous mice are viable and express half of normal levels of ATX and LPA. However, 
they are hyper-responsive to hypoxia-induced vasoconstriction and remodeling, and 
prone to develop pulmonary hypertension [25]. Knockdown of ATX in zebrafish embryos 
by morpholino antisense oligonucleotides also causes aberrant vascular connections with 
normal initial sprouting; interestingly, while knockdown of each single LPA receptor by 
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morpholino antisense oligonucleotides show little phenotype, attenuating LPA1 and LPA4 
signaling recapitulated the ATX knockdown vascular defects [43]. 
As described above, ATX and LPA-signaling contributes to the development of embryonic 
vasculature in multiple species and LPA-receptor signaling affects vEC- and SMC-function 
in mature mice. LPA is also implicated in the development and progression of CAD. Levels 
of vessel-associated LPA increase during progression of atherosclerosis [44, 45] and are 
substantially higher in advanced lesions [46]. Cholesterol feeding influences levels and 
distribution of plasma LPA in rabbits [47]. Additionally, feeding mice a chow diet 
supplemented with unsaturated LPA mimics the inflammatory effects of Western diets 
[48]. LPA that is generated during atherosclerosis may have pro-atherosclerotic, pro-
inflammatory, and pro-thrombotic effects [4]. 
 
Cardiovascular Disease Burden2 
 
Coronary artery disease (CAD) is due to a narrowing of the heart’s blood vessels 
(stenosis) on account of the buildup of atherosclerotic plaques. Based on data from the 
National Health and Nutrition Examination Survey (NHANES), in 2013, CAD accounted 
for 1 out of every 7 deaths. Each year roughly 660,000 Americans suffer from a new 
myocardial infarction (MI), better known as a heart attack, and 305,000 have a recurrent 
attack. It is estimated that 15.5 million Americans over the age of 20 suffer from this 
disease with a prevalence of 7.6% and 5.0% of adult men and women respectively. The 
high prevalence of this disease is coupled with a high mortality rate that makes this 
                                               
2 Data presented in this section are from the AHA’s annual publication on Heart Disease and 
Stroke Statistics [2]. 
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disease such an impactful epidemic throughout the world. In fact, 34% of individuals who 
experience a coronary event -- defined as a MI, ischemic heart failure, or unstable angina 
-- will die of it. Data from large trials including the Framingham Heart Study, 
Atherosclerosis Risk in Communities Study, and several others indicate that within 1 year 
following a first MI 18% of men and 23% of women over the age of 45 will die. Within 5 
years those numbers increase to 36% in men and 47% in women. These high rates of 
prevalence and subsequent consequences in mortality associated with CAD make it 
imperative that efforts in medical research are dedicated to understanding, predicting and 
treating not just CAD but CVD as a whole. 
 
Risk Factors of Cardiovascular Disease 
Framingham Heart Study Defines Classic Risk Factors 
Classical risk factors for the development of CVD were first discovered through the 
Framingham Heart Study in 1948. These classical risk factors include both modifiable 
lifestyle behaviors and non-modifiable risk factors. Modifiable risk factors include 
dyslipidemia, hypertension, physical inactivity, type 2 diabetes, alcohol consumption and 
smoking [49, 50] whereas some of the non-modifiable risk factors include a family history 
of disease as well as aging itself. It is worth mentioning that in the United States there has 
been a significant decline in the incidence of modifiable risk factors such as smoking in 
adults which is currently at 16.9% (down from 24.1% in 1998) as well as certain aspects 
of nutritional quality, specifically the prevalence of ideal levels of diet which increased from 
0.7% to 1.5% in adults from 2004 to 2012 [3].  This is good news, but smoking is still 
attributed to at least one third of all CAD related deaths and poor nutrition was the leading 
risk factor in 2010 for death and disability with 678,000 annual deaths attributable to all 
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causes [3]. Unfortunately, the prevalence of other modifiable risk factors has increased 
such as the death rate attributable to hypertension which increased 8.2% from 2003 to 
2013 and the prevalence of type 2 diabetes in children and adolescents has increased 
30.5% from 2001 to 2009 [3].  Lastly, based on data from 2009 and 2012, greater than 
100 million adults in the United States over 20 years of age have total cholesterol over 
200 mg/dL; and roughly 31 million have total cholesterol levels over 240 mg/dL [3]. 
 
Cardiovascular Disease Pathogenesis 
 
Classifying the Progression of CAD 
CVD is representative of several subcategories of disease such as CAD or ischemic heart 
disease, stroke, peripheral artery disease, heart failure and others. This section will focus 
on the pathogenesis of CAD which is the more deadly and the more costly subcategory of 
CVD. In 1994 and 1995, Herbert Stary led the AHA’s Committee on Vascular Lesion along 
with the Council on Ateriosclerosis and created a histology based scoring system to define 
atherosclerotic plaque progression which has become known as the Stary scoring system 
[51, 52]. 
Naïve healthy arteries consist of a tunica intima layer composed of a single endothelial 
cell layer separating the lumen of the blood vessel from an underlying subendothelial 
matrix and a layer of internal elastic lamina. The tunica media surrounds the tunica intima 
and consists of layers of vascular smooth muscle cells and internal elastic lamina that act 
in consortium to both resist the stretch from the blood pressure as well as regulate vessel 
diameter. The outermost layer is the tunica adventitia which is primarily connective tissue 
and supportive structures such as blood vessels, known as the vasa vasorum, and nerves. 
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Type I plaques begin to develop during the first decade of life and are characterized by 
the deposition of low density lipoprotein cholesterol (LDL-C), which becomes oxidized over 
time, and an accumulation of foam cells in the subintimal space of coronary arteries [52]. 
Foam cells are lipid laden macrophage-like cells that develop as circulating monocytes, 
infiltrate the intimal layer through activated vascular endothelial cells (vECs), differentiate 
into macrophages and endocytose oxidized LDL-C (oxLDL) particles. A key step in type I 
plaque progression is the activation of vECs which tends to occur primarily in areas of 
turbulent or disturbed blood flow, typically around a curvature or bifurcation in the artery 
[53, 54]. The mechanical stress induced by the turbulent flow on vECs results in the 
recruitment of leukocyte adhesion molecules such as ICAM-1 and VCAM-1 on their 
luminal surface [54, 55]. It is through these adhesion molecules that circulating monocytes 
are able to “stick” to the vEC layer and infiltrate the subintimal space via diapedesis, a 
process that will be expanded upon later in this chapter. This process of vEC activation, 
monocyte infiltration and uptake of oxLDL via macrophages will continue to occur 
throughout the development of CAD and plays a primary role in the continued 
development of atherosclerotic plaques. 
The appearance of yellow fatty streaks on a vessel wall signifies the next state in the 
development of CAD [51, 52]. These fatty streaks are representative of a large 
accumulation of foam cells that are swollen with endocytosed oxLDL. Only one feature 
distinguishes Type II from Type III plaques and that is the generation of an extracellular 
lipid pool in addition to the fatty streaks [51, 52].  
Type II and III plaques are prone to give rise to Type IV plaques or atheromas. Atheromas 
are known for their well-defined lipid core [51] that develops as outward remodeling of the 
vessel progresses. In coronary vessels, a distance of ~200µm from the lumen is far 
enough to generate an ischemic environment subsequently leading to apoptosis and the 
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beginnings of a necrotic core [56]. Along with creating an ischemic environment, this 
extracellular pool of lipids accumulates insoluble crystals of cholesterol, which are toxic, 
and trigger nearby cells to undergo apoptosis [56, 57]. In a healthy physiological state, 
macrophages participate in efferocytosis, which is classified as a process in which 
apoptotic cells are “cleaned up” or cleared away in the tissue. However, the foam cells 
present in atherosclerotic tissue are not classical macrophages and are unable to carry 
out efferocytosis properly [58]; consequently, dead cell fragments and the artifacts of 
apoptotic cells remain in the tissue contributing to increased inflammation and a 
prothrombotic “stew” [56, 59]. High concentrations of the highly thrombotic protein tissue 
factor (TF) contribute significantly to the ability of the necrotic core to induce thrombosis if 
exposed to the circulation [60].  At this stage in CAD, there is still little stenosis of the 
coronary artery but there is still risk of artery occlusion due to thrombosis should the 
contents of the plaque leak into the bloodstream via rupture.  
True stenosis occurs in Type V atherosclerotic plaques. A Type V plaque is characterized 
by the neointimal accumulation of migrated dedifferentiated vascular smooth muscle cells 
(vSMCs) which generate a tough fibrous cap between the fatty necrotic core and the lumen 
of the blood vessel [51]. The continued proliferation of vSMCs in the neointima in concert 
with increased deposition of extracellular matrix leads to the growth of the plaque into the 
lumen of the blood vessel which can, over time, lead to reduced blood flow or even 
occlusion of the artery [56, 59]. Interestingly, the generation of a fibrous cap over the 
atherosclerotic plaques makes the diseased tissue less likely to rupture. Type V plaques 
are susceptible to a plethora of developmental changes that lead to the most clinically 
relevant classification of plaques, Type VI plaques.  
Type VI plaques experience intraplaque hemorrhage, fission, intimal denudation and 
expansive calcium deposition all of which leave the atheroma susceptible to rupture and 
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subsequent thrombogenesis and MI [51, 52]. Intraplaque hemorrhage occurs through 
rupture of leaky neovessels that have grown into the plaque from the vasa vasorum and 
sharply increase inflammation through the lysis of red blood cells, which contributes 
plasma membrane cholesterol to the necrotic core, and exposure of hemoglobin (Hb) to 
the local environment [56, 61]. Hb is a highly inflammatory protein outside of the red blood 
cell and contributes significantly to oxidative damage and reactive oxygen species (ROS) 
[61]. Fissures are essentially tears or breaks in the endothelial or fibrous lining of the 
plaque that potentially exposes the contents of the plaque to the circulation [62]. Typically 
these fissures reseal as vECs proliferate and cover the exposed underlying tissue [56], 
but it is particularly compromising to the integrity of the plaque as repeated fissures 
increases susceptibility to rupture [63, 64]. Intimal or endothelial denudation is a process 
describing the erosion of the vEC layer or fibrous cap overlying the highly pathogenic 
extracellular matrix and necrotic core of the atheroma [65]. Lastly, calcium deposits occur 
in the ECM, the necrotic core, and in the remnants of cells that have undergone apoptosis 
[56, 59]. The pathology of calcified atheroma is unclear; however the extent of calcification 
in the plaque can be used as a biomarker for advanced progression of disease [66, 67]. 
Many of these processes occur throughout plaque progression and are not restricted to 
Type VI plaques alone; they do however occur continuously and contribute to the 
development and subsequent erosion and rupture of the atheroma. 
Murine Models of Atherosclerosis 
Wild-type mice are resistant to the spontaneous development of atherosclerosis likely due 
to their drastically different lipoprotein profile compared to humans. In humans, most of 
the circulating cholesterol is found in the LDL-C whereas in mice it is in the HDL-C. Wild-
type mice are also resistant to diet-induced hypercholesterolemia because, unlike 
humans, they do not absorb dietary cholesterol efficiently; specifically, humans absorb 
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between 53.5 and 57.2% of cholesterol when fed a high cholesterol diet [68] compared to 
C57BL/6 mice that exhibit 30% absorption of cholesterol when fed a high fat/high 
cholesterol diet [69]. Investigating the role of cholesterol and lipoproteins in mice began in 
1992 when both Nobuya Maeda and Jan Breslow’s groups independently reported their 
findings that Apoe-/- mice spontaneously develop  hypercholesterolemia and 
atherosclerosis [70, 71]. One year later Ishibashi et al. reported the generation of the Ldlr-
/- mouse and the observation that a high cholesterol diet induces severe 
hypercholesterolemia in these mice [72]. On regular chow diet Apoe-/- and Ldlr-/- mice 
display a ≈4- to 5-fold and ≈2-fold increase in total plasma cholesterol compared to wild-
type mice [72, 73]. ApoE is required for the clearance of cholesterol-rich chylomicrons and 
VLDL-C particles from the plasma and mice deficient in this protein show marked 
increases in plasma chylomicrons and VLDL while showing no increase in LDL-C. The 
Ldlr-/- mouse is a better model for human familial hypercholesterolemia as they both exhibit 
significant increases in their LDL-C; however, unlike the Apoe-/- mouse, mice deficient in 
LDLr do not spontaneously develop atherosclerosis on chow diet. When placed on a high 
cholesterol diet, Ldlr-/- mouse plasma cholesterol increases up to 1,500mg/dL.  
These mouse models are not without their limitations. For example, the lipoprotein profile 
of Apoe-/- mice is very different from the LDL-C heavy profile of humans. Additionally, while 
both strains are capable of producing extensive atherosclerotic lesions, plaque rupture is 
a rare occurrence and typically requires additional insults such as surgical manipulations 
[74], overexpression of human proapoptotic p53 [75], or using aged mice (60+ weeks old) 
[76].  
Limitations aside, the Apoe-/- and Ldlr-/- mice provide a useful model of atherosclerosis in 
mice and their lesions are comparable to human disease. Both Apoe-/- and Ldlr-/- mice on 
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Western diet develop lesions that can be scored using the Stary System previously 
described (see Table 1.1, taken from Whitman, S 2004  [77]). 
Endothelial Cell Dysfunction Contributes to CAD Development 
vECs compose a monolayer of cells that separates the circulating blood from the rest of 
the blood vessel. They play a pivotal role in the vasculature through inhibiting platelet 
activation and thus thrombogenesis through the production of both adenosine 
monophosphate [78] and nitric oxide (NO) [56, 59, 79, 80]. NO and prostacyclin production 
in vECs are important vasodilators that triggers SMC relaxation in response to increased 
forces on the vessel wall due to high blood pressure [80-82]. Morphologically, vECs 
comprise a highly organized monolayer typically aligned elongated in parallel with the 
unidirectional high shear stress from laminar blood flow [59, 83, 84]. This parallel 
alignment permits tight cell-cell contact maintaining both adaptive signaling [59, 85], to 
inhibit proinflammatory gene expression of NF-κB through Rac-dependent ROS 
production and p21 activated kinase signaling [86], and a highly regulated selective barrier 
between the circulation and underlying ECM [56]. During cases of peripheral tissue 
inflammation, complex leukocyte-vEC interactions permit the capture and adherence of 
circulating leukocytes to the endothelium and facilitate transmigration across the vEC 
monolayer [55]. These aforementioned processes are tightly regulated and maintained in 
the healthy vasculature but undergo dynamic phenotypic alterations in atherosusceptible 
regions experiencing disturbed blood flow and low shear stress.  
Regions of the proximal aorta and the coronary arteries where inner curvature or 
bifurcations of the vessel occur are known to be susceptible to atherosclerosis [53, 83]. 
The unidirectional high shear stress typical of laminar blood flow in atheroprotected 
regions turns into turbulent blood flow with drastic changes to flow direction. Changes in 
flow dynamics and direction lead to vEC activation and alter their morphology from the 
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parallel elongated arrangement into a pathological “cobblestone” appearance [87]. This 
altered vEC morphology coincides with dysfunction in many of the vEC processes 
mentioned above. Activated vECs display enhanced inflammation and a reduction in NO 
production [82], a hallmark of endothelial dysfunction, resulting in a diminished ability to 
regulate vessel lumen diameter in response to increases in blood pressure as well as NO-
dependent inhibition of platelet activation. Both laminar and disturbed blood flow is 
detected in vECs by the Rho family GTPases RhoA, Rac, and cdc42 which permits 
cytoskeletal remodeling but the lack of directional flow in the atherosusceptible regions 
hinders the vECs from forming tight cell-cell contact and maintaining the adaptive signaling 
[88-90] mentioned previously. Compromised “cobblestone” vECs experience endothelial 
barrier dysfunction, heightened proinflammatory signaling and ROS production. Enhanced 
proinflammatory signaling leads to expression of the leukocyte adhesion molecules 
VCAM-1 and ICAM-1 and subsequent invasion of inflammatory cells into the vessel [55], 
as mentioned before, as well as increased deposition of LDL-C into the subintimal space. 
Accumulated LDL-C is modified to oxLDL which then binds to CD36 and lectin-like oxLDL 
receptor 1 (LOX-1) on vECs [91] leading to increased activation of ICAM-1 [92] 
perpetuating the progression of monocyte invasion and plaque development. Endothelial 
expression of adhesion molecules contributing to atherosclerosis is supported in murine 
models of atherosclerosis in which Apoe-/- Icam1-/- double knockout mice show decreased 
lesion sizes compared to Apoe-/- controls [93]. Another vEC-expressed cytokine with links 
to monocyte recruitment in the context of CAD is CXCL1 by binding to its ligand CXCR2 
on circulating monocytes prompting cell arrest [94].  
A Role for Leukocytes and Inflammation in CAD 
This section will focus on the subpopulation of leukocytes known as monocytes as they 
are the predominant cell type found in atherosclerotic lesions. Monocytes make up roughly 
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5 to 10% of the total leukocytes in the circulation and are comprised of two main subtypes, 
GR1+/Lys6Chigh and GR1-/Lys6Clow [95]. GR1+/Lys6Chigh monocytes express CCR2, a cell 
surface receptor capable of binding monocyte chemoattractant protein 1 (MCP-1) on 
activated vECs, and are the primary subtype responsible for extravasation into peripheral 
tissue at sites of inflammation [96]. Upon infiltration into inflamed peripheral tissue, 
monocytes will differentiate into one of four known macrophage subsets. M1 macrophages 
differentiate from monocytes exposed to LPS and/or IFNγ and are the subset responsible 
for attacking and eliminating pathogens [97, 98]. M2 macrophages come from monocytes 
treated with IL-4 or IL-13 and are implicated in tissue repair probably following the initial 
M1 response in inflammation [97, 98]. A unique macrophage subset has emerged from 
exposure of oxidized phospholipids, such as oxPAPC, to monocytes and bears what is 
called a Mox phenotype which appears to be a blend of both M1 and M2 phenotypes [99]. 
Lastly, there is a subset of macrophages known as the M(Hb) macrophage which will be 
discussed later in this section. Classically monocyte/macrophages are known for their role 
in the innate immune response; however, there are significant maladaptive behaviors that 
contribute to the development and progression of CAD.  
As mentioned before, GR1+/Lys6Chigh monocytes harbor CCR2 on their plasma membrane 
and are capable of binding MCP-1 expressed on activated vECs. During the early stages 
of plaque development, increased expression of MCP-1, ICAM-1, VCAM-1 and 
macrophage colony stimulating factor (M-CSF) [56] on the cell surface of activated vECs 
is a crucial step in the recruitment of monocytes and their transmigration into the subintimal 
space of blood vessels. Monocytes that differentiate into macrophages with the M1 
phenotype express high levels of the scavenger receptors CD36, LOX-1, and macrophage 
scavenger receptor class A (SR-A) all of which aggressively facilitate the uptake of oxLDL 
into the macrophage [100, 101]. Typically free LDL-C binds LDL-C receptor (LDLR) where 
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it is endocytosed in a clathrin coated pit and acidification of the vesicle liberates the LDL-
C from its receptor where it can act to inhibit HMGCoA reductase-dependent cholesterol 
synthesis [56]. In the developing plaque however, LDL-C modified to oxLDL is 
endocytosed via the aforementioned scavenger receptors and leads to unregulated 
cholesterol uptake, heightened proinflammatory cytokine production, and foam cell 
formation [56, 91, 102, 103]. OxLDL internalization provides specific ligands for the 
nuclear hormone receptor PPARγ [104] whose activity leads to increased expression of 
CD36 creating a positive feedback loop for oxLDL uptake and the exacerbation of the 
foam cell phenotype [105-107]. Cd36-/- mice on an atherogenic Apoe-/- background fed 
Western diet show pronounced reductions in aortic tree lesion formation (76.5%) 
compared to control mice [108].  
It was mentioned previously that ischemia in the atheroma leads to hypoxia-induced 
apoptosis and formation of the necrotic core. Profound oxLDL uptake in foam cells can 
also contribute to growth of the necrotic core as the formation of cholesterol crystals 
triggers foam cell death leaving behind the toxic cholesterol crystals, oxidized lipids, and 
cell remnants [58, 109]. M1 macrophage phenotypic switching to a foam cell diminishes 
its ability to carry out efferocytosis, the process of cleaning up apoptotic cell fragments, 
contributing to the continuous growth of the necrotic core 
Lastly, as mentioned before, intraplaque hemorrhage results in the accumulation of 
cholesterol and Hb in the plaque providing a source of ROS and oxidative damage. The 
tissues endogenous protection against Hb-induced oxidative damage is through its 
binding to haptoglobin (Hp) forming a Hb:Hp complex which can be cleared by resident 
macrophages through the CD136 receptor [110]. Macrophages that uptake Hb:Hp 
develop a phenotype known as M(Hb) and are unique in that they are very resistant to the 
uptake of oxLDL in vitro [111]. M(Hb) macrophages are therefore considered to be 
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protective in the context of atherosclerosis in that they do not develop into foam cells and 
are capable of eliminating proinflammatory Hb from the atheroma. 
Phenotypic Switching of Smooth Muscle Cells in Atherosclerosis 
Vascular SMCs reside in the tunica media of blood vessels from arterioles up to the largest 
of the arteries, the aorta, while being absent in the capillaries; structurally, SMCs are 
arranged in an elongated fashion parallel to one another but perpendicular to the direction 
of blood flow. The primary role of SMCs in the tunica media is to regulate the vessel lumen 
diameter in response to changes in blood pressure (the myogenic mechanism), or external 
stimuli from the vECs or the sympathetic nervous system, through coordinated contraction 
and relaxation. Vascular SMCs are not terminally differentiated and therefore harbor 
significant plasticity [56, 59]. In healthy blood vessels, SMCs maintain a “contractile” 
phenotype that is characterized by low levels of proliferation and diminished capacity to 
secrete ECM proteins [54]. Contractile SMC markers are smooth muscle alpha-actin 
(ACTA2), smooth muscle 22α (SM22) and smooth muscle myosin heavy chain (SM-MHC) 
[112]. Prostaglandin2 (PGI2) [113] and NO [114] secreted from vECs act as potent 
vasodilators by acting on signaling pathways in SMCs, but these molecules also play a 
significant role in maintaining the previously mentioned contractile phenotype. PGI2 
stimulates adenylyl cyclase-dependent cAMP generation capable of inhibiting myosin light 
chain kinase [115, 116], a kinase whose phosphorylation of the myosin light chain 
stimulates SMC contraction through myosin-actin crossbridge formation, hence leading to 
SMC relaxation. Aside from inhibiting crossbridge formation, PGI2 signaling decreases 
intracellular Ca2+, adding to its role as a vasodilator, but also inhibits SMC proliferation 
and growth [115, 116]. NO signaling leads to guanylyl cyclase-dependent cGMP 
production [117], a second messenger that stimulates myosin light chain phosphatase 
activity [117]. Myosin light chain phosphatase hydrolyzes the phosphate from myosin light 
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chain and breaks myosin-actin crossbridges resulting in SMC relaxation. Similar to PGI2, 
NO-dependent cGMP production leads to decreased intracellular Ca2+ and inhibits 
proliferation and growth in SMCs [118] . 
SMCs in CAD and other vascular injury models exhibit a vastly different phenotype than 
the contractile SMCs described above. During atherosclerotic plaque development SMCs 
dedifferentiate and migrate to the subintimal space, usually above the extracellular lipid 
pool/necrotic core, and both vigorously proliferate and secrete ECM proteins such as 
collagen and elastin to form a tough fibrous cap [119]. Pronounced SMC proliferation in 
the subintimal region creates a condition known as neointimal hyperplasia and is 
characterized best by significant increases in the intima size. vEC dysfunction increases 
susceptibility to atherosclerosis and may contribute to SMC phenotypic switching from a 
contractile state to a proliferative one due to loss of the NO-dependent inhibition of 
proliferation in SMCs. These “proliferative” SMCs downregulate expression of their 
contractile markers, ACTA2, SM22 and SM-MHC, and express macrophage markers such 
as CD68 [112].  Data suggest a role for the DNA-binding protein Krüppel-like factor-4 in 
binding the G/C repressor element on the promoter of SMC marker genes, leading to their 
downregulation [112]. Phenotypic switching may also push SMCs towards a macrophage-
like state capable of internalizing oxLDL in atherosclerotic plaques; in fact, evidence 
suggests that up to 50% of oil red-O stained cells in plaques display ACTA2-positive 
staining and thus may significantly contribute to the foam cell population [120]. In vitro, 
vascular SMCs treated with oxidized phospholipids, such as oxPAPC, oxLDL, and 
unsaturated LPA for 72 hours display phenotypic switching characterized by decreased 
expression of SMC markers, upregulation of CD68 and even positive oil red-O staining 
suggesting foam cell formation [121, 122].  
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LPA and Atherosclerosis 
LPA-mediated effects on vEC barrier function and SMC phenotypes have been reported. 
Not surprisingly, LPA has also been implicated in CAD by eliciting effects through both 
vEC and macrophages. Ex vivo perfusion of murine carotid artery with mildly oxidized 
LDL-C (moxLDL) leads to an LPA-dependent increase in monocyte rolling and adhesion 
that can be completely inhibited by the addition of the LPA1/3 antagonist Ki16425 [14]. It 
appears that LPA is generated from LPC on moxLDL by ATX and blocking the enzyme 
with inhibitor S32826 diminishes the rolling and adhesion of monocytes to the vessel wall 
[14]. Intravenous injection (i.v.) of unsaturated 20:4 LPA, but not saturated 18:0 LPA, 
increases atherosclerotic lesion formation in Apoe-/- mice fed high-fat diet for 4 weeks 
displaying significantly increased macrophage Mac-2+ staining [14]. Ldlr-/- mice fed chow 
diet supplemented with unsaturated LPA resulted in lesion formation similar to Western 
diet fed mice, which was ameliorated by the addition of the ATX inhibitor PF8380 [123]. 
Evidence also supports a role for LPA in foam cell formation as the treatment of primary 
human monocytes with 5µM oleoyl LPA for 16 hours increases oxLDL uptake measured 
by oil red-O, and increases CD36 expression on the cell surface [124]. Additionally, it 
appears as though the LPA-dependent upregulation CD36 only occurs when the human 
CD36 promoter contains the PPAR responsive element suggesting LPA is a ligand for 
PPARγ [124]. 
 
Identification of Novel Risk of CAD through Genome Wide Association Studies 
(GWAS) 
Once the human genome was sequenced a whole new avenue of identifying heritable risk 
of disease opened up. Technology quickly permitted the sequencing of thousands of 
individual genomes both faster and cheaper until present day GWAS are capable of 
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generating massive quantities of genomic data on a population scale. More specifically, 
genomes from populations of patients diagnosed with cardiovascular disease were 
sequenced by SNP genotyping and compared to a healthy control population in order to 
identify single nucleotide polymorphisms (SNPs) that could predict one’s increased risk of 
disease. SNPs are the most common form of DNA variation that occur in individuals and 
are single nucleotide differences. A SNP occurs, on average, once every 300 base pairs 
which translates to roughly 10 million SNPs in the human genome [125]. By comparing 
SNP frequency in patients with CAD versus healthy populations, scientists are able to 
identify “risk alleles” or SNPs that associate with disease. A meta-analysis was published 
in Nature Genetics in 2011 that compared the results of several GWAS studies looking at 
CAD and identified 13 novel risk loci as well as reaffirming 10 previously identified SNPs. 
One of these novel risk loci termed rs17114036 is located in the final intron of the gene 
PPAP2B that encodes the lipid phosphate phosphatase 3 enzyme [4].  
Polymorphisms in PPAP2B Associate with CAD 
The novel risk locus in PPAP2B is found at 1p32.2. The risk allele is an adenine (A) with 
a frequency of 0.91 while the other protective allele is a guanine (G) at a frequency of 
0.09. rs17114036 bears a composite p-value of 3.81 x 10-19 suggesting a significant 
correlation with disease and an odds ratio of 1.17[4]. Another important consideration is 
that while three novel loci from this meta-analysis were found in genes that are associated 
with traditional risk factors of CAD, the majority of SNPs, including rs17114036, are found 
in gene regions that have no previous implication in the development of atherosclerosis.  
GWAS are capable of identifying risk alleles pertaining to a particular disease; however, 
the SNP reported may not be the particular locus causing the functional insult. Commonly, 
SNPs or alleles exhibit non-Mendelian genetic patterns and tend to associate together in 
nonrandom fashion with other SNPs in close proximity. This particular genetic 
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phenomenon is known as linkage disequilibrium and a grouping of SNPs in linkage 
disequilibrium is termed a haplotype. Rs17114036 is in linkage disequilibrium with roughly 
20 proxy SNPs with an r2 of 0.81 or higher, any one of which could be the functional 
disease-causing locus. This tendency to travel as a haplotype is important because of 
subsequent investigations led by Jake Lusis at UCLA and Chris O’Callaghan at Oxford 
looking into SNPs that are in linkage disequilibrium with rs17114036. Erbilgin et al. 
identified a proxy SNP, rs6588635, which associates with the earlier identified SNP 
rs17114036 at an r2 = 0.831. Utilizing this proxy SNP as a biomarker that is found to be in 
linkage disequilibrium with the original rs17114036, the group from UCLA reported marked 
changes in PPAP2B expression in human aortic endothelial cells (HAECs) relative to an 
individual’s SNP genotype. In fact, individuals homozygous for the proxy SNP risk allele, 
in this case a thymine (T), show marked decreases in expression relative to those who 
are heterozygous (CT) suggesting that possessing the homozygous risk allele genotype 
(TT) renders the HAEC unable to express PPAP2B to the same degree as heterozygotes. 
Reschen et al. sought to identify regions of the genome that are subject to transcriptional 
regulation following exposure to atherogenic stimuli such as oxLDL. In their study 
published in PLOS Genetics in 2015, Reschen et al. demonstrated using FAIRE-seq and 
ChIP-seq that the conversion of naïve human monocytes to foam cells via exposure to 
oxLDL results in dramatic remodeling of open chromatin regions. One site in particular 
harbors the SNP rs72664324 that lies within the gene PPAP2B. Sequencing the regions 
of newly exposed open chromatin revealed that the aforementioned locus falls within a 
C/EBPβ binding motif (CCAAT) and that the risk allele disrupts this motif (CCGAT) 
rendering the transcription factor unable to bind. In collaboration with the group we looked 
at PPAP2B expression of LPP3 in monocytes before and after oxLDL exposure. While 
naïve monocytes show very modest levels of LPP3 protein, observed via immunoblot, and 
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LPP3-dependent phosphatase activity, oxLDL treatment significantly increases both LPP3 
levels and LPP3-dependent phosphatase activity roughly 3-fold.  Similar to the HAECs 
investigated by Lusis et al. [126], monocytes from individuals homozygous for the risk 
allele exhibited a reduced ability to upregulate PPAP2B expression relative to 
heterozygote monocytes following oxLDL treatment.  
Large-scale GWAS analysis combined with independent research investigations into 
genotype specific SNP activity in PPAP2B suggests that the risk alleles responsible for an 
increase in an individual’s risk of CAD appear to be acting, at least in part, in a cis manner 
by reducing the gene’s expression in various human vascular cells. 
 
PPAP2B encodes Lipid Phosphate Phosphatase 3 
 
PPAP2B encodes the protein LPP3 that belongs to a family of proteins known as lipid 
phosphate phosphatases or LPPs. LPPs are transmembrane enzymes capable of 
degrading various phospholipids such as lysophosphatidic acid (LPA), sphingosine-1-
phosphate (S1P), ceramide-1-phosphate (C1P), phosphatidic acid (PA), and a few others.  
Structure and Function of the LPPs3 
Structurally, the LPPs contain six transmembrane domains with 5 extramembrane loops 
[127]. Their catalytic domains are found on the third and fifth loop facing the 
extracellular/luminal surface and the LPPs’ enzymatic activity are dependent upon a 
                                               
3  Portions of this section were taken from Mueller et al. [15]. Some additions and 
modifications to the text and figures have been made for clarity of information. 
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variably glycosylated site on the third loop. Additionally, both the N- and C- termini are 
located on the cytosolic surface (Figure 1.2). The LPP family consists of three proteins 
LPP1, LPP2 and LPP3 encoded by the genes PPAP2A, PPAP2C and PPAP2B 
respectively. Spatially speaking, the LPPs’ localization varies depending on the cell type 
and degree of glycosylation, but can range from the endoplasmic reticulum, the Golgi, and 
the plasma membrane. These proteins are capable of forming both hetero- and homo 
oligomers in the plasma membrane while retaining enzymatic activity that is independent 
of the other LPPs in the complex [128].  
Although the three LPP enzymes demonstrate similar catalytic activities and substrate 
preferences in vitro, the phenotypes of mice with targeted inactivation of the Ppap2 genes 
establishes that their functions are non-redundant. Primary cells isolated from mice 
harboring an exon trap inactivated allele of Ppap2a gene display a reduced ability to 
dephosphorylate exogenously provided LPA, indicating a role for LPP1 as a cell surface 
“ecto” LPA phosphatase [129].  Mice homozygous for an inactivated allele of the Ppap2c 
gene, encoding murine LPP2, are phenotypically indistinguishable [130]. By contrast, 
inactivation of Ppap2b results in embryonic lethality in part to due to failure of extra-
embryonic vasculature [131]. Media from cultured embryonic fibroblasts isolated from 
Ppap2b-null mice contains 2.6-fold higher levels of LPA suggesting that the other LPPs 
cannot compensate for the regulation of extracellular accumulation of LPA. 
Mukherjee et al. published a study in 2013 demonstrating a role for the LPP3 homologs in 
Drosophila, Wunen and Wunen2, in generating and regulating phospholipid gradients in 
vivo [132]. Normally germ cells in the developing Drosophila embryo begin as a cluster of 
cells at Stage 9, separate and migrate in an organized fashion into the mesoderm by Stage 
12 where they partition bilaterally to interact with somatic gonadal precursor cells. As the 
germ cells migrate they tend to avoid somatic tissues expressing wun and wun2 
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suggesting that the phosphatases play a role in directing migration. In fact, when Wunen 
and Wunen2 are knocked out in somatic tissues the germ cells’ migration pattern is 
dramatically disrupted. Mukherjee et al. defined the maximum range of influence of 
Wunen-expressing cells on germ cells as approximately 33µm.  
LPP3 Modulates LPA-dependent Vascular Endothelial Cell (vEC) Function 
LPP3 is clearly important in the development of multiple species, but its role in the mature 
vasculature is less understood. As it turns out, endothelial cell-specific deletion of Ppap2b 
is embryonically lethal due to vascular defects similar to what was observed in the Ppap2b-
null mice [22]. To study the effects of endothelial deletion of LPP3 in a murine vascular 
injury model, a tamoxifen-inducible model of endothelial cell-specific deletion was 
achieved by breeding Ppap2bfl/fl mice to transgenic mice expressing a recombinant 
estrogen receptor-Cre fusion protein under the control of the tyrosine kinase Tek promoter 
(ERT2-Cre). Following LPS injections, mice targeted for endothelial cell deletion of LPP3 
(ERT2-∆) displayed enhanced systemic inflammation detected by a 3.3-fold increase in 
IL-6 and a 1.9-fold increase in KC compared to the control mice (fl/fl) suggesting that LPP3 
in the endothelium is anti-inflammatory. ERT2-∆ mice also displayed marked differences 
in endothelial barrier function compared to the fl/fl counterparts. Deletion of LPP3 in the 
endothelial cells results in ~2.2-fold increase in vascular leakage as measured by Evans 
blue dye (EBD) leakage into the lungs which is exacerbated when mice are injected with 
LPS. This effect on endothelial barrier function is specific to endothelial cells and not the 
hematopoietic deletion of LPP3 as ERT2-∆ bone marrow transplantation into fl/fl mice 
showed no changes in EBD leakage whereas EBD leakage into the lungs of ERT2-∆ mice 
harboring fl/fl bone marrow was pronounced. Finally, and potentially most importantly, 
compromised endothelial barrier function in mice lacking endothelial LPP3 is ameliorated 
upon the administration of either ATX inhibitors or a pan-LPA receptor antagonist 
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suggesting that LPA signaling, at least in part, is responsible for this phenotype. Data from 
Panchatcharam et al. strongly implicates a role for LPP3 in protecting endothelial barrier 
function as well as systemic inflammation and that the former role is through the regulation 
of LPA signaling [22].  
Endothelial cell-specific deletion of LPP3 leads to a decrease in endothelial barrier 
function in mice as quantified by EBD leakage into the lungs suggesting a physiological 
role for LPP3 in maintaining vascular endothelial barrier integrity. In human umbilical vein 
endothelial cells (HUVECs) LPP3 is localized in areas of cell-cell contact sites while it 
appears absent in areas of non-contact sites [84]. Yukiura et al. showed in 2015 that 
treatment of HUVECS with 1µM LPA induced stress fiber formation, increased the 
incidence of intracellular gaps and increased endothelial cell permeability as measured by 
leakage of FITC-labelled dextran across a monolayer of cells. LPP3 plays a critical role 
regulating this LPA-induced stress fiber formation which appears to be signaling through 
LPA6. Reducing LPP3 expression using PPAP2B-siRNAs results in HUVEC stress fiber 
formation at a dose of 0.1µM LPA that is otherwise absent in cells treated with control-
siRNA. Additionally, silencing LPA6 using siRNA abolishes LPA-induced stress fiber 
formation providing a mechanistic role for LPP3 in regulating LPA-induced endothelial cell 
remodeling and vascular permeability. 
Wu et al. demonstrated another potential role for LPP3 in maintaining vascular health in 
2015 [83]. In atherosusceptible areas of the vasculature harboring disturbed blood flow 
and low shear stress, PPAP2B appears to be downregulated in vECs by miRNA-92a. As 
mentioned previously, disturbed flow and low shear stress alters the morphology and 
alignment of vECs from a parallel alignment to the classic cobblestone arrangement 
leading to increased vascular permeability, inflammation and expression of adhesion 
molecules. By reducing PPAP2B expression using siRNA in HAECs under 
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atheroprotective (laminar) flow; HAECs take on the cobblestone morphology similar to 
those in an atherosusceptible flow that is accompanied by increased expression of 
inflammatory cytokines and adhesion molecules MCP1 and VCAM1 respectively. 
Interestingly, use of the LPA receptor 1 and 2 antagonist ki16425 ameliorated MCP1 and 
VCAM1 upregulation. These data allude to another mechanistic role for LPP3 in regulating 
LPA-dependent remodeling of HAECs in the context of atherosusceptible blood flow.  
LPP3 Limits Neointimal Hyperplasia and Inflammation in mice 
Our lab has also identified a role for LPP3 in limiting the development of neointimal 
hyperplasia following carotid artery ligation [133]. In wild-type mice, Ppap2b expression 
significantly increases 7 and 28 days post-ligation and LPP3 levels are significantly 
increased at 28 days post ligation while there is apparent elevation at 14 days. SMC-
specific LPP3 deletion in mice (SM-Ppap2bΔ) resulted in ≈3- to 4-fold increases in the 
intimal area compared to Ppap2bfl/fl mice 4 weeks after carotid artery ligation suggesting 
that LPP3 limits the development of neointimal hyperplasia. Uninjured vessels from SM-
Ppap2bΔ mice have marked downregulation of SMC markers Acta2, Tagln, Myh11, and 
Cnn (≈1.8-, 2.3-, 3.9-, and 3.0-fold respectively) relative to the control mice. SMCs isolated 
from the thoracic aorta of SM-Ppap2bΔ also demonstrate increased proliferation and 
migration compared to controls. 
 
Overview 
 
There is little question that CAD is the leading cause of death in both men and women 
worldwide and a major socio-economic burden in the United States. The multi-factoral 
disease arises from both environmental and heritable insults that incorporate the 
dysfunction of nearly all vascular-cell types and many other tissues as well. Significant 
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evidence points to a role for the ATX-LPA-LPP3 axis in the development and progression 
of atherosclerotic plaques in part because of their influence on so many of the vascular 
tissues contributing to disease, but even more so is the considerable genomic data 
implicating a risk loci in PPAP2B that confers an increase in CAD risk. The work presented 
in this dissertation is to demonstrate 1) that Ppap2b expression limits atherosclerotic 
lesion formation in a murine model of atherosclerosis (Chapter 2) 2) CAD associated risk-
alleles decrease expression of PPAP2B in a cis-dependent manner (Chapter 2 and 3) and 
3) LPA content increases in plasma fractions containing atherogenic LDL-C in murine 
models of hyperlipidemia and atherosclerosis. 
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Table 1.1 
 
 
Lesion Stage and Timeframe for Development in both Apoe-/- and Ldlr-/- Mice [77] 
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Figure 1.1 
Lysophosphatidic acid. A potent lysophospholipid signaling molecule consisting of a 
phosphate group bound to a glycerol backbone and a variable fatty acid chain that 
signals through one of six known GPCRs (LPA1-6).  
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Figure 1.2 
Structure of lipid phosphate phosphatases. The LPPs contain six 
transmembrane domains with 5 extramembrane loops [127]. Their catalytic 
domains are found on the third and fifth loop facing the extracellular/luminal 
surface and the LPPs’ enzymatic activity are dependent upon a variably 
glycosylated site on the third loop. Additionally, both the N- and C- termini are 
located on the cytosolic surface. Illustration by Matt Hazzard, University of 
Kentucky, Information Technology. 
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Chapter 2: Ppap2b Expression Regulates CAD in a Tissue-specific Manner 
Introduction 
CAD is the leading cause of death in both men and women worldwide and is defined as a 
narrowing of the coronary arteries as a result of the growth and accumulation of 
atherosclerotic plaques. The development of atherosclerotic lesions is a complex process 
initiated by the deposition of LDL-C in coronary artery vessel wall and involves the 
dysfunction of multiple vascular tissues as well as unchecked inflammation. Advanced 
lesions harbor a highly prothrombotic necrotic core that, upon plaque rupture, is exposed 
to the circulation, stimulating thrombosis and potentially MI. Risk of CAD has a strong 
heritable component and advances in genome sequencing have identified upwards of 46 
disease-associated loci many of which are independent of the traditional risk factors [134]. 
A meta-analysis of GWAS studies looking into CAD-associated SNPs identified a 
noncoding polymorphism termed rs17114036 that confers an increase in risk of disease 
[4]. Rs17114036 lies within the final intron of PPAP2B at chromosomal band 1p32.2, which 
is on the same chromosome of the LDL-C regulator PCSK9 and could thus be acting in 
trans affecting PCSK9 and cholesterol levels. Searching publically available databases 
revealed a SNP in linkage disequilibrium with rs17114036 that shows allele-dependent 
variations in the expression of PPAP2B, but not PCSK9, in peripheral blood cells 
suggesting that the SNP is capable of acting in a cis-manner and is not changing PCSK9 
expression (unpublished data; see Chapter 3). Supporting this data, the CAD-associated 
risk allele correlates with decreased expression of PPAP2B in HAECs [126]; additionally, 
it has been shown to inhibit C/EBPβ-dependent upregulation of PPAP2B in primary human 
macrophages exposed to oxLDL by interrupting a CCAAT binding motif [135]. 
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PPAP2B encodes the protein LPP3, a member of the integral membrane protein LPP 
family whose primary enzymatic function is the degradation of phospholipids such as LPA, 
S1P, C1P, PA and others [136]. Germline deletion of LPP3 is embryonically lethal due to 
vascular defects [137]; whereas the other LPPs show unremarkable phenotypes 
suggesting a nonredundant role for LPP3 in development [138]. LPP3 homologs, Wunen 
and Wunen2, play a large role in generating phospholipid gradients, up to a distance of 
33μm, that is critical in directing the migration of germ cells [132].  Our lab has previously 
identified a role for SMC-specific LPP3 in limiting neoinitimal hyperplasia and inflammation 
in murine models of vascular injury [133]; as well as a role for endothelial cell-specific 
LPP3 in maintaining vEC barrier function in murine models of systemic inflammation [22]. 
Furthermore, endothelial cell Ppap2b expression is downregulated in atherosusceptible 
regions of murine aorta where turbulent blood flow drives phenotypic alterations and vEC 
dysfunction [83]. Considering CAD-associated risk allele-dependent effects on PPAP2B 
as well as LPP3’s role in murine vascular models of injury, systemic inflammation and 
turbulent nonlinear flow, we hypothesize that LPP3 is protective in murine models of CAD. 
Materials and Methods 
Animals 
All procedures conformed to the recommendations of Guide for the Care and Use of 
Laboratory Animals (Department of Health, Education and Welfare publication number 
NIH 78-23, 1996), and were approved by the Institutional Animal Care and Use 
Committee. The production, initial characterization, and backcrossing of Ppap2bfl/fl mice 
to a C57BL/6 background for >10 generations has previously been described [137, 139]. 
In order to generate mice susceptible to atherosclerosis, Ppap2bfl/fl were crossed to LDLr-
/- mice obtained from The Jackson Laboratory (Bar Harbor, ME) to yield Ppap2bfl/fl LDLr-/- 
mice. Generation of an atherosusceptible inducible global LPP3 KO mouse: To generate 
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mice with an inducible global reduction in Ppap2b, female Ppap2bfl/fl LDLr-/- mice were 
crossed to male Ppap2bfl/flLDLr-/-mice expressing Cre recombinase under the control of 
the inducible MX-1 promoter to generate mx1-ppap2bΔ Ldlr-/- (referred to as MX-1Δ) mice 
following polyinosinic-polycytidylic acid (pI:pC) treatment. pI:pC (Sigma Cat#P1530-
100mg) was dissolved in sterile 0.9% saline (concentration of 10mg/mL) and 50µL was 
administered via i.p. injection between post-natal days 3 to 5. Littermates not harboring 
Cre recombinase were used as controls. Generation of an atherosusceptible SMC-specific 
LPP3 KO mouse: To generate mice with SMC-specific Ppap2b deletion, female Ppap2bfl/fl 
LDLr-/- mice were crossed to male Ppap2bfl/flLDLr-/-mice expressing Cre recombinase 
under the control of the SM22 promoter to generate sm22-ppap2bΔ (referred to as SM22-
Δ) mice. Littermates not harboring Cre recombinase were used as controls. Generation of 
Leukocyte-specific LPP3 KO Mice: To generate mice with leukocyte-specific Ppap2b 
deletion, female Ppap2bfl/fl mice were crossed to male Ppap2bfl/fl mice expressing Cre 
recombinase under the control of the LysM promoter to generate lysm-ppap2bΔ (referred 
to as LysM-Δ) mice. Littermates not harboring Cre recombinase were used as controls. 
Mice were housed in cages with HEPA-filtered air in rooms on 12-hour light cycles, and 
fed RD Western Diet (Research Diets Cat#D12079B) ad libitum for 12 weeks. 
Immunoprecipitation of LPP3 
10µL/sample of protein G Sepharose beads (GE Healthcare Cat# 17-0618-01) was 
washed three times with cold 1x PBS, and then resuspended in 20µL/sample of 1x PBS. 
Antibody (1mg/mL) was incubated with the protein G Sepharose beads for 1 hour at 4°C 
with periodic mixing. The beads-antibody mixture were washed again three times with cold 
1x PBS, and then resuspended in 20µL/sample of 1x PBS. 100µg of whole protein was 
added to the beads-antibody solution and incubated for 1 hour at 4°C with periodic mixing. 
The beads-antibody-protein mixture was once again washed three times with cold 1x PBS. 
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Phosphatase activity assay 
Protein G Sepharose beads bound to LPP3 protein were resuspended in 30µL of ddH2O, 
20µL of 5x Assay buffer containing 50mM tris base and 5mM EDTA pH 7.4, and 50µL of 
0.2mM C17-sphingosine-1-phosphate in 6.4mM Triton X-100. Samples were incubated at 
37°C in an Eppendorf thermomixer at 1,400rpm for 10 minutes. The reaction was stopped 
by adding 400µL of 0.1M HCl to each sample and placed on ice. Samples were then 
processed for lipid extraction. 
Lipid extraction for analysis via mass spectroscopy 
500µL of sample in 0.1M HCl were added to a 12mL glass lipid extraction tube containing 
1mL of chloroform, 2mL of methanol, and 50µL of 1µM D7-sphingosine-1-phosphate as 
an internal standard. Samples in the lipid extraction tubes were vortexed for 5 minutes, 
and then placed on ice/kept at 4°C for at least 1 hour. 1mL of chloroform and 1.3mL of 
0.1M HCl was added to the lipid extraction tubes and vortexed again for 5 minutes. The 
samples were centrifuged at 3,000×g for 10 minutes at room temperature, and the lower 
aqueous was transferred to 4mL screw cap glass tube using a Pasteur pipette being 
careful not to include the protein interphase. Samples were evaporated to dryness using 
nitrogen in an N-evap under a fume hood. Once the samples were completely dried, 100µL 
of methanol was added and the tubes were vortexed. Samples sat at room temperature 
for 10 to 15 minutes and then transferred to an autosampler insert vial for analysis via 
Agilent Zorbax C8 column and quantified by tandem mass spectrometry using an ABI 
4000 QTrap hybrid linear ion trap triple quadrupole mass spectrometer. The mass 
spectrometer was operated in selective reaction monitoring mode to measure lipid species 
specific precursor product ion pairs with quantification accomplished by reference to 
calibration curves generated using synthetic standards obtained from Avanti Polar Lipids 
that were independently quantitated by phosphorous analysis as described previously. 
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Quantification of Atherosclerosis 
Aortas were cleaned of the adventitia and dissected from the aortic root to the iliac 
bifurcation and stored in 10% formalin for 24 to 48 hours. After treatment with 
paraformaldehyde, the aortas were transferred to a 0.9% Saline solution and stored at 
4°C for at least one day. Aortas were cut open longitudinally, exposing the intimal surface, 
and secured with pins to be photographed. Atherosclerosis was quantified on the intimal 
surface of the aorta by an en face technique described previously [140]. 
Quantification of LPA and cholesterol from mouse aorta 
Aortas were cleaned of the adipose tissue and dissected from the aortic root to the iliac 
bifurcation. The aorta was cut 3mm below the left subclavian artery (this section of the 
aorta is defined as the proximal aorta) and the tissue was weighed. Aortic roots were 
homogenized in 0.5mL of 0.1M HCl and underwent lipid extraction as described 
previously. Internal standards used for this experiment were C17-LPA, C17-LPC, and D7-
cholesterol. Levels of LPA and cholesterol were normalized the tissue weight. Note: S1P 
was undetectable in the proximal aortic tissue. 
Gene Expression Analysis of Proximal Aortas 
Murine proximal aorta was collected as described above in the Quantification of LPA, and 
cholesterol. Tissue was weighed and stored in RNAlater® Solution (Ambion AM7020) at -
80°C. Proximal aortas were homogenized and treated with the Qiagen RNeasy Fibrous 
Tissue Mini Kit (Qiagen Cat# 74704) for the extraction of RNA. 1.0µg of RNA was used 
for the generation of a cDNA library using MultiScribe™ Reverse Transcriptase (Life 
Technologies Cat#4311235). cDNA was diluted 1:10 and used in a reaction with the 
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TaqMan® Fast Universal PCR Master Mix (2X) (Life Technologies Cat#4364103)  with 
VIC/FAM primers from Life Technologies designed for specific gene targets.  
Immunoblotting of Proximal Aortic Tissue 
Murine proximal aorta was collected as described above in the Quantification of LPA, 
and cholesterol. Tissue was homogenized in lysis buffer containing: 50mM Tris Base; 
500mM NaCl; 4mM MgCl2; 1% Triton X-100; 1mM PMSF protease inhibitor. Protein 
concentrations were determined with the Pierce™ BCA Protein Assay Kit (Cat# 23225) 
and 40µg of total protein was added to a 10% polyacrylamide gel which was then 
transferred to a nitrocellulose membrane. Antibody dilutions were as follows: LPP3 
(1:200) and beta-actin (1:5,000). Membranes were scanned using a Li-Cor Odyssey 
scanner. 
Isolating Plasma from Peripheral Blood in Mice 
Peripheral whole blood was collected from mice via the retro-orbital vein while mice were 
anesthetized with isoflurane. Whole blood was collected in a 1.5 mL Eppendorf tube 
containing 10 µL of 0.5 M EDTA and 50 µL CTAD (BD Vacutainer Ref# 367947). Blood 
samples were centrifuged at 12,000 rpm for 4 minutes and the plasma fraction collected. 
Samples were placed on dry ice and subsequently stored at -80°C. 
Measuring Total Cholesterol and Lipoprotein Cholesterol Distributions in Murine 
Plasma 
Total plasma cholesterol was measured using the Wako Diagnostics Cholesterol E Assay 
(Wako Diagnostics Cat#439-175001) according to the manufacturer’s protocol. Plasma 
lipoprotein cholesterol distributions were determined via fast-performance liquid 
chromatography (FPLC). In short, 40µL of plasma from mice, diluted to a concentration of 
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1mg/mL of total plasma cholesterol, was injected on to a Superose 6 FPLC column. 
Cholesterol concentrations are determined by enzymatic colorimetric assay (Wako 
Diagnostics) reading at 600nm as the elute flows off of the column. 
Measuring Total Triglyceride Content in Murine Plasma 
Total plasma triglycerides was measured using the Wako Diagnostics L-type TG M Assay 
and the Multi-Calibrator Lipid Standard to generate a standard curve (Wako Diagnostics 
Cat# 461-08992, 461-09092, 464-01601) according to the manufacturer’s protocol. 
Measuring Phospholipid Content in Murine Plasma 
50 µL of plasma was added to 450 µL of 0.1 M HCl and underwent lipid extraction as 
previously described in “Lipid extraction for analysis via mass spectroscopy” 
Isolation and Culture of Bone Marrow Derived Macrophages 
Femur and tibia isolated from mice were cut at both ends and flushed with 5mL pre-
warmed (37 degree C) DMEM Glutamax media using a 25 gauge needle. Red blood 
cells were lysed with 0.8% ammonium chloride in 1x PBS for 5 minutes. Media-cell 
suspension was pressed through a 70μm nylon mesh filter and centrifuged at 1000×g for 
5 minutes. The cell pellet was resuspended in DMEM Glutamax containing 10% FBS, 
1% PenStrep and 10% L929 media then transferred to a 6 well plate at a concentration 
of 1 million cells per well. After 72 hours the wells were washed with sterile 1x PBS and 
cultured in DMEM Glutamax containing 10% FBS, 1%PenStrep and 10% L929 media. 
Cells were cultured for 7 to 10 days while refreshing media every 2 to 3 days. Culture 
conditions were 37°C at 5% CO2. 
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Isolation and Culture of SMCs 
Mice were anesthetized terminally with isoflurane, then doused in 70% ethanol and cut 
open from the abdomen through the thorax. A 20mL syringe attached to a butterfly needle 
(21 G3/4 X12” Vacutainer BD Cat# 367281) was used to inject 20mL of 1x PBS (kept at 
37ºC) into the left ventricle and the vascular systems was perfused with a minimum speed, 
after cutting open the femoral artery or the artery near the kidney. The perfusion was 
performed twice, with a total of 40mL sterile 1x PBS at 37°C perfusion. The aorta was 
separated from surrounding tissue starting from the aorta arch until the kidney vessel. 
Enough care was taken to isolate the aorta without any fat bodies and any other 
surrounding tissue. After isolation, the aorta was placed in isolation buffer (60mm plate 
having 4ml of pre-warmth to 37°C isolation buffer) and flushed with isolation buffer to 
remove all the RBCs. The aorta was transferred into a new 60mm plate containing 
isolation buffer. The dish was incubated at 37°C while the rest of the animals were 
dissected. Once two aortas per 60mm dish were collected, they were subjected to 2.5mL 
of collagenase digestion buffer (3.1mg – 3.9mg collagenase type II dissolved in 5ml of 
isolation buffer kept at 37°C) to remove the adventitia. The digestion was done for 20 
minutes at 37°C incubator on the rocker. After digestion, aortas were transferred to a new 
60mm dish with fresh isolation medium. The adventitia was gently removed by pulling over 
the other end or tearing it. Aortas were washed once again and kept in the fresh isolation 
medium until all of them were done. Finally, two aortas were placed in a 60mm dish, 
covered with 2.5ml DMEM media (25mM glucose with 10% FBS and 1% PenStrep) and 
incubated at 37°C for 12 to 18 hours till next day. Culture conditions should be at 5% CO2. 
On the next day the aortas were subjected to elastase and collagenase digestion using 
2.5ml of digestion medium (containing elastase and collagenase) at 37ºC in a rotating 
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rocker and after 22 minutes the aorta were gently sucked in a glass Pasteur pipette 15-20 
times and once again placed in 37ºC. The whole digestion procedure was for 45min 
including all the manipulation. 8ml of DMEM (25mM glucose, 10% FBS and 1% PenStrep) 
was added to the digested aorta and centrifuged at 800rpm for 10min at 22ºC. The pellet 
was plated in a 60mm dish containing 2.5ml of DMEM (25mM) with 10% FBS and 2.5ml 
of proliferation media. Cells were gently aspirated and separated with a 10ml pipette and 
left for 24hr. After 24hr (on the next day) the plate was washed 4 to 5 times with sterile 
PBS and 2.5ml of DMEM (25mM) with 10% FBS and 2.5ml of proliferation media was 
added again. Wait till confluence (takes three to four days). For RNA isolation use the 
culture at about 70% confluence. 
Aortic Root Sectioning and Immunofluorescent Imaging of Aortic Arches 
Aortic roots were sectioned as described previously [141]. Hearts were excised, the aorta 
was cut at its base as close to the heart as possible, and stored in OCT compound at -
80°C. The hearts were cut horizontally ≈3mm from the base of the aortic root. The 
remaining heart-aortic root was placed in a tissue mold with the root perpendicular to the 
bottom surface of the mold and covered in OCT compound. The refrozen tissue block was 
mounted to the cryostat chuck with the ventricular tissue facing outward. The ventricular 
tissue was sectioned away until the aortic sinus is reached. Serial sections were collected 
at 10μm/section, and 8 to 10 slides per aorta until the aortic wall was no longer visible. 
Slides were stored at -20°C until used.  
Microscope slides containing frozen tissue sections were submerged in chilled acetone 
for 10 minutes and then incubated in Redusol 0.05% Cr3O3 for 2 minutes at 40°C. Slides 
were washed 5 to 6 times in automation buffer (GeneTex Cat# GTX 30931) and then 
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submerged in methanol containing hydrogen peroxide (3.2%) at 40°C for 2 minutes. Slides 
were washed 5 times in automation buffer and incubated with Triton X-100 0 (0.5%) for 
10 minutes at 40°C. Again, slides were washed 5 times with automation buffer and 
incubated with the blocking agent (goat serum 15μL/mL) for 5 minutes at 40°C. Slides 
were washed 5 times with automation buffer and incubated with the primary antibody for 
20 minutes at 40°C. Primary antibodies used were LPP3 (Biosensis Cat# M-1560; 1:100), 
Smooth muscle alpha-actin (Abcam Cat# ab5694; 1:100), CD68 (Abcam Cat# ab53444; 
1:100), PECAM (BD Biosciences Cat# 553370; 1:100) and podocalyxin (R&D Systems 
Cat# AF1556; 1:100). Slides were washed again 5 times in automation buffer and covered 
in the immunofluorescent antibody (R&D Systems; 1:500) and incubated for 1 hour in the 
dark at room temperature. Slides were washed 5 times in automation buffer and 
submerged in Sudan Black (1% Sudan black in 70% EtOH) for 1 hour at room temperature 
before a final wash with automation buffer and imaging. Imaging was performed using a 
Nikon A1R confocal microscope with a spectral detector. 
Statistical Analysis 
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was 
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value < 
0.05 is regarded as significant. Two-way ANOVA was used when multiple comparisons 
were made. Statistical analysis was performed using GraphPad Prism 7.
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Results 
Noncoding SNPs Decrease oxLDL-induced PPAP2B Upregulation and Impair 
C/EBPβ Binding 
A meta-analysis of several GWAS investigations has implicated the gene PPAP2B in the 
development of CAD in humans conferring an increase in risk of disease for those 
harboring the risk allele. Rs17114036, the original risk loci implicated in the meta-analysis, 
lies in a noncoding region of PPAP2B, specifically in the final intron. We provided 
additional evidence by searching publically available microarray data and found that a 
proxySNP (rs9970807) is associated with decreased expression of PPAP2B in peripheral 
blood cell [142] – This is discussed in further detail in Chapter 3. Subsequent 
investigations into SNPs in linkage disequilibrium with rs17114036 reveal HAECs 
homozygous for the risk allele exhibit a diminished capacity to upregulate PPAP2B at 
baseline as well as following treatment with oxPAPC relative to heterozygote cells; 
therefore, the risk loci may act in a cis-manner on the gene in which it resides. A study 
exploring changes in transcriptional regulation during the lipid-induced transition of 
macrophages to foam cells identified rs72664324, in a noncoding region of PPAP2B, 
which is subject to dramatic chromatin remodeling. This SNP is in linkage disequilibrium 
with the CAD risk locus rs17114036 with an r2 > 0.8 and falls within a C/EBP binding 
motif. As mentioned in the introduction, the risk allele G disrupts the CCAAT binding motif, 
diminishing C/EBP binding, and correlates with lower PPAP2B expression relative to the 
protective G allele. 
In collaboration with Chris O’Callaghan’s group at Oxford, we demonstrated with Western 
blotting that primary human macrophages display marked increases in LPP3 protein 
following exposure to oxLDL compared to vehicle treatment (Figure 2.1a) LPP3-specific 
phosphatase activity was significantly increased in oxLDL treated macrophages versus 
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vehicle controls determined by incubating immunoprecipitated LPP3 with LPA (Figure 
2.1b) or S1P (Figure 2.1c) and measuring their respective product formation over time. 
These data support O’Callaghan’s groups’ work demonstrating a functional role for oxLDL-
dependent C/EBP binding to the rs72664324 loci to potentially drive increased 
expression of PPAP2B. 
Risk loci in PPAP2B’s locus at 1p32.2 are also on the same chromosome as the master 
LDL-C regulator PCSK9 at 1p32.3; therein, it is feasible that these risk loci are acting in 
on PCSK9 expression because PCSK9 levels can dramatically impact circulating LDL-C, 
and thus the development of atherosclerotic lesions. Looking at the previously mentioned 
proxySNP, rs9970807, we found no association with the risk allele and PCSK9 expression 
suggesting that SNPs in linkage disequilibrium with rs17114036 does not act on PCSK9 
[142]. Evidence provided by our group, Jake Lusis’ and Chris O’Callaghan’s groups 
demonstrate risk allele-dependent cis effects on PPAP2B expression. Considering LPP3’s 
role regulating levels of LPA in addition to the ATX-LPA-LPP3 axis’ extensive impact on 
vascular development, maintenance and pathogenesis it is conceivable that CAD-risk loci 
in PPAP2B are acting in cis to confer increased risk of CAD through diminished levels of 
LPP3. 
LPP3 Expression is Upregulated in Mammalian Models of Atherosclerosis 
Mounting genome-sequencing data has implicated PPAP2B in the risk of developing CAD 
through the presence of risk allele associations. Indeed, SNPs in linkage disequilibrium 
with rs17114036 display allelic-dependent variations in PPAP2B expression observed 
through independent studies investigating different vascular tissues. LPP3 expression is 
apparent in foam cells of human atheroma; however, little is known about its regulation in 
the progression of CAD. C57BL/6 mice are resistant to hypercholesterolemia and thus the 
development of atherosclerosis even on a high cholesterol diet and indeed display no 
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signs of plaque formation in the aortic roots of mice after 12 weeks of Western diet (Figure 
2.2 left panel). Apoe-/- mice are very susceptible to hypercholesterolemia and lesion 
formation and following Western diet treatment show obvious upregulation of positive 
LPP3 staining in the vessel lesions that is not observed in the IgG control (Figure 2.2 
middle and right panels). To delineate cell-specific LPP3 localization we analyzed the 
aortic roots of C57BL/6 mice and Ldlr-/- mice, another model of murine atherosclerosis, 
after 12 weeks of Western diet. Immunofluorescent confocal imaging shows colocalization 
of LPP3 with endothelial marker CD31 in C57BL/6 roots (Figure 2.3 top panel) consistent 
with vEC expression of LPP3; however, no LPP3 staining was observed in the remaining 
intima or media. Ldlr-/- aortic root lesions display pronounced positive LPP3 staining in 
both the endothelial cells as well as throughout the vessel/lesion wall (Figure 2.3 bottom 
panel).  LPP3 also shows colocalization with SMC marker SMA (Figure 2.4 top panel) and 
macrophage maker CD68 (Figure 2.4 bottom panel) in the subintima indicating 
upregulation of LPP3 in these cells within atherosclerotic lesions. Colocalization of LPP3 
and podocalyxin in Ldlr-/- roots (Figure 2.5) suggests, in endothelial cells, that LPP3 is 
localized to the apical membrane. To determine if CAD-dependent LPP3 upregulation is 
unique to mice, we examined LPP3 expression in porcine coronary arteries with 
pronounced lesion formation. LPP3 expression is substantial and colocalizes with SMA 
throughout porcine vessel lesions (Figure 2.6) suggesting that LPP3 is upregulated in 
multiple mammalian species with CAD. Finally, to delineate that the upregulation of LPP3 
is specific to atherosclerotic lesions and not just the vasculature of hypercholesterolemic 
mice, we analyzed LPP3 protein in atherosusceptible (proximal aorta) and atheroprotected 
(thoracic aorta) regions of murine aorta with Western blotting. Indeed, LPP3 was 
upregulated only in the proximal aorta of Apoe-/- and LDLr-/- compared to the thoracic aorta 
(Figure 2.7). Consistent with our observations in the C57BL/6 aortic roots, LPP3 levels 
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were lower in the proximal aorta of wildtype mice, compared to its hypercholesterolemic 
counterparts, and was comparable to the levels observed in the thoracic aorta. 
We found that the rs17114036 and rs72664324 SNP regions in PPAP2B are conserved 
in the mouse monocyte cell line RAW264.7 and that the rs17114036 locus serves as a 
binding site for the transcription factor c-Fos. The monocyte cell line contains the risk allele 
for rs72664324 (G/C) but the protective allele for rs17114036 (G/C). We designed major 
(Hrs4324G/C, Mrs4324G/C, Hrs4036A/T) and minor (Hrs4324A/T, Hrs4036G/C) allele-
containing oligos with human and mouse DNA sequences containing the SNP regions and 
performed DNA affinity precipitation assays. Western blotting of RAW264.7 nuclear 
extracts that were immunoprecipitated with Hrs4324G/C (risk allele) did not display 
binding to C/EBP; however nuclear extracts immunoprecipitated with Hrs4324A/T 
(protective allele) did (Figure 2.8a), thus supporting the observations of Reschen et al. 
[135]. Similarly, Hrs4036A/T (risk allele) did not exhibit c-Fos binding whereas Western 
blots run with nuclear extracts immunoprecipitated with Hrs4036G/C (protective allele) and 
Mrs4036G/C display c-Fos binding (Figure 2.8b). Development of CAD coincides with 
increased expression of LPP3 in the SMCs and macrophages within lesions; additionally, 
the CAD-associated risk loci are conserved in a mouse-derived cell line and murine 
C/EBP and c-Fos transcription factors exhibit allele-specific binding to human and mouse 
oligos containing the SNP alleles suggesting that the phosphatase may play a role in the 
development and/or progression of disease. 
Inducible Global Reduction of Ppap2b Increases Lesion Formation in Murine 
Models of Atherosclerosis 
Our lab has previously identified a role for endothelial-derived LPP3 in the maintenance 
of vEC barrier function, in a LPA-dependent manner, and reducing inflammation in a 
model of LPS-induced systemic inflammation in vivo; as well as a role for SMC-specific 
45 
LPP3 decreasing neointimal hyperplasia and IL-6 expression following carotid artery 
ligation in vivo. Seeing that LPP3 reduces vEC barrier dysfunction, limits neointimal 
hyperplasia following injury and limits proinflammatory cytokine expression, all of which 
are hallmarks of CAD, its upregulation in atherosclerotic lesions could be a vascular 
mechanism to combat CAD. To test this hypothesis we examined the development of 
atherosclerotic lesions in a murine model of CAD. 
Both germline deletion and endothelial cell-specific deletion of Ppap2b are embryonically 
lethal as described previously. In order to study the effects of a global reduction in LPP3 
in the context of atherosclerosis we generated an inducible global knockdown of Ppap2b 
by crossing Ppap2bfl/fl Ldlr-/- (referred to as fl/fl henceforth) mice with mice expressing Cre 
recombinase under the control of the inducible MX-1 promoter to generate mx1-ppap2bΔ 
Ldlr-/- (referred to as MX-1Δ) mice following pI:pC treatment at postnatal days 3 to 5. MX-
1-mediated knockdown of Ppap2b was confirmed through relative gene expression 
analysis using qRT-PCR on bone marrow cells (Figure 2.9a). Upon weaning, mice were 
placed on a Western diet for 12 weeks to induce hyperlipidemia and atherosclerotic lesion 
formation. We used Western blotting to measure proximal aortic LPP3 and observed 
diminished levels of the phosphatase in MX-1Δ mice compared to fl/fl controls (Figure 
2.9b). Confocal immunofluorescent imaging of aortic root lesions shows colocalization of 
LPP3 and vEC marker PECAM in fl/fl mice, which is absent in MX-1Δ mice (Figure 3.8c). 
Ppap2b deficiency did not alter body weight in either male or female mice (Table 2.1) nor 
was there a difference in blood pressure among fl/fl and MX-1Δ mice (Table 2.2) 
determined by tail-cuff measurement. We next analyzed circulating plasma lipids using 
enzymatic colorimetric assays provided by Wako Diagnostics and FPLC. There were no 
differences in total plasma cholesterol or the cholesterol distribution (Figure 2.10a and b) 
between MX-1 Δ and fl/fl controls; similarly, total plasma triglycerides remained 
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unchanged (Figure 2.10c). LPP3 enzymatically inactivates a variety of bioactive 
phospholipids such as LPA and S1P that are found in abundance in the plasma and are 
known to alter vEC barrier function. We looked at levels of LPP3 substrates in the plasma 
using HPLC MS/MS and found that MX-1Δ mice display significant increases in total LPA 
(≈2.2-fold, p<0.001) and S1P (≈1.5-fold, p<0.01) but not LPC compared to controls (Figure 
2.10d) indicating that global reductions in LPP3 alter its phospholipid substrates in the 
circulation. MX-1Δ mice have 30% (p<0.01) increase in lesion formation in the proximal 
aorta compared to the fl/fl control mice reported as percent of total area using en face 
analysis (Figure 2.11a). Coinciding with the increase in atherosclerosis development, lipid 
analysis of the proximal aortas revealed ≈2-fold increase in total LPA content (p<0.05) 
compared to fl/fl mice (Figure 2.11b). Relative gene expression analyses in the proximal 
aortas using qRT-PCR reveal ≈1.9-fold increases in expression of macrophage marker 
Cd68 (p<0.05) in MX-1Δ mice and a trend towards increased proinflammatory Il-6 relative 
to fl/fl control mice (Figure 2.11c). Confocal immunofluorescent imaging of aortic root 
lesions from the MX-1Δ and fl/fl mice, in accordance to the Cd68 expression, appears to 
show increased positive CD68 staining in the Ppap2b deficient mice (Figure 2.11d). 
Leukocyte-adhesion molecule ICAM-1 expression is markedly upregulated in the lesions 
of MX-1Δ mice compared to fl/fl as well (Figure 2.12). 
Leukocyte-derived LPP3 Fails to Protect Against CAD 
MX-1Δ lesions showed increased levels of ICAM-1 which is consistent with a 
preponderance of macrophage infiltration into the vessel wall [55] and consistent with our 
observations of increased CD68 staining in lesions and Cd68 expression in proximal aorta 
of MX-1Δ compared to fl/fl mice. The inducible MX-1 promoter is expressed in epithelial 
and endothelial cells throughout the body including aorta, liver, lung, spleen, etc. [citation]; 
it also shows pronounced expression in hematopoietic cells including monocytes. 
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Because LPP3 expression is upregulated during the conversion of primary human 
macrophages to foam cells in vitro [135] and global Ppap2b deficiency increases 
macrophage markers in lesions we investigated whether leukocyte-specific expression of 
LPP3 conveys protection against lesion formation in mice. 
We generated a murine model of myeloid-specific deficiency in Ppap2b by crossing 
Ppap2bfl/fl mice with mice harboring Cre recombinase under the control of the LysM 
promoter to yield Lysm-ppap2bΔ offspring. We transplanted Lysm-ppap2bΔ (LysM-Δ) and 
Ppap2bfl/fl bone marrow cells into lethally irradiated Ldlr-/- host mice (referred to as LysM-
Δ-LDLr and fl/fl-LDLr respectively for this study). LysM-mediated deletion of Ppap2b was 
confirmed using relative gene expression analysis of bone marrow-derived macrophages 
(BMDMs) (Figure 2.13a). As before, mice were fed Western diet for 12 weeks to induce 
hyperlipidemia and lesion formation. LysM-Δ-LDLr mice show no change in plasma total 
cholesterol compared to fl/fl-LDLr mice (Figure 2.13b). In contrast to observations in mice 
with global reductions in Ppap2b, leukocyte-specific deficiency of Ppap2b did not alter 
circulating levels of LPA; however, we did see an increase in total circulating S1P (p<0.05, 
Figure 2.13c). Similar to our observations in human macrophages, BMDMs from Ppap2bfl/fl 
mice treated with oxLDL (50μg/mL) for 48 hours show significant upregulation of Ppap2b 
expression following treatment with oxLDL (Figure 2.13a). Ppap2b deficient foam cells 
exhibit significantly increased levels of proinflammatory Il-1 and Il-12b (≈2.7-fold, p<0.01 
and ≈6.4-fold, p<0.01 respectively) relative to BMDMs from Ppap2bfl/fl mice (Figure 2.13b). 
En face analysis of the proximal aortas revealed no differences in atherosclerotic lesion 
formation between LysM-Δ-LDLr mice and their fl/fl-LDLr controls (Figure 2.14) suggesting 
that leukocyte-derived LPP3 is not sufficient to confer the same protection to 
atherosclerosis as was observed in the MX-1 model. These data suggest that while 
leukocyte-derived LPP3 alone is not sufficient to protect against the formation of 
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atherosclerotic lesions, it does play a role in regulating foam cell LPA accumulation and 
proinflammatory cytokine expression. 
SMC-specific Ppap2b Expression is Athero-protective in Mice 
We next investigated whether LPP3 expressed by SMCs alters the development of CAD 
in mice. Utilizing Cre recombinase under the control of the SM22 promoter, we generated 
SMC-specific knockout of LPP3 in mice on an Ldlr-/- background (SM22-Δ). SMCs were 
isolated from the aorta of SM22-Δ and fl/fl mice and knockdown of Ppap2b was confirmed 
with relative gene expression analysis using qRT-PCR (Figure 2.15a). Similar to the two 
previously described mouse models, SM22-Δ and fl/fl mice show no differences in 
cholesterol or total circulating LPA following 12 weeks on Western diet (Figure 2.15b and 
c). A ≈2.7-fold increase (P<0.001) in lesion formation was observed in the proximal aorta 
of SM22-Δ mice compared to fl/fl (Figure 2.16a). Analysis of the proximal aortas of these 
mice reveal a ≈1.9-fold increase (p<0.05) in SM22-Δ total LPA content compared to fl/fl 
controls (Figure 2.16b); as well as, ≈5.2-fold upregulation (p<0.05) of Il-6 expression in 
SM22-Δ proximal aorta (Figure 2.16c). Confocal immunofluorescent imaging of aortic root 
lesions display a pattern of increased CD68 staining in SM22-Δ lesions compared to fl/fl 
controls (Figure 2.16d). These data implicate SMC-derived LPP3 in conferring protection 
against atherosclerotic lesion formation in mice and reduced LPP3 in SMCs results in an 
increase in proinflammatory Il-6 expression as well an increase in the area of CD68 
positive cells.  
Phenotypic Switching of Contractile SMCs to Foam Cells Increases C/EBPβ 
binding in PPAP2B 
SMC-derived LPP3 is known to limit the development of intimal hyperplasia and reduce 
expression of inflammatory cytokine Il-6 in mice which very well may be the mechanism 
of protection we see in our murine model of CAD presented in this study. Recent evidence 
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indicates that SMCs contribute to foam cell populations in atherosclerotic lesions and up 
to 50% of oil red-O stained cells in plaques may be of SMC origin [112, 120, 122]. 
Cholesterol loading of murine vascular SMCs in vitro causes a phenotypic switch of 
contractile SMC to a foam cell-like state characterized by downregulation of contractile 
SMC markers such as Acta2 and upregulation of macrophage marker Cd68 [112]. Our lab 
has previously reported downregulation of Acta2 and Tagln in uninjured vessels from 
Sm22-ppap2bΔ compared to Ppap2bfl/fl controls suggesting an absence of LPP3 
contributes to dedifferentiation of SMCs [133]. We investigated whether PPAP2B 
expression is altered in the phenotypic switching of a SMC to a foam cell in vitro. 
Loading human coronary artery SMCs (caSMCs) with cyclodextran-cholesterol (10µg/mL) 
for 72-hours (referred to as SMC foam cells) results in significant decreases in TAGLN 
and ACTA2 (p<0.0001) as well as significant increases in CD68 expression (p<0.01) that 
was not observed in vehicle treated SMCs (referred to as SMCs) (Figure 2.17a). SMC 
foam cells exhibited a ≈2.4-fold increase (p<0.05) in PPAP2B expression compared to 
SMCs (Figure 2.16b). SMC foam cells also display ≈3.0-fold upregulation (p<0.05) of IL-6 
expression compared to vehicle treated controls (Figure 2.17b) suggesting heightened 
inflammation from these cells. 
SMC conversion to SMC foam cells results in a 2.3-fold increase (p<0.05) in CEBPB 
expression whereas other transcription factors show no change (Figure 2.17c). 
Interestingly, Western blotting with SMC foam cell nuclear extracts immunoprecipitated 
with Hrs4324A/T (protective allele) and not Hrs4324G/C (risk allele, show C/EBP binding 
that is not observed in the vehicle treated SMCs (Figure 2.18) indicating that cholesterol 
loading induces C/EBP localization to the nucleus. 
Discussion 
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PPAP2B has been implicated in development of CAD due to the presence of noncoding 
SNPs in the final intron of the gene that confers an increase in risk of disease [4]. A 
proxySNP in linkage disequilibrium with rs17114036 is associated with decreased 
PPAP2B expression in human peripheral blood cells [142]. HAECs homozygous for the 
risk allele have a diminished ability to upregulate PPAP2B expression associated with 
exposure to oxPAPC compared to heterozygote cells [126]. In this study we present data 
obtained in collaboration with Chris O’Callaghan’s group at Oxford that demonstrates 
human macrophages display an oxLDL-induced upregulation of LPP3 protein and LPP3-
associated phosphatase activity compared to vehicle treated macrophages (Figure 2.1). 
LPP3 expression is also upregulated in models of vascular injury [22, 133] and limits 
development of neointimal hyperplasia. We compared murine models of atherosclerosis, 
Ldlr-/- and Apoe-/- mice, to C57BL/6 wildtype mice, which are known to be resistant to 
hyperlipidemia and lesion formation. LPP3 expression appears absent in the vessel 
subintima and media of C57BL/6 mice but is dramatically upregulated in Apoe-/- and Ldr-/- 
lesions as well as atherosusceptible regions of the proximal aorta compared to 
atheroprotected thoracic aorta (Figure 2.2, 2.3 and 2.7). We also demonstrated murine 
C/EBP binding to the protective allele of rs72664324 and an additional transcription 
factor, c-Fos, which binds to the protective allele of rs17114036 (Figure 2.8). We 
hypothesized that LPP3 is protective in murine models of atherosclerosis. Using a model 
of global reduction of Ppap2b expression driven by Cre Recombinase under the control of 
the MX-1 promoter we generated adult animals with reduced LPP3 expression on the Ldlr-
/- background. MX-1Δ mice developed larger lesion formation (Figure 2.11a) despite no 
differences in circulating cholesterol levels (Figure 2.10a). To test whether there is a cell-
specific effect we generated mice with leukocyte-specific and SMC-specific deletion of 
Ppap2b. LysM-Δ-LDLr mice show no differences in development of atherosclerosis after 
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12-weeks on Western diet (Figure 2.14). Contrary to LysM-Δ-LDLr mice, SM22-Δ mice 
displayed greater atherosclerotic lesion formation compared to controls (Figure 2.16a) 
implicating SMC-derived LPP3 as a protective agent in the context of CAD. Finally, we 
examined the expression of PPAP2B in the phenotypic switching of primary human SMCs 
to SMC foam cells. Similar to observations in primary human macrophages, caSMCs 
upregulate PPAP2B expression 2.4-fold compared to controls (Figure 2.17b). CEBPB 
expression is increased 2.3-fold in SMC foam cells compared to SMCs (Figure 2.17c) and 
treatment of caSMCs with cyclodextran-cholesterol, to drive the phenotypic switch, 
stimulates C/EBP-β binding to the rs72664324 protective allele (Figure 2.18) suggesting 
similar epigenetic changes in chromatin structure may be affecting C/EBP-dependent 
PPAP2B expression in SMCs that were observed in primary human macrophages. 
Disease-associated noncoding SNPs identified in GWAS analyses carry out their 
mechanism of action in either a cis- or trans-manner. Cis-acting SNPs typically alter the 
expression of the gene in which they reside, are at least 1Mb proximal to the start of the 
gene or are at least 1Mb distal to the end of the gene; whereas trans-acting SNPs are 
capable of changing the expression of genes up to anywhere else in the genome and have 
been shown to act on genes upwards of 50Mb away [143]. Rs17114036 in PPAP2B is at 
locus 1p32.2, which happens to be on the same chromosome as the master LDL-C 
regulator PCSK9 at locus 1p32.3. PCSK9 binds LDLr driving internalization and 
subsequent lysosomal degradation of the LDLr-PCKS9 complex [144]. Decreased LDLr 
in the liver leads to increases in plasma LDL-C; in fact, individuals with gain-of-function 
mutations in PCSK9 are classified as having familial hypercholesterolemia, have profound 
levels of circulating LDL-C and experience premature development of CAD between ages 
30-40 [145]. Despite evidence from microarray databases demonstrating no altered rs-
9970807-dependent PCSK9 expression it is still conceivable that rs17114036 could act 
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as a trans-regulator of PCKS9 and increase risk of disease by altering LDL-C. In this study 
we demonstrate a protective role for LPP3 in the development of atherosclerotic lesion 
formations in mice on an Ldlr-/- background. By using mice deficient in the LDLr we can 
eliminate any PCSK9-dependent effects that is confirmed in our models by observing 
LPP3-dependent protection in CAD, which despite no differences in circulating cholesterol 
levels (Figures 2.10a and 2.15b). Taking into consideration that CAD-associated risk 
alleles are associated with diminished expression of PPAP2B and that reductions in 
Ppap2b in mice result in exacerbated lesion formation independent of PCSK9-mediated 
alterations in cholesterol we posit that CAD-associated rs17114036 confers its increased 
risk of disease through a cis-regulatory effect on PPAP2B. 
In a study published in PLOS Genetics in 2015, Reschen et al. [135] investigated changes 
in transcriptional regulation induced during the oxLDL-induced conversion of 
macrophages to foam cells, a critical process in the progression of CAD [135]. 
Formaldehyde-assisted inducible regulatory element sequencing (FAIRE-seq) analysis 
reveals dynamic remodeling of open chromatin regions throughout the genome including 
in a region of PPAP2B, which harbors rs72664324. Rs72664324 is in linkage 
disequilibrium with CAD risk-associated allele rs17114036 with an r2 >0.8 and happens to 
be in a CCAAT binding domain for the transcriptional regulator C/EBP-β. The risk allele 
interrupts the binding motif and inhibits oxLDL-induced C/EBP-β binding; subsequently, 
upregulation of PPAP2B expression in the conversion of human macrophages to foam 
cells was diminished in cells homozygous for the CAD-risk allele (GG) compared to cells 
that were heterozygotes (AG). SMC-specific LPP3 expression limits the development of 
atherosclerotic lesions in our model implicating the phosphatase as being protective in 
CAD. PPAP2B upregulation in foam cells may be an intrinsic means of protection although 
the mechanism remains to be described. In the present study we show that primary human 
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caSMCs show similar upregulation of PPAP2B expression and cholesterol-dependent 
C/EBP-β binding to rs72664324 (2.17b and 2.18) that was observed by Reschen et al. in 
primary human macrophages, albeit an allelic-dependent variation in PPAP2B expression 
should still be confirmed. Because SMC-derived LPP3 is sufficient to confer protection 
against lesion formation in mice, and that C/EBP binding to rs72664324 is inhibited in 
macrophages homozygous for the CAD-associated risk allele, it is feasible that individuals 
homozygous for the rs17114036 risk allele are at greater risk of developing CAD due 
inhibited C/EBP-dependent upregulation of PPAP2B in vascular SMCs. 
In this study we demonstrate a protective role for LPP3 in the development of lesion 
formations in a murine model of atherosclerosis. Global reductions in LPP3 resulted in 
increased lesion formation (Figure 2.11a) independent of changes in cholesterol (Figure 
2.10a). The MX-1 promoter is inducible in a wide range of epithelial cells throughout the 
body including liver, lungs, spleen, aorta, and hematopoietic cells [146]. Confocal 
immunofluorescent staining showed MX-1-mediated deletion of Ppap2b in the vEC of 
aortic root lesions (Figure 2.9c). MX-1Δ mice also showed significant increases in total 
LPA in their circulation and their proximal aortas compared to fl/fl controls. Our lab has 
previously identified a role for endothelial cell-specific LPP3 in maintaining vEC barrier 
function [22]. vEC-specific deletion of Ppap2b increased vascular permeability which could 
be ameliorated with a pan-receptor antagonist BrP-LPA and the ATX inhibitor PF8380 
suggesting that LPA signaling is mediating the LPP3-dependent barrier dysfunction. 
Similar reports on LPA1 and LPA6 suggest that LPA induces vEC barrier dysfunction and 
that siRNAs targeting LPP3 exacerbate the LPA6-dependent cytoskeletal changes in 
HUVEC cells [84]. Considering the role of vEC dysfunction in the development and 
progression of CAD, it is feasible that MX-1Δ mice develop increased lesion formation 
through an LPP3-LPA dependent increase in vEC barrier permeability. Similarly, 
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increased lesion formation in SM22-Δ mice coincided with increased total LPA content in 
the proximal aorta compared to fl/fl controls (Figure 2.16b). Our lab has previously 
identified a role for LPP3 in regulating LPA-dependent SMC migration and proliferation. 
Presumably, the decreases in SMC-LPP3 could confer LPA-dependent migration and 
proliferation of vascular SMCs driving an increase the lesion development in these mice. 
We propose a model of LPP3-dependent protection against the development and 
progression of CAD in mice that is independent of cholesterol and LDLr effects and that 
individuals harboring CAD-associated risk alleles in PPAP2B are at greater risk of disease 
due to a diminished ability to upregulate LPP3 expression (Figure 2.17). 
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Table 2.1 
Global deletion of LPP3 does not affect body weight. Mice were placed on Western 
diet for 12 weeks in order to induce hyperlipidemia and development of atherosclerosis. 
Prior to take down, mouse weights were recorded with respect to sex.  
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Table 2.2 
Global deletion of LPP3 does not alter blood pressure. Blood pressure was recorded 
using the non-invasive CODA® tail-cuff blood pressure system. 25 blood pressure 
readings were taken from each mouse every day for 5 days and averaged. Daily 
averages were then used to determine the average blood pressure reading for each 
mouse. 
57 
Figure 2.1
oxLDL increases LPP3 expression and LPP3-specific phosphatase activity. (A) 
Primary human macrophages were treated with oxLDL (50µg/mL) for 48 hours and LPP3 
protein was determined by Western blotting and normalized to beta-actin. (B and C) LPP3 
was immunoprecipitated from vehicle or oxLDL treated macrophage lysates (n=3 donors 
per condition) and phosphatase activity was determined by LC MS/MS from samples 
incubated with (B) LPA and measuring the generation of MAG or (C) incubating with S1P 
and measuring sphingosine generation.  Data shown are mean ± SEM. *P<0.05 by 
unpaired Student’s t-test. 
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Figure 2.2 
LPP3-positive staining is upregulated in Apoe-/- atherosclerotic lesions. C57BL/6 
wildtype mice and atherosusceptible Apoe-/- mice were fed Western diet for 12 weeks. 
Immunohistochemical staining of aortic roots of type mice and Apoe-/- mice was performed 
with rabbit anti-LPP3 (Left and Middle) or rabbit anti-IgG (Right) as an immunoglobulin 
control. Scale bar = 300µm. 
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Figure 2.3 
LPP3 expression in LDLr-/- mouse atherosclerotic lesions compared to C57BL/6 
mice. (Top) C57BL/6 wild-type mice and (Bottom) Ldlr-/- mice were fed Western diet for 
12 weeks. Aortic root sections were stained for LPP3 (Green) and endothelial marker 
PECAM (Red) as described in Materials and Methods. Scale bar = 100µm. 
60 
Figure 2.4 
LPP3 colocalizes with SMCs, and macrophages, in LDLr-/- mouse atherosclerotic 
lesions. Aortic root sections from Ldlr-/- mice fed Western diet for 12 weeks were stained 
with LPP3 (Green) and macrophage marker CD68 (red; top) or SMC marker smooth 
muscle alpha-actin (Red; bottom) as described in Materials and Methods. Scale bar = 
100µm 
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Figure 2.5 
LPP3 localizes to the apical membrane of aortic endothelial cells. Aortic root sections 
from Ldlr-/- mice fed Western diet for 12 weeks were immunofluorescently stained with 
antibodies to LPP3 (Green) and apical membrane marker podocalyxin (Red) as described 
in Materials and Methods. Scale bar = 100µm 
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Figure 2.6 
LPP3 is abundantly expresesed in porcine atherosclerotic lesions. Aortic root 
sections from Ldlr-/- mice fed Western diet for 12 weeks were immunofluorescently stained 
with antibodies to LPP3 (Green) and SMC marker smooth muscle alpha-actin (Red) as 
described in Materials and Methods. Scale bar = 100µm 
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Figure 2.7 
LPP3 expression in atherosusceptible regions of murine aorta. LPP3 in 
atherosusceptible proximal aorta and atheroprotected thoracic aorta of C57BL/6 wild-type, 
Ldlr-/- and Apoe-/- mice (n=3 tissue from each genotype was pooled) was measured by 
immunoblot analysis (Top). LPP3 at ≈37kD was normalized to beta-actin at ≈42kD as 
described in the Methods and Materials. (Bottom) Western blot quantification normalized 
to beta-actin. Data presented as mean ± SEM.  
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Figure 2.8 
C/EBPβ binding in mouse monocyte cell line RAW264.7 RAW264.7 cells were 
treated with oxLDL (50μg/mL) for 24 hours. Transcription factor binding determined by 
DNA affinity precipitation assay (DNAP) using biotin-labeled oligos for rs72664324 risk 
and protective alleles and rs17114036 risk and protective alleles with nuclear extracts as 
described in Materials and Methods. After DNAP, C/EBPβ (Left) and c-Fos (Right) 
binding was determined with Western blotting. 
65 
Figure 2.9 
Reduced Ppap2b expression in bone marrow and proximal aorta from MX-1Δ mice. 
Ppap2bfl/fl mice without (fl/fl) or with Mx1-Cre transgene (MX-1Δ) on Ldlr-/- background 
were injected with pI:pC (50μL of 10mg/mL) between postnatal days 3 and 5. (A) Bone 
marrow cells were isolated from the femurs of MX-1Δ and fl/fl mice (n=3 of each genotype) 
and qRT-PCR analysis was performed as described in Methods and Materials. Data are 
presented as mean ± SEM. *P<0.05 determined by Students t-test. (B) Following 12 
weeks on Western diet, protein lysates from the proximal aortas of MX-1Δ and fl/fl mice 
were analyzed by Western blotting. LPP3 levels were quantified by normalizing to beta-
actin as described previously. Data are presented as mean ± SEM. P<0.05 determined by 
Students t-test. (C) Aortic root sections fl/fl and MX-1Δ were stained with 
immunofluorescent antibodies to LPP3 (Red) and PECAM (Green) as described in 
Materials and Methods.  
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Figure 2.10 
Global reductions in Ppap2b alter LPP3-specific plasma phospholipid substrates 
but not cholesterol or triglycerides. Peripheral blood was collected from mice via 
retro-orbital vein. (A) Total circulating cholesterol was measured using enzymatic 
colorimetric assays from Wako Diagnostics (n=14 fl/fl; n=15 MX-1Δ). (B) Plasma 
cholesterol (20μg) was separated by size exclusion chromatograph as described in 
Methods and Materials. Cholesterol detected at 600nm is reported (mg/dL) over time 
(seconds) (C) Total plasma triglycerides were measured using enzymatic colorimetric 
assays from Wako Diagnostics (n=7 fl/fl; n=9 MX-1Δ). (D) Plasma lipid content (from 
50μL plasma) was determined using LC MS/MS as previously described (n=15 mice per 
genotype). Data are represented as mean ± SEM. **P<0.01; ***P<0.001 determined with 
Students t-test. 
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Figure 2.11 
Global reduction of LPP3 increases atherosclerotic lesion formation and CD68 
expression in murine aorta. Mice were fed Western diet for 12 weeks (A) 
Atherosclerosis was quantified using the en face technique in proximal aorta (n=12 fl/fl; 
n=14 MX-1Δ). Values are reported as lesion percent of the proximal aorta area (% Arch 
Area). Individual percent and mean ± SEM are presented. (B) Proximal aortas were 
homogenized and subjected to lipid extraction and LC MS/MS as described in materials 
and methods. (C) Gene expression analysis by qRT-PCR from proximal aorta. (D) Aortic 
root sections from MX-1Δ and fl/fl were immunofluorescently stained with antibodies to 
LPP3 (Red), SMA (Blue) and CD68 (Green) as described in Materials and Methods. 
Data are presented as mean ± SEM. *P<0.05 determined by Student’s t-test. 
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Figure 2.12 
LPP3 limits ICAM-1 expression in murine models of atherosclerosis. Mice were fed 
Western diet for 12 weeks. Aortic root sections from MX-1Δ and fl/fl were stained with 
antibodies to ICAM-1 (Green). 
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Figure 2.13 
OxLDL-induces upregulation of Ppap2b in murine macrophages and deletion of 
leukocyte-specific LPP3 does not alter plasma cholesterol. (A) Bone marrow-
derived macrophages were isolated from fl/fl and LysM-Δ mice femurs and cultured as 
described in methods and materials. Macrophages were treated with vehicle, LDL 
(50μg/mL) or oxLDL (50μg/mL) for 48 hours. Expression was analyzed by qRT-PCR for 
(A) Ppap2b. ***P<0.001; ****P<0.0001 determined by two-way ANOVA. (B) Il1b and 
Il12b expression. **P<0.01 determined by Student’s t-test. (C) Total circulating 
cholesterol was measured using enzymatic colorimetric assays from Wako Diagnostics 
(n=9 fl/fl; n=10 LysM-Δ). Data are presented as mean ± SEM. *P<0.05 determined by 
Student’s t-test. (D) Lipids were extracted from 50μL of plasma (n=10 mice per 
genotype) and lipid content was determined using LC MS/MS as previously described. 
Data are presented as mean ± SEM. *P<0.05 determined by Student’s t-test. 
70 
Figure 2.14 
Leukocyte-specific LPP3 does not limit lesion formation in mice but does 
upregulate proinflammatory cytokines in foam cells. Mice were fed Western diet for 
12 weeks. Atherosclerosis was quantified using the en face technique in proximal aorta 
(n=10 fl/fl; n=10 LysM-Δ). Values are reported as lesion percent of the proximal aorta 
area (% Arch Area). Individual percent and mean ± SEM are presented. 
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Figure 2.15 
SMC-specific deletion of Ppap2b does not alter circulating lipids. (A) SMCs were 
isolated from fl/fl and SM22-Δ mice aortas and cultured as described in methods and 
materials. Ppap2b expression was determined by qRT-PCR. (B) Total circulating 
cholesterol was measured using enzymatic colorimetric assays from Wako Diagnostics 
(n=8 fl/fl; n=7 SM22-Δ). (C) Lipid content from 50μL of plasma was determined using LC 
MS/MS as previously described (n=10 fl/fl; n=10 SM22-Δ). Data are presented as mean 
± SEM. 
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Figure 2.16 
SMC-specific LPP3 limits the development of atherosclerotic lesions in mice. Mice 
were fed Western diet for 12 weeks (A) Atherosclerosis is quantified using the en face 
technique in proximal aorta (n=10 fl/fl; n=7 SM22-Δ). Values are reported as lesion 
percent of the proximal aorta area (% Arch Area). Individual percent and mean ± SEM 
are presented. B) Lipid content from proximal aorta determined by LC MS/MS as 
described in Materials and Methods. (C) Proximal aorta gene expression determined by 
qRT-PCR analysis. (D) Aortic root sections from MX-1Δ and fl/fl were stained with 
antibodies to LPP3 (red), SMA (blue) and CD68 (green) as described in Materials and 
Methods. Data are presented as mean ± SEM. P<0.05 determined by Student’s t-test. 
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Figure 2.17 
SMC to foam cell phenotypic switching increases PPAP2B expression in human 
caSMCs. Human caSMCs are treated with vehicle or cyclodextran-cholesterol 
(10μg/mL) for 72 hours. (A, B and C) Gene expression determined by qRT-PCR 
analysis as described in Materials and Methods. Data are presented as mean ± SEM. 
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 determined by Student’s t-test.
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Figure 2.18 
Primary human caSMCs exhibit cholesterol-induced C/EBPβ binding to the CAD-
associated protective allele. Human caSMCs were treated with cyclodextran-
cholesterol (10μg/mL) for 72 hours. DNA affinity precipitation assay (DNAP) was 
performed by incubating biotin-labeled oligos for rs9970807 risk and protective alleles 
and rs72664324 risk and protective alleles with nuclear extracts as described in 
Materials and Methods. After DNAP, C/EBPβ binding was determined with Western 
blotting. 
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Figure 2.19 
Accumulation of oxLDL in atherosusceptible vessel walls stimulates C/EBP binding to 
the SNP region of PPAP2B to drive expression of LPP3. However, presence of the CAD-
associated risk allele impedes this upregulation by breaking C/ETP’s binding motif 
leaving the vessels prone to unchecked inflammation and progression of 
atherosclerosis. 
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Chapter 3: Peripheral Blood does not Upregulate PPAP2B Expression 
Following Acute Myocardial Infarction 
Introduction 
Acute myocardial infarction (acute MI) is a leading cause of morbidity and mortality 
worldwide. Acute MI is said to occur when myocardial ischemia, a lack of blood supply to 
the heart tissue, overwhelms myocardial repair mechanisms that maintain normal 
myocardial cell function and homeostasis ultimately resulting in irreparable ischemia-
induced damage and death of the myocardium most distal to the infarct site. 
Atherosclerotic plaque rupture resulting in the generation of an intracoronary thrombus is 
the most common cause of acute MI [147]. CAD is defined as a narrowing of the coronary 
blood vessels as a result of the accumulation of atherosclerotic plaques. These lipid-laden 
plaques develop throughout life and as early as the first decade in atherosusceptible blood 
vessels and are initiated by the deposition of LDL-C within the tunica intima [52, 53]. LDL-
C is modified to a proinflammatory oxLDL microparticle that triggers vEC activation and 
subsequent recruitment of leukocytes such as monocytes and neutrophils [55, 56]. While 
the role of neutrophils in CAD is uncertain, monocyte/macrophage conversion to foam 
cells is a well-understood phenomenon that generously contributes to the progression of 
disease. As individuals’ age, CAD progresses, and early lesions marked by fatty streaks 
develop into complex atheroma with a highly thrombotic necrotic core laden with oxidized 
lipids underlying a tough fibrous cap that grows into the vessel lumen [51-53]. If rupture 
occurs there is potential for generation of an intracoronary thrombus, with platelet 
deposition, white blood cell accumulation with our without fibrin formation that can 
ultimately result in acute MI. 
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CAD is the leading cause of death in both men and women worldwide and carries with it 
a wide range of risk factors. Modifiable risk factors for CAD include poor nutrition 
(development of type II diabetes), sedentary lifestyle, tobacco use, hypertension and high 
LDL-C [49, 50]. The latter two can be modifiable with appropriate medication. Non-
modifiable risk factors include the male sex, age, and inherited genetic risk. Analyses of 
GWAS have revealed up to 47 distinct genetic risk loci that associate with an increased 
risk of CAD [134]. A meta-analysis published in 2011 identified a genetic risk locus; a 
noncoding SNP termed rs17114036, in the gene PPAP2B conferring an increase in risk 
of CAD [4]. SNPs identified from GWAS are not necessarily the disease-causing locus but 
may merely be in linkage disequilibrium with the culprit polymorphism; therefore 
polymorphisms in close proximity to the GWAS-identified SNP (proxySNPs) in high 
linkage disequilibrium (r2>0.8) should also be considered. Additionally, noncoding SNPs 
implicated in disease may confer their risk through cis-mediated effects on the gene they 
reside or are nearest to, or through trans-mediated effects on genes anywhere else on the 
chromosome.  
PPAP2B encodes LPP3, a member of the LPP family responsible for dephosphorylating 
bioactive phospholipids such as LPA, S1P, C1P, and PA. Our lab has previously identified 
tissue-specific roles for LPP3 in maintaining vEC barrier function [22] as well as limiting 
neointimal hyperplasia following vascular injury [133]. 
In the current chapter we examined expression of PPAP2B in blood cells in healthy 
volunteers and in patients suffering from acute MI. First, we examined LPP3 expression 
in human blood cells. Then, we identified, using publically available microarray data [142, 
148], a proxySNP in linkage disequilibrium with rs17114036 (r2>0.901) that is associated 
with decreased expression of PPAP2B in peripheral blood cells [142]. We failed to observe 
allele-dependent variation in LPP3 expression in neutrophils from volunteers either 
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homozygous or heterozygous for the rs17114036 risk allele. Finally, investigating PPAP2B 
expression in the peripheral blood from patients with acute MI, stable ischemic heart 
disease (SIHD) or healthy volunteers reveals no significant changes in expression among 
the three cohorts.  
Materials and Methods 
Patients and study design 
This study was approved by the University of Kentucky Institutional Review Board 
(Protocol #: 11-0367). Subjects were asked to donate blood for research purposes. 30 – 
50 cc of venous blood was collected by phlebotomy. Normal volunteers were at least 18 
years old were recruited from laboratory and staff personnel by word-of-mouth.   Women 
and minorities were included.  Children were excluded because they are not routinely 
employed as laboratory or staff personnel and because they are not a patient population 
that normally develops CAD.  Individuals with acute MI were recruited from the cardiac 
catheterization laboratory at UK Chandler Medical Center, from the cardiology outpatient 
clinics at the Gill Heart Institute and the UK Good Samaritan Professional Building. 
Patients with SIHD were referred by their treating physician. 
Genotyping of LPP3 rs17114036 polymorphism 
DNA isolated from peripheral whole blood is collected from healthy donors as well as 
patients that have consented to participate in the IRB approved study protocol. DNA was 
isolated from whole blood (300µL) using the Maxwell® 16 Blood DNA Purification Kit 
protocol (Promega Cat# AS1010). Genotyping was performed according to the TaqMan 
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SNP Genotyping Assay for rs17114036 (Life Technologies Cat# 4351379) with an Applied 
Biosystems 7500 Fast Real-Time PCR System, 11.25µL of DNA along with 12.50µL of 
TaqMan Universal Mix (2x) and 1.25µL of 20x SNP assay primers were added to a 
MicroAmp® Fast Optical 96-well reaction plate (Life Technologies Cat#4346906). The 
plate was run using the “SNP Genotyping Assay” configuration on the RT-PCR software. 
Donors were classified as being homozygous for the risk allele (A/A), heterozygous (A/G), 
or homozygous for the protective allele (G/G). 
RNA quantification of PPAP2B from human whole blood 
RNA isolated from peripheral whole blood was collected from healthy donors as well as 
patients. RNA was isolated from whole blood (300 – 500µL) using RiboPure™ RNA 
Purification Blood Kit (Life Technologies Cat# AM1928) protocol. RNA was treated with 
DNase for the removal of DNA contaminates (provided in the RiboPure™ blood kit). 1.0µg 
of RNA was used to generate a cDNA library using the SuperScript® VILO cDNA 
Synthesis Kit (Life Technologies Cat# 11754-050). RNA samples in the SuperScript® 
reaction mix were incubated at 25°C for 10 minutes, 42°C for 60 minutes, and the reaction 
terminated at 85°C for 5 minutes. 1.0µg of cDNA was used for qRT-PCR using primers 
designed for generated a 65bp amplicon in PPAP2B spanning exons 1 and 2 (Life 
Technologies Cat# 4331182 Hs00170359_m1). qRT-PCR was performed on the Applied 
Biosystems 7500 Fast Real-Time PCR System. Transcript copy number of PPAP2B was 
determined using a copy number calibration curve generated using serial dilutions of a 
copy number control designed for the region of PPAP2B for which the aforementioned Life 
Technologies’ primers span as described below. Relative gene expression is quantified 
using the ΔΔCT method using ribosomal 18s as an endogenous control. 
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Generation of a copy number calibration control for qRT-PCR analysis of PPAP2B 
In order to generate an amplicon that was detected by the qRT-PCR primers obtained 
from Life Technologies, oligo primers were designed to cover >70 base pairs in both 
directions starting from the border of exons 1 and 2 of PPAP2B (Operon Forward Primer: 
AACAACAACCCGAGGAGGAG; Reverse primer: GCAGTAAAACCCTCGGTGGT). PCR 
cycle set up: 94°C for 1:00 minute; [94°C for :30; 60° for :30; 72° for :30] x 35 cycles; 72° 
for 2:00 minutes. PCR amplicons generated from this PCR were run on a 1% agarose gel 
at 100mV until the bands were detectable at their expected size of 138bp. The DNA bands 
were cut from the gel and weighed. In a 1.5mL Eppendorf tube, the gel-DNA bands were 
treated with 3 volumes of Qiagen Buffer QG (Qiagen Cat#19063) for 1 volume of gel 
(300µL Qiagen buffer for every 100mg of gel). Samples were incubated at 55°C for 10:00 
minutes with frequent vortexing. Once the gel was dissolved, 1 volume of 100% 
isopropanol was added for every 1 volume of gel and mixed well. The DNA-gel mixture 
was then run through Qiagen quick spin columns 700µL at a time, and finally washed with 
PE Buffer (provided in the QIAquick Gel Extraction Kit Cat#28704). The DNA was eluted 
from the column with 50µL of ddH2O and was quantified via Thermo Scientific Nano Drop 
2000. Calculation of the amplicon copy number in the eluted sample was performed 
assuming that double stranded DNA is 660g/mol/bp. 
Isolation of neutrophils from whole blood 
18 to 20cc of whole blood in ACD was added to a 50mL conical vial containing 12mL of 
6% Dextran. The solution was gently mixed and redistributed into four 15mL conical tubes 
and allowed to sit at room temperature for 45 minutes. Once the red blood cells (RBCs) 
have settled out of solution, the top yellow layer was removed and combined in a 50mL 
conical tube. This fraction was centrifuged at 1,150rpm for 12 minutes using a low braking 
speed at 4°C. The supernatant was discarded, and the pellet resuspended in 12mL of ice 
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cold ddH2O for no more than 30 seconds in order to lyse the RBCs. 4mL of 0.6M KCl was 
added to the solution in order to neutralize the osmotic shock. The volume was increased 
to 50mL using ice cold 1x PBS and centrifuged at 1,300rpm for 6 minutes using a high 
brake at 4°C. The RBC lysis step was repeated with ddH2O and KCl until no more RBCs 
were visible in the pellet after centrifugation. The supernatant was discarded and the pellet 
resuspended in 2.5mL of 1x PBS and kept chilled. 3mL of Ficoll Histopaque 1119 (Sigma 
Aldrich Cat# 11191-100mL) was added to a separate sterile 15mL conical tube. The 
resuspended pellet was carefully layered on top of the Ficoll while tilting the conical tube 
45°. The mixture was centrifuged at 1,500rpm using a low brake for 30 minutes at 4°C. 
The supernatant was discarded leaving the neutrophil pellet. The pellet was resuspended 
in 1mL of 1x PBS in order to perform a cell count. The neutrophil pellet was lysed at a 
concentration of 5.0 x 106 cells/mL in Buffer containing: 50mM Tris Base; 500mM NaCl; 
4mM MgCl2; 1% Triton X-100; 1mM PMSF protease inhibitor. 
Immunoblotting of Neutrophil Protein Lysates 
Protein lysates were treated with PNGase F (New England Biolabs Cat# P0705S) 
according to the manufacturer’s protocol. Protein concentrations were determined with the 
Pierce™ BCA Protein Assay Kit (Cat# 23225) and 20µg of total protein was added to a 
10% polyacrylamide gel and transferred to nitrocellulose membrane. Antibody dilutions 
were as follows: LPP3 (1:200) and beta-actin (1:5,000). As an alternative loading control, 
after the protein transfer, gels were placed in 0.1% coomassie stain overnight and 
destained for 2 hours in 10% acetic acid, 50% methanol and 405 ddH2O. Gels and 
membranes were imaged with a Li-Cor Odyssey Scanner. 
Statistical Analysis 
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was 
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value < 
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0.05 is regarded as significant. ANOVA was used when multiple comparisons were made. 
Statistical analysis was performed using GraphPad Prism 7. 
Results 
Neutrophils express detectable levels of LPP3 
We evaluated LPP3 expression in separate blood fractions and observed that neutrophils 
(PMNs), but not other leukocytes, platelets or red blood cells, express detectable levels of 
LPP3 by Western blot (Figure 3.2a). We also determined LPP3-specific phosphatase 
activity is significantly higher in the PMN fractions compared to the other blood cells by 
immunoprecipating LPP3, incubating the lysates with LPA and measuring the production 
of monoacylglyercol via HPLC MS/MS (Figure 3.2b). 
Similar observations are discussed in Chapter 2 when we looked at LPP3 expression in 
human macrophages treated with vehicle or oxLDL (50µg/mL). Naïve macrophages 
exposed to vehicle show nearly undetectable levels of LPP3 but treatment with oxLDL for 
48 hours resulted in significant increases in expression (Figure 2.1a). 
Rs17114036 proxySNP rs9970807 associates with lower PPAP2B expression in 
leukocytes 
A meta-analysis was published in 2011 that associated a SNP in PPAP2B, rs17114036, 
with CAD. The CARDIoGRAM Consortium reported that the SNP rs17114036, located 
within the final intron of the gene PPAP2B, was highly predictive of CAD (odds ratio 1.17; 
P = 3.81 X 10-19). Based on those observations, we interrogated publically available data 
sets using information obtained with software tools and data available online at 
http://www.sanger.ac.uk/resources/software/genevar/ (details provided in 45 and 
http://compute1.lsrc.duke.edu/softwares/SNPExpress/1_database.php (details provided 
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in 46. Using rs9970807 as a proxy SNP (r2=0.901), we found a significantly lower 
expression of most of the PPAP2B exons in mRNA isolated from peripheral blood 
monocytes from individuals with the risk-associated allele (Table 2.1). In contrast, the 
proxySNP did not associated with altered expression of PRKAA2, encoding the α2 
catalytic sub-unit of AMP-activated protein kinase, which is the closest known structural 
gene to rs17114036 located ~66,000bp from PPAP2B on the opposite strand of the 
chromosome in either blood cells (which express PRKAA2 at low levels), or in skin and 
adipose tissue where the gene is expressed more strongly. We also queried the 
SNPExpress database for an allele-associated change in PCKS9 expression but no 
significant changes were observed in any of the probed exons (Table 2.2). These 
observations support our hypothesis that the major allele of rs9970807, (and therefore, 
the risk allele in rs17114036), is associated with decreased expression of LPP3. 
Individuals homozygous for rs17114036 risk allele show no change in neutrophil-
specific LPP3 
Data from online microarray databases demonstrate a significantly lower level of PPAP2B 
expression in PBMCs associated with rs9970807, a proxySNP in linkage disequilibrium 
with rs17114036. Given the high expression of LPP3 in neutrophils we investigated 
whether individuals homozygous for the CAD-associated risk allele for rs17114036 
express lower levels of LPP3 compared to heterozygote PMNs. 75 volunteers were 
enrolled in the study. The PMN fraction was isolated as described in materials and 
methods and LPP3 expression was determined with Western blot. We were unable to 
detect a difference in LPP3 expression between genotypes with Western blotting (Figure 
2.3). We observed a risk allele frequency of 0.90 and a protective allele frequency of 0.10 
in this cohort. 
Peripheral blood from patients with acute myocardial infarction does not have 
upregulated PPAP2B expression 
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PMNs exhibit high levels of LPP3 expression, but no difference was observed in the tissue 
from volunteers homozygous for the rs17114036 risk allele and those who were 
heterozygous. The microarray database SNPExpress shows risk allele-associated 
decreases in PPAP2B in PBMCs, which include monocytes but not the poly-nucleated 
neutrophils suggesting that the SNP-effect may be cell-specific. As mentioned previously, 
in a collaborative study with Reschen et al., our lab observed an upregulation of PPAP2B 
during the conversion of primary human macrophages to foam cells (Figure 2.1) that 
coincides with a CAD-associated risk allele-dependent variation of PPAP2B expression, 
the details of which were described in greater detail in Chapter 2, further supporting the 
concept of a tissue-specific SNP-effect. Mounting genomic data supports a role for SNP-
mediated PPAP2B expression in increasing an individual’s risk of developing CAD and 
recent collaborative data suggests monocytes can upregulate LPP3 in response to a 
characteristic CAD process; therefore, we hypothesized that PPAP2B expression would 
be upregulated in the blood of patients with acute MI, another critical event in CAD. 
To explore this possibility, we performed a pilot study that enrolled 29 subjects who either 
healthy (n=10), had SIHD (n=10) or presented with acute MI (n=9). Blood was collected 
within 24 hours of presented with MI. The demographics and clinical information on 
subjects are presented in Table 2.3. We were unable to detect LPP3 reliably by Western 
blotting and so we employed gene expression analysis. There was no observable 
difference in PPAP2B expression between the three cohorts determined by qRT-PCR 
using the ΔΔCT method (Figure 2.5).  To eliminate the possibility that comparative 
quantification overlooked any differences in expression we generated a copy number 
standard targeting PPAP2B. qRT-PCR using a standard curve revealed no differences in 
absolute PPAP2B copy number between the three cohorts (Figure 2.6).  We observed a 
risk allele frequency of 0.86 and a protective allele frequency of 0.14 in our pilot study. 
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Discussion 
 
There is a strong heritable component, aside from modifiable lifestyle behaviors, that 
contributes to varying degrees of risk of developing CAD [4, 49, 50, 126, 134]. In 2011 a 
meta-analysis confirmed 10 previously known risk-associated loci as well as identified 13 
novel loci that contribute to an increased risk of disease [4].  Many of the aforementioned 
loci, including rs17114036 in the final intron of PPAP2B, are not found in genes identified 
as traditional risk factors. SNPs identified in GWAS analyses are not necessarily the 
disease-causing loci and may simply represent a haplotype of many SNPs in linkage 
disequilibrium; in fact, rs17114036 is in linkage disequilibrium with roughly 20 SNPs 
(Figure 2.1). We interrogated publically available microarray databases [142, 148] and 
identified rs9970807, a proxySNP to rs17114036 (r2=0.901), as having an allele-
dependent association with decreased PPAP2B expression in blood cells (Table 3.1) that 
was not observed in PCSK9 (Table 3.2). We hypothesized that individuals homozygous 
for the major allele (the risk allele) will exhibit decreased PPAP2B expression and thus 
levels of its respective protein LPP3. We enrolled 75 volunteers in our study that were 
genotyped for the SNP rs17114036 and evaluated levels of LPP3 in their PMNs with 
Western blotting; however, we saw no differences in LPP3 based on the individuals’ 
genotypes (Figure 3.3). Recent evidence leads us to believe that the SNP-effect on 
PPAP2B expression is tissue-dependent and could be observed in models evaluating 
CAD processes such as foam cell formation (Figure 2.1) [135]. A hallmark event in CAD 
is the rupture of the atherosclerotic plaque and subsequent MI; we therefore investigated 
whether PPAP2B expression increases in peripheral blood cells from patients suffering 
acute MI or SIHD relative to healthy controls. We enrolled 29 volunteers to our study and, 
using RNA isolated from their peripheral blood, determined PPAP2B expression levels. 
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We saw no differences in expression among the three cohorts enlisted in our study 
suggesting that PPAP2B is not increased in circulating blood cells of patients with acute 
MI or SIHD (Figure 3.4).  
Data from SNPExpress are derived from peripheral blood mononuclear cells, which are 
mononuclear blood cells such as lymphocytes and monocytes. We looked at LPP3 
expression in blood cells and observed detectable levels exclusively in the neutrophil 
(PMN) fraction and not other leukocytes, platelets or red blood cells (Figure 3.2). Because 
of this observation we investigated LPP3 expression relative to the rs17114036 SNP 
genotype in neutrophils. Lysates from neutrophils show marked variability in LPP3 bands 
on a Western blot likely due to the proteins variable glycosylation coupled with the 
interindividual variation in its expression. We treated lysates bound for a Western blot with 
PNGase F, an amidase that cleaves between the innermost GlcNAc and asparagine 
residues of high mannose, hybrid, and complex oligosaccharides from N-linked 
glycoproteins, effectively removing glycans from LPP3 in order to generate one solid 
quantifiable band at ≈31kDa. However, as mentioned previously, no detectable difference 
was observed between lysates from homozygotes and heterozygotes (Figure 3.3) 
suggesting that a SNP-mediated effect on LPP3 expression is not taking place in the PMN 
fraction.  A sample size determination analysis reveals that a group sample size n=28 for 
both genotypes would be required to achieve 90% power to reject the null hypothesis of 
equal means when the population mean difference is μ1 - μ2 = 0.6 - 0.7 = -0.1 with a 
standard deviation for both groups of 0.2 and with a significance level (alpha) of 0.050 
using a two-sided two-sample equal-variance t-test.  
 
Acute MI is a defining moment in the progression of CAD as it is confers life threatening 
risks to patients both in its acute phase through arrhythmia and sudden cardiac death as 
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well as chronic sustained damage leading to left ventricular dysfunction and heart failure. 
Generation of a thrombus in a coronary artery creates an ischemic environment in the 
surrounding myocardium which immediately begins to necrose resulting in the release of 
several measurable proteins into the circulation such as cardiac troponins T and I, 
myoglobin and CK-MB [149]. Because the CAD-related process of foam cell formation 
evoked upregulation of PPAP2B in monocytes we hypothesized that the gene’s 
expression is also altered in another critical CAD event, MI. We investigated whether 
peripheral blood from patients suffering from acute MI would demonstrate altered 
expression of PPAP2B compared to patients with SIHD or healthy volunteers. Amy Chen 
and I recruited volunteers for this study in accordance to the University of Kentucky IRB 
approved protocol 11-0367 and analyzed PPAP2B expression in the three cohorts. 
Neither comparative qRT-PCR nor absolute copy number qRT-PCR analysis revealed any 
difference in the expression of PPAP2B suggesting that the gene’s expression is 
unaffected following acute MI or in patients with SIHD (Figure 3.4). A sample size 
determination analysis reveals that in a one-way ANOVA study, sample sizes of n=43 for 
each group whose means are to be compared. The total sample of 129 subjects achieves 
90% power to detect differences among the means versus the alternative of equal means 
using an F test with a 0.0500 significance level. The size of the variation in the means is 
represented by their standard deviation which is 10.50. The common standard deviation 
within a group is assumed to be 32.94. Alternatively, the upregulation of LPP3 observed 
in our collaborative efforts with Reschen et al. may be dependent on cholesterol-specific 
effects within vascular tissue and not the blood cells in circulation. One potential drawback 
from this particular study is that we looked at RNA from all peripheral blood cells whereas 
monocyte-specific LPP3 expression was affected upon oxLDL treatment. 
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CAD is the leading cause of death for both men and women worldwide and is 
characterized by the narrowing of coronary arteries due to the accumulation of 
atherosclerotic plaques within the vessel wall. CAD is considered a multi-factoral disease 
involving uncontrolled inflammation, intravascular deposition of lipids, endothelial 
dysfunction and dynamic vessel remodeling; all of which may lead to plaque rupture, 
triggering thrombogenesis and MI.  660,000 Americans suffer from their first MI every year 
and statistics say that 36% of men and 47% of women will die within 5 years of their initial 
MI [150]. Predicting individuals’ risk of developing CAD is imperative to initiating 
preventative care and lifestyle changes that may slow the progression of disease. The 
Framingham Heart Study in 1948 was pivotal in identifying many of the classical risk 
factors that are associated with CAD today. However, in spite of improvements in 
modifiable risk factors, CAD remains the primary cause of death in the United States. CAD 
has a strong heritable component and with the onset of genome-wide sequencing 
technology, our capacity to predict genetically-associated CAD risk has tremendously 
expanded.  In 2016 the number of CAD-risk associated loci is up to 47, many of which are 
not found in genes identified as traditional risk factors. Rs17114036 was identified as a 
noncoding intronic SNP in PPAP2B that incurs an increase in CAD risk [4]. In the study 
presented here we identified, based on publically available microarray data, a decrease in 
PPAP2B expression in PBMCs associated with the risk allele of rs9970807, a proxySNP 
in linkage disequilibrium with rs17114036; additionally, we investigated whether a SNP-
dependent variation in LPP3 expression was detectable in human PMNs; as well as, 
whether peripheral blood from patients with acute MI exhibit altered PPAP2B expression. 
Although no differences were observed in neutrophil-specific LPP3 levels or peripheral 
blood PPAP2B following acute MI, we can rule out the possibility that rs17114036 plays a 
major role in the basal expression of LPP3 in PMNs and that acute MI or SCD contribute 
to changes in PPAP2B expression.  
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Table 3.1 
rs9970807 Associates with Decreased Expression of PPAP2B Exons in PBMCs 
SNPExpress software is downloadable free of charge from Columbia University 
Medical Center’s website and was developed by Dongliang Ge and David Goldstein 
[142]. I performed a real-time association test for PPAP2B and the rs17114036 
proxySNP rs9970807. Output data displays genotype-specific expression of PPAP2B 
exon probes and their respective p-value and beta coefficient of regression. Exon probes 
showing significant (P<0.05) genotype-specific variation in expression are highlighted in 
yellow. 
Exon 
Probe ID 
p-Value 
Beta 
Coefficient 
Transcript 0.5252 6.367 
2414371 0.5693 5.414 
2414373 0.007934 44.45 
2414374 0.001704 60.11 
2414380 1.60E-04 147.5 
2414381 0.1643 -35.21 
2414386 2.44E-04 81.23 
2414387 0.001353 68.95 
2414398 0.009513 188.4 
2414418 9.09E-05 77.81 
2414419 0.3132 37.46 
2414420 0.2352 -78.01 
2414421 0.008217 14.27 
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Table 3.2 
No observable association between rs9970807 and changes in expression of 
PCSK9 Exons in PBMCs 
SNPExpress software is downloadable free of charge from Columbia University 
Medical Center’s website and was developed by Dongliang Ge and David Goldstein 
[142]. I performed a real-time association test for PCSK9 and the rs17114036 proxySNP 
rs9970807. Output data displays genotype-specific expression of PCSK9 exon probes 
and their respective p-value and beta coefficient of regression. None of the exon probes 
displayed significant differences. 
Exon 
Probe ID 
p-Value 
Beta 
Coefficient 
Transcript 0.9126 0.6958 
2337420 0.458 -4.3 
2337421 0.6604 -4.861 
2337422 0.1879 -105.7 
2337423 0.09877 12.06 
2337425 0.8072 -3.246 
2337426 0.1993 -39.41 
2337429 0.4829 -54.96 
2337431 0.7079 2.321 
2337432 0.4198 -16.39 
2337433 0.1557 -23.16 
2337434 0.4395 6.272 
2337435 
241
0.8142 2.69 
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Table 3.3 
 Volunteer Demographics and Clinical History 
Healthy SIHD Acute MI 
Total Volunteers 10 10 9 
Genotype 
A/A 9 9 5 
A/G 1 1 0 
G/G 0 0 1 
Average Age 25.6 67.9 51.9 
Demographics 
Male 6 (60.0%) 9 (90.0%) 5 (55.5%) 
Female 4 (40.0%) 1 (10.0%) 4 (44.4%) 
BMI 23.3 ± 3.8 29.6 ± 1.6 34.9 ± 8.2 
Labs 
Sodium  - 140 ± 4.3 139 ± 4.5 
Creatinine  - 1.3 ± 0.5 0.97 ± 0.3 
Past Medical History 
Hypertension 0 (0.0%) 4 (40.0%) 8 (88.9%) 
Obesity 1 (10.0%) 1 (10.0%) 3 (33.3%) 
Tobacco 0 (0.0%) 0 (0.0%) 6 (66.7%) 
Diabetes 0 (0.0%) 2 (20.0%) 4 (44.4%) 
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Figure 3.1 
SNP Map of PPAP2B: ProxySNPs in linkage disequilibrium (r2 threshold > 0.8) with 
rs17114036 were identified using SNP Annotation and Proxy Search software provided 
by the Broad Institute. Relative SNP locations were determined using NCBI dbSNP 
Short Genetic Variations GeneView. 
94 
Figure 3.2 
LPP3 is primarily expressed in the neutrophil (PMN) fraction in murine blood. (A) 
Western blot analysis of LPP3 in lysates containing 40 mg total protein from the 
indicated cells. M/L = monocyte / lymphocyte fraction. (B) LPA phosphatase activity was 
measured in plasma and isolated blood cells. Results are presented as mean ± SD from 
3 independent experiments. #P < 0.001 by Student’s t-test [133].
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Figure 3.3 
Individuals homozygous for rs17114036 risk allele show no change in 
neutrophil-specific LPP3. Peripheral blood PMNs were isolated from volunteers 
and genotyped for rs17114036 as described in materials and methods. (Top) 
Western blot analysis was performed using antibodies to LPP3 (1:200) and 
(Bottom) quantified by normalizing to coomassie stained band at ≈75kDa. Data are 
presented as mean ± SEM. 
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Figure 3.4 
Peripheral blood from patients with acute myocardial infarction does not 
have upregulated PPAP2B expression. RNA was isolated from volunteer 
peripheral blood as described in materials and methods. (A) Comparative qRT-
PCR showing relative expression of PPAP2B and (B) copy number qRT-PCR 
based on a calibration curve generated from in house PPAP2B standards. Blue 
circles represent samples from volunteers heterozygous for the risk allele and 
orange circles are from samples from those homozygous to the protective allele. 
All other circles are samples from volunteers homozygous for the risk allele. Data 
are presented as mean ± SEM.  
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Chapter 4: Lysophosphatidic Acid Redistributes to Atherogenic 
Lipoprotein Fractions in Hyperlipidemic Mice 
Introduction 
LPA is a potent bioactive lysophospholipid that is found in nearly all eukaryotic tissues and 
biological fluids including the plasma, ascites and bronchoalveolar lavage fluid. Our lab 
and others have observed significant accumulation of LPA in both human and mouse 
atherosclerotic plaques (Figure 4.1). LPA binds to any one of its six known GPCRs (LPA1-
6) and elicits a multitude of responses in nearly every cell type studied [10, 11, 21, 24, 26,
84, 151-153]. LPA receptor signaling has been shown to modify vEC barrier function, SMC 
dedifferentiation, migration and proliferation, and even increase foam cell formation in 
macrophages in vitro. Thus LPA is poised to serve as an important regulator of vascular 
tissue function. Plasma LPA increases in human disease-states from acute MI to ovarian 
cancer. Feeding atherosusceptible Ldlr-/- mice chow diet supplemented with unsaturated 
LPA increases the formation of atherosclerotic lesions compared to saturated LPA or 
regular chow diet alone.  
LPA is carried in plasma bound to proteins, largely albumin, in both human and mice. 
Recent evidence suggests that LPA could associate with atherogenic LDL-C through the 
conversion of its precursor LPC into LPA by the actions of the ENPP2 ATX. ATX is a 
secreted lysophospholipase D found in both human and mouse plasma. Levels of ATX 
correlate with circulating LPA levels, and genetic deletion or pharmacological inhibition of 
ATX decreases circulating LPA, indicating that ATX is the primary determinant of plasma 
LPA levels. LPC has been reported to be a major phospholipid component of LDL-C and 
enzymatic cleavage of its choline head group by ATX generates LPA. The precursor 
molecule to LPC is phosphatidylcholine (PC), which is found in abundance in dairy 
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products as well as red meat. Feeding Western diet significantly increases unsaturated 
LPA species 20:4 in the plasma of Ldlr-/- mice.  
To investigate the dietary contribution to circulating LPA levels, C57BL/6, Apoe-/- and Ldlr-
/- mice were fed either chow or Western diet for 3 weeks or 12 weeks. Western diet feeding 
Apoe and Ldlr mice increased LPA in the plasma fractions containing low-density 
atherogenic associated VLDL-C and LDL-C which was not observed in C57BL/6 mice. 
Globally reducing LPP3, the enzyme responsible for hydrolyzing LPA, increases total 
plasma LPA without altering LPA levels between lipoprotein and protein fractions in the 
plasma. 
Materials and Methods 
Animals 
All procedures conformed to the recommendations of Guide for the Care and Use of 
Laboratory Animals (Department of Health, Education and Welfare publication number 
NIH 78-23, 1996), and were approved by the Institutional Animal Care and Use 
Committee. C57BL/6, Apoe-/- and Ldlr-/- mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). MX-1Δ and fl/fl mice were generated as described in Chapter 3 
Materials and Methods. Mice were housed in cages with HEPA-filtered air in rooms on 12-
hour light cycles, and fed Chow diet or RD Western Diet (Research Diets Cat#D12079B) 
ad libitum for specified time points. 
Isolating Plasma from Peripheral Blood in Mice 
In the morning, peripheral whole blood was collected from mice via the retro-orbital vein 
while mice were anesthetized with isoflurane. Whole blood was collected in a 1.5 mL 
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Eppendorf tube containing 10 µL of 0.5 M EDTA and 50 µL CTAD (BD Vacutainer Ref# 
367947). Blood samples were centrifuged at 12,000 rpm for 4 minutes and the plasma 
fraction collected. Samples were placed on dry ice and subsequently stored at -80°C. 
Measuring Total Cholesterol and Lipoprotein Cholesterol Distributions in Murine 
Plasma 
Total plasma cholesterol was measured using the Wako Diagnostics Cholesterol E Assay 
(Wako Diagnostics Cat#439-175001) according to the manufacturer’s protocol. Plasma 
lipoprotein cholesterol distributions were determined via fast-performance liquid 
chromatography (FPLC). In short, 40µL of plasma from mice, diluted to a concentration of 
1µg/µL of total plasma cholesterol, was injected on to a Superose6 FPLC column. 
Cholesterol concentrations are determined by enzymatic colorimetric assay (Wako 
Diagnostics) reading at 600nm as the elute flows off of the column. 
Measuring Phospholipid Content in Murine Plasma 
50 µL of plasma was added to 450 µL of 0.1 M HCl and underwent lipid extraction as 
previously described in “Lipid extraction for analysis via mass spectroscopy” 
FPLC Fractionation of Plasma for Determination of LPA 
40µL of plasma from mice was injected into a Superose 6 HPLC column at a flow rate of 
0.4mL/minute. Fractions were collected between 18 and 48 minutes and subjected to lipid 
extraction as described below. 
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Lipid extraction for analysis via mass spectroscopy 
500µL of sample in 0.1M HCl were added to a 12mL glass lipid extraction tube containing 
1mL of chloroform, 2mL of methanol, and 50µL of 1µM D7-sphingosine-1-phosphate as 
an internal standard. Samples in the lipid extraction tubes were vortexed for 5 minutes, 
and then placed on ice/kept at 4°C for at least 1 hour. 1mL of chloroform and 1.3mL of 
0.1M HCl was added to the lipid extraction tubes and vortexed again for 5 minutes. The 
samples were centrifuged at 3,000rcf for 10 minutes at room temperature, and the lower 
aqueous phase was transferred to 4mL screw cap glass tube using a Pasteur pipette being 
careful not to include the protein interphase. Samples were evaporated to dryness using 
nitrogen in an N-evap under a fume hood. Once the samples were completely dried, 100µL 
of methanol was added and the tubes were vortexed. Samples sat at room temperature 
for 10 to 15 minutes and then transferred to an autosampler insert vial for analysis via 
Agilent Zorbax C8 column and quantified by tandem mass spectrometry using an ABI 
4000 QTrap hybrid linear ion trap triple quadrupole mass spectrometer. The mass 
spectrometer was operated in selective reaction monitoring mode to measure lipid species 
specific precursor product ion pairs with quantification accomplished by reference to 
calibration curves generated using synthetic standards obtained from Avanti Polar Lipids 
that were independently quantitated by phosphorous analysis as described previously. 
Statistical Analysis 
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was 
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value < 
0.05 is regarded as significant. Two way ANOVA was used when multiple comparisons 
were made. Statistical analysis was performed using GraphPad Prism 7.
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Results 
Cholesterol-rich diet increases circulating LPA in hyperlipidemic mouse models 
We placed C57BL/6 wild-type, hyperlipidemic Apoe-/- and Ldlr-/- mice on normal chow and 
Western diet for 3 weeks or 12 weeks. As expected, total plasma cholesterol were 
elevated in the hyperlipidemic Apoe-/- and Ldlr-/- mice and increased upon Western diet 
feeding for 3 weeks as well as 12 weeks (Figure 4.2a). Total plasma LPA was 75% higher 
in the hyperlipidemic mice on chow diet and nearly 4-fold in Apoe-/- and Ldlr-/- on Western 
diet for 3 weeks compared to levels in C57BL6 wild-type control on the same diet. (Figure 
4.2b). 
Hyperlipidemia increases unsaturated LPA levels in fractions containing 
atherogenic lipoproteins in mice 
LPA is primarily bound to plasma proteins in mice and humans; however, its precursor 
LPC is a major phospholipid component of lipoproteins in humans. We investigated 
whether hyperlipidemia changed the plasma LPA content in the atherogenic-lipoproteins. 
For the analysis, plasma was separated by size exclusion chromatography and fractions 
were subjected to LC MS/MS to measure LPA content. 
C57BL/6 and Apoe-/- mice show LPA content localized primarily in the late fractions 16 to 
21 containing HDL-C or plasma proteins whereas Ldlr-/- plasma show small increases in 
fractions 1 to 10 that typically contain LDL-C (Figure 4.3 top). Western diet feeding for 3 
weeks results in a dramatic increase in LPA in plasma fractions containing LDL-C in 
hyperlipidemic mice. The wild-type control plasma looks similar to its chow fed 
counterpart. Apoe-/- and Ldlr-/- mouse plasma shows substantial increases in fractions 1 
through 6 that contain the atherogenic VLDL-C and LDL-C (Figure 4.3 bottom). C57BL/6 
mice fed Western diet for 12 weeks show only modest increases in total cholesterol 
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compared to 3 weeks or chow diet (Figure 4.2a). Prolonged feeding of Western diet alters 
the LPA content in the lower density fractions in C57BL/6 mice; specifically the 
unsaturated LPA content (percent of total). The majority of LPA content in chow fed wild-
type mice is found in fractions 18 to 23 but increases in fractions 13 to 18 in mice fed 
Western diet for 12 weeks (Figure 4.4). 
Although LPA increases in fractions typically containing atherogenic-associated LDL-C in 
hyperlipidemic mice, we cannot say with certainty that these fractions contain their 
predicted LDL-C. Using size exclusion chromatography we simultaneously measured 
plasma total cholesterol (mg/dL) as it eluted out of the column with an enzymatic 
colorimetric assay as described in the Materials and Methods. Overlaying the cholesterol 
distribution curve with the corresponding time in which each fraction is collected, we see 
a tight overlap of LPA content with the total plasma cholesterol (Figure 4.5). 
Global reduction of LPP3 does not alter plasma-LPA localization 
LPP3 is a member of the LPP family of phosphatases who dephosphorylate LPA and limit 
LPA receptor signaling. Our lab has previously shown that endothelial cell-specific deletion 
of LPP3 results in a significant LPA-dependent decrease in vEC barrier function [22] 
suggesting that the phosphatase plays a role in limiting LPA-induced vEC permeability. In 
Chapter 3 I reported that the global LPP3-deficient MX-1Δ mice fed Western diet have 
significantly increased lesion formation compared to fl/fl control mice (Figure 211a)  that 
coincides with increased circulating plasma LPA (Figure 2.10d) as well as increased LPA 
in the proximal aorta (Figure 2.11b). We hypothesized that global reductions in LPP3 
would lead to increased LPA content in the plasma fractions containing LDL-C compared 
to fl/fl controls. 
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Plasma from MX-1Δ and fl/fl mice was separated by size exclusion chromatography as 
previously described and LPA content was determined with LC MS/MS. As expected we 
observed increased total LPA content in plasma from MX-1Δ mice compared to fl/fl 
controls (Figure 4.6); however, we were unable to detect any differences in the LPA 
content from fractions containing LDL-C (Figure 4.7). 
Discussion 
LPA accumulates in human atheroma and hyperlipidemic Apoe and Ldlr mice fed Western 
diet for weeks (Figure 4.1a). Interestingly, we observed dramatic increases in unsaturated 
LPA species 18:1, 20:3, 20:4, 20:5, 22:5 and 22:6 in hyperlipidemic mouse atheroma 
compared to saturated 16:0 and 18:0 species which were still increased but not to the 
same extent (Figure 4.1b). ApoE-/- and Ldlr-/- mice fed chow diet have increased 
cholesterol and total LPA compared to C57BL/6 controls fed the same diet (Figure 4.2). 
Feeding Western diet for 3 weeks dramatically increases plasma cholesterol and total LPA 
content in hyperlipidemic mice compared to wild-type controls (Figure 4.2b). Plasma LPA 
from wild-type mice and Apoe-/- fed chow diet was observed in fractions containing HDL-
C and plasma proteins (Figure 4.3). Ldlr-/- mice fed chow diet have LPA content in fractions 
containing HDL-C and plasma proteins, but also have slight increases fractions 1 through 
10 containing LDL-C (Figure 4.3). Feeding Western diet for 3 weeks increases plasma 
LPA content in fractions 1 through 10 in hyperlipidemic mice but not wild-type mice 
suggesting increased LPA association with LDL-C. Interestingly, the unsaturated LPA 
content is markedly increased in hyperlipidemic plasma fractions that contain LDL-C 
compared to saturated LPA. While wild-type mice show only modestly increased total 
plasma LPA content and no increase in LPA content in fractions containing LDL-C (Figure 
4.3), feeding C57BL/6 mice Western diet for 12 weeks increases the proportion of plasma 
LPA content in lower density fractions 13 to 18 whereas LPA content is primarily found in 
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fractions 18 to 23 in chow fed mice. Additionally, we demonstrated that the plasma 
cholesterol distribution overlaps with the collected fractions used for determined LPA and 
increased LPA content in fractions 1 through 10 of hyperlipidemic mice correlates with 
sharp increases in plasma cholesterol (Figure 4.5). Finally, we show that while global 
reductions in LPP3 increases total plasma LPA it does not increase LPA content in 
fractions containing LDL-C relative to control mice. 
The Increased accumulation of unsaturated LPA in fractions containing LDL-C in 
hyperlipidemic mice (Figure 4.3) is interesting in the context of atherosclerosis. Navab et 
al., demonstrates that intestinally-derived unsaturated, but not saturated, LPA increases 
atherosclerotic lesion formation in Ldlr-/- mice [123]. Navab et al.’s observations are also 
supported in a study published by Zhou et al., where i.v. administration of 20:4 unsaturated 
LPA, but not 18:0 saturated LPA, increased atherosclerotic lesion formation in Ldlr-/- mice, 
which could be inhibited with LPA1/3 antagonist Ki16425 [14]. In the latter study, 
unsaturated LPA administration coincided with increased CD68 positive staining in 
atheromas and upregulation of vEC adhesion molecule CXCL1. Wild-type mice fed 
Western diet for 12 weeks resulted in an increase in LPA content, specifically the 
unsaturated species, into the lower density plasma fractions 13 to 18 suggesting that 
LPA’s association with fractions containing LDL-C in the plasma can be affected by diet 
and not solely through hyperlipidemia. In either case, it is feasible that a cholesterol-
enriched diet leads to increases in unsaturated LPA accumulation in circulating LDL-C 
that is deposited within the vessel wall and propagates LPA receptor signaling to drive 
multi-tissue dysfunction and lesion formation. 
Limitations of this study heed further investigation and lacks some important physiological 
read-outs. For instance total triglyceride measurements would be helpful in the 
interpretation of Figure 4.4 in which C57BL6 mice were fed Western diet for 12 weeks. 
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The LPA distribution shifts to the lower density fractions which cannot be attributed to an 
increase in cholesterol. Perhaps an increase in circulating triglycerides could account for 
differences between chow and Western diet fed LPA distributions. Likewise I did not 
perform an analysis of the total LPA in the mice represented in Figure 4.4 that would be 
useful in determining there was change in absolute LPA between chow diet and prolonged 
Western diet administration. Lastly, while we are able to demonstrate that the cholesterol 
distribution in plasma correlates with the fractions we are collecting and associating with 
LPA we still have not shown physical LPA-LDL-C binding in these fractions. To address 
this point Dr. Fred Onono has performed immunoprecipitation of ApoB from human 
plasma and determined LPA content using LC MS/MS. He observed that 10 to 65% of 
total circulating LPA is physically associated with the LDL-C protein ApoB depending on 
whether the individual was in a fed or fasted state (Data not shown). 
To summarize, Western diet fed hyperlipidemic mice demonstrate dramatic increases in 
LPA content in the LDL-C plasma fractions relative to their chow fed counterparts and 
specifically in the unsaturated species suggesting that LPA in hyperlipidemic models may 
be bound to LDL-C and could elicit a multitude of effects on the vasculature via LPA 
receptor signaling. Additionally, LDL-C may in fact be a source of not just LPC, but also 
LPA in atherosclerotic lesions that would be supported by our observation of increased 
unsaturated LPA species in murine lesions. Aside from models of hyperlipidemia, 
unsaturated LPA content in the LDL-C plasma fractions are affected by prolonged 
administration of cholesterol-enriched diet which may be of relevance considering recent 
investigations by Zhou et al., and Navab et al. demonstrating a role for both circulatory 
and intestinally-derived unsaturated LPA in increasing atherosclerotic lesion formation in 
mice. 
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Figure 4.1 
LPA accumulates in human and murine atheroma. Human atheroma and mouse 
proximal aortas were subjected to lipid extraction to determine LPA concentrations. LPA 
presented as pmol and normalized to 10 nmol of phosphate calculated using a 
phosphate binding protein assay (abcam). Human atheroma and chow diet fed mouse 
samples are represented in blue while Western diet fed mouse samples are represented 
in red. Data are presented as mean ± SD. *P<0.05 
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Figure 4.2 
Total plasma LPA increases in hyperlipidemic mice fed Western diet. C57BL/6 
(blue), Apoe-/- (red), and Ldlr-/- (green) mice were fed normal chow or Western diet for 3 
or 12 weeks. (A) Total plasma cholesterol (mg/dL) from three cohorts (n=5 for each 
genotype). (B) Total plasma LPA (µmols) determined with HPLC MS/MS from mice fed 
normal chow and Western diet for 3 weeks (n=5 for each genotype). Data are presented 
as mean ± SEM.  
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Figure 4.3 
Western diet induces the redistribution of LPA in plasma of hyperlipidemic mice. 
C57BL/6, Apoe-/-, and Ldlr-/- mice were fed (Top) normal chow or (Bottom) Western diet 
for 3 weeks. Plasma was injected into a FPLC column and fractionated as described in 
methods and materials. Plasma LPA (pmol/Fraction) is presented as total LPA (yellow), 
saturated LPA (red) and unsaturated LPA (green). 
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Figure 4.4 
Prolonged Western diet feeding shifts plasma LPA to lower density fractions in 
wild-type mice. C57BL/6 mice were fed (Top) normal chow (n=3) or (Bottom) Western 
diet (n=3) for 12 weeks. Plasma was injected into a FPLC column and fractionated as 
described in Methods and Materials. Plasma LPA (% of total) is represented as total LPA 
(yellow), saturated LPA (red) and unsaturated LPA (green). Data are presented as mean 
± SEM. 
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Figure 4.5 
Plasma LPA fractions correlate with total cholesterol curves. Representative image 
of LPA (pmol/fraction) and plasma cholesterol (mg/dL) from MX-1Δ mouse plasma. 
Plasma was injected into a FPLC column and fractionated as described in Methods and 
Materials. Cholesterol concentration was determined using enzymatic colorimetric assay 
reading at 600nm as the elute flows off of the column. LPA fractions are given at their 
respective time of collection during the fractionation process. 
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Figure 4.6 
Global reduction of LPP3 does not alter plasma LPA distribution. (Top) fl/fl (n=2) 
and (Bottom) MX-1Δ (n=5) mice were fed Western diet for 12 weeks. Plasma was 
injected into a FPLC column and fractionated as described in methods and materials. 
Plasma LPA (pmol/Fraction) is represented as total LPA (yellow), saturated LPA (red) 
and unsaturated LPA (green). Data are presented as mean ± SEM.  
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Figure 4.7 
LPA species subtype does not change with global reductions in LPP3. ) MX-1Δ 
(n=5) mice were fed Western diet for 12 weeks. Plasma was injected into a FPLC 
column and fractionated as described in methods and materials. LPA (pmol/Fraction) 
from MX-1Δ (red) and fl/fl (black) mice was compared based on species: (Top) Total 
LPA, (Middle) saturated LPA and (Bottom) unsaturated LPA. Data are presented as 
mean ± SEM. 
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Chapter 5: Discussion 
So far this dissertation has provided a detailed discussion on mechanisms of 
atherosclerosis and proposes a role for the ATX-LPA-LPP3 signaling axis in the 
development and regulation of disease. I provide evidence that LPP3 expression limits 
lesion formation in murine models of atherosclerosis and that CAD-associated risk loci 
within PPAP2B decrease its expression in a cis-manner. Finally, I demonstrate LPA 
content increases in plasma fractions containing LDL-C in hyperlipidemic mice on a 
cholesterol-enriched diet. In this chapter I will review data presented in this dissertation 
and discuss the overarching potential for CAD-associated risk alleles to limit PPAP2B 
expression in atherosclerosis driving local increases in LPA signaling that may be 
exacerbated based on a diet. 
CAD-associated risk loci decrease PPAP2B expression in a cis-manner 
In Chapter 2 I present data that our lab generated in collaboration with Reschen et al. that 
demonstrates upregulation of LPP3 protein in human foam cells that is absent in naïve 
vehicle treated macrophages (Figure 2.1). These data support observations from the 
Oxford group that the CAD-associated SNP rs72664324 diminishes the ability of 
macrophages to upregulate PPAP2B expression upon exposure to oxLDL by breaking a 
C/ETP binding motif. In fact, when macrophages were treated with oxLDL Reschen et al. 
observed open chromatin site remodeling in the region of PPAP2B that harbors 
rs72664324 using FAIRE-seq. rs72664324 is a proxySNP in linkage disequilibrium with 
rs17114036 and is in a C/EBP CCAAT binding motif. Presence of the protective allele 
(A) facilitates the transcription factor binding and subsequent expression of PPAP2B; 
however, presence of the risk allele (G) disrupts this motif resulting in the diminished 
upregulation of PPAP2B as described above. Their study reveals a mechanism for 
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PPAP2B upregulation in a key cellular process in atherosclerosis that is limited by a cis-
acting CAD-associated risk allele in rs72664324. 
I present additional evidence in Chapter 3 that CAD-associated risk alleles are acting in a 
cis-manner on PPAP2B. I searched a publically available database for microarray data 
looking at SNP-mediated effects on gene expression. Table 3.1 contains PPAP2B exon 
probes that displayed significant decreases in expression associated with the risk allele of 
rs9970807, another proxySNP in linkage disequilibrium with rs17114036. The CAD-
associated risk loci are found on chromosome 1; interestingly, PCSK9 is also found on 
chromosome 1 and is considered a master regulator of cholesterol and, as such, is highly 
implicated in the development of CAD. To rule out that risk loci in PPAP2B are not 
conferring increased risk of disease by modifying PCSK9 transcript levels in a trans-
manner, I searched the database for the same SNP-mediated effects on PCSK9 
expression. Table 3.2 contains PCSK9 exon probes; however, unlike PPAP2B, the 
PCKS9 exon probes expression were unaffected by the presence of rs9970807. This 
suggests that CAD-associated risk alleles are, in relation to PCSK9, not acting in a trans-
manner but do regulate PPAP2B expression in cis. 
It is worth mentioning that a study published by Erbilgin et al. also demonstrates risk allele-
dependent decreases in PPAP2B expression in HAECs. Taking these data together, CAD-
associated risk alleles identified within PPAP2B are capable of regulating PPAP2B’s 
expression in a cis-manner and demonstrate no trans-mediated effects on PCSK9 
expression. 
Ppap2b expression limits lesion formation in murine models of atherosclerosis 
In Chapter 2 I provide evidence that LPP3 expression increases in murine models of 
atherosclerosis that is not observed in healthy vasculature (Figure 2.2 through 2.7). We 
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also demonstrated the same C/ETP binding to rs72664324 in a macrophage mouse line 
RAW264.7 that was observed in human macrophages by Reschen et al. These data 
suggest that atherosclerotic vessels upregulate LPP3 in response to disease. 
We next generated a murine model of atherosclerosis with global leukocyte-specific and 
SMC-specific reductions in LPP3. Our inducible global Ppap2b knockout mice had a 30% 
increase in atherosclerotic lesion formation compared to fl/fl control mice (Figure 2.11a) 
despite no differences in plasma cholesterol (Figure 2.10a). Increased atherosclerosis 
coincided with increased plasma LPA (Figure 2.10d) as well as an accumulation of LPA 
within the proximal aortas of MX-1 mice compared to their controls (Figure 2.11b). 
Interestingly, increased Cd68 expression was observed in the proximal aortas determined 
by qRT-PCR (Figure 2.11c) that is supported by increased positive CD68 staining in aortic 
root lesions (Figure 2.11d). ICAM-1 staining was also dramatically higher in MX-1 aortic 
root lesions compared to fl/fl mice suggesting an increase in the vEC adhesion molecule 
(Figure 2.12). We detected no differences in lesion formation in the leukocyte-specific 
deletion of Ppap2b (Figure 2.14); however BMDMs from LysM- mice have increased 
proinflammatory Il1b and Il12b expression compared to fl/fl control cells (Figure 2.13b). 
This observation suggests that while leukocyte-derived LPP3 may be insufficient to confer 
protection against lesion formation, it is important in limiting inflammation. Finally, we 
observed increased lesion formation in mice deficient in SMC-derived LPP3 (Figure16a) 
despite, again, no differences in plasma cholesterol (Figure 2.15b). Proximal aortas from 
mice deficient in LPP3 from SMCs show significantly higher LPA content (Figure 2.16b) 
as well as Il6 expression (Figure 2.16c) and their aortic root lesions have increased CD68 
expression (Figure 2.16d) similar to what was observed in the global LPP3 knockouts. 
Chapter 2 provides evidence that SMCs also upregulate PPAP2B in response to 
cholesterol loading (Figure 2.17b). This is an interesting observation considering data 
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generated in our collaboration with Reschen et al., that macrophages upregulate LPP3 in 
response to oxLDL-induced foam cell formation. Recent evidence proposes that SMCs 
make up nearly 50% of foam cells present in atherosclerotic plaques, and therefore their 
PPAP2Bs role in their phenotypic conversion may be an interesting cellular mechanism to 
investigate. 
Global reductions in LPP3 in our murine model resulted in increased expression of Cd68 
in proximal aortas. CD68 positive staining in the aortic root lesions of MX-1 and SM22- 
mice were also increased compared to their respective controls. This observation can be 
explained by the simple fact that a larger lesion size suggests more foam cells. 
Alternatively, as is suggested by the increased ICAM-1 staining in MX-1 lesions, there 
could be an increased propensity for leukocyte infiltration into the vessel wall when LPP3 
is absent. This latter hypothesis would have to be investigated with cell sorting using 
FACS. Liping Yang from our lab has preliminary data that aorta from SM22- mice do 
have increased CD68 positive cells compared to fl/fl controls but more experiments should 
be carried out to confirm this observation. Our lab has previously shown that mice with 
targeted inactivation of LPP3 in their endothelial cells have decreased endothelial barrier 
function [22] and increased vEC permeability increases leukocyte infiltration into vessels 
and increases lesion formation [154]. In our model of LPP3-dependent vascular barrier 
function, the increased endothelial permeability in LPP3-deficient mice could be 
attenuated with an ATX inhibitor or a LPA receptor pan antagonist suggesting that LPA 
signaling is regulating the observed phenotype. LPA signaling has been shown to regulate 
vEC barrier function before and could provide a mechanism for increased atherosclerotic 
lesion formation in these mice. 
Myeloid cell-specific deletion of LPP3 did not increase the development of atherosclerotic 
lesions in mice suggesting that the phosphatase in macrophages in not important in 
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protecting mice from disease (Figure 2.14). However, another way to interpret the data is 
that the expression of LPP3 from macrophages is insufficient to confer protection 
compared to the overall net expression of the phosphatase in lesion cells. As discussed 
in “Chapter 1: Structure and Function of the LPPs”, LPP3 homologs are capable of 
generating phospholipid gradients and thus affecting cells upwards of 33µm away [132]. 
It is feasible then that LPP3 expressed in SMCs (as well as other lesion cells not of myeloid 
lineage) in the LysM- mice is capable of conferring protection to lesion development by 
affecting cell types in a paracrine or non-autonomous manner, possibly through the 
regulation of LPA or other phospholipid substrates. However, in both the global and the 
SMC-specific models of LPP3 deficiency, enough of the phosphatase has been knocked 
out to abrogate the non-autonomous manner of protection. 
LPA content increases in plasma fractions containing LDL-C in hyperlipidemic 
mice 
I present preliminary evidence in Chapter 4 that LPA content increases in plasma fractions 
containing LDL-C in hyperlipidemic mice. Previously, LPA was found primarily bound to 
plasma proteins; however its precursor molecule, LPC, is known to be a major 
phospholipid component of plasma lipoproteins [155]. Interestingly, unsaturated LPA 
content demonstrates large increases in the plasma fractions containing LDL-C from 
Apoe-/- and Ldlr-/- mice fed Western diet for 3 weeks (Figure 4.3). Unsaturated LPA has 
been shown to increase atherosclerotic lesion formation in several investigations [14, 123] 
and its increase in LDL-C would propose a mechanism in which atherogenic LPA species 
are introduced into the vessel wall with LDL-C deposition. 
Overview 
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In this dissertation I present a model for LPP3 in limiting the lesion formation in murine 
models of atherosclerosis which supports our hypothesis that CAD-associated risk loci in 
PPAP2B are acting in a cis-mediated fashion to diminish LPP3 expression in individual’s 
homozygous for the risk alleles (Figure 5.1). LPP3 plays a protective role in the 
development and progression of atherosclerosis by limiting LPA signaling in the vessel 
wall, resulting from deposition of LDL-C carrying atherogenic unsaturated LPA, and 
individuals who are unable to upregulate PPAP2B in response to atherosclerotic stimuli 
are at increased risk of CAD. 
120 
Figure 5.1 
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Figure 5.1 (Caption) 
Proposed model for ATX –LPA–LPP3 nexus in atherosclerosis and it complications. 
Top, At least a portion of circulating ATX may derive from adipose tissue. Middle, ATX -
derived LPA has potent effects on several blood and vascular cells that could potentially 
contribute to biological events that underlie atherosclerosis. In addition, atherosclerotic 
plaque is enriched in LPA. Bottom, Circulating and secreted ATX may interact with 
integrins and through non–integrin-mediated mechanisms to generate a local gradient of 
LPA. ATX contains a catalytic phosphodiesterase (PDE) domain, a nuclease like (NUC) 
domain and integrin binding somatomedin B like (SMB) domains. LPA signaling through 
G-protein–couple receptors LPA1–6 and possible receptor for advanced glycan end 
products (RAGE) may be terminated by enzymatic dephosphorylation catalyzed by 
LPPs. Whether ATX promotes and LPP3 suppresses atherosclerosis remains to be 
established. Illustration by Matt Hazzard, University of Kentucky, Information 
Technology. LDL indicates low-density lipoprotein; LPC, lysophophosphatidyl choline; 
and lyso-PLD, lysophospholipase D [156]. 
122 
References 
1. Compressed mortality file: underlying cause of death 1999–2013. 2016, Centers
for Disease Control and Prevention: Atlanta, GA: Centers for Disease Control and
Prevention.
2. Mozaffarian, D., et al., Heart Disease and Stroke Statistics-2016 Update: A Report
From the American Heart Association. Circulation, 2016. 133(4): p. e38-e360.
3. Mozaffarian D, B.E., Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de
Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez
MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid
DJ, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K,
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh
RW, Turner MB, Heart Disease and Stroke Statistics -- 2016 Update: a report from
the American Heart Association. Circulation, 2016. 133(4): p. e38-e360.
4. Schunkert, H., et al., Large-scale association analysis identifies 13 new
susceptibility loci for coronary artery disease. Nat Genet, 2011. 43(4): p. 333-8.
5. Choi, J.W., et al., LPA receptors: subtypes and biological actions. Annu Rev
Pharmacol Toxicol, 2010. 50: p. 157-86.
6. Blaho, V.A. and T. Hla, Regulation of mammalian physiology, development, and
disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.
Chem Rev, 2011. 111(10): p. 6299-320.
7. Moolenaar, W.H. and T. Hla, SnapShot: Bioactive lysophospholipids. Cell, 2012.
148(1-2): p. 378-378.e2.
8. Tigyi, G., Physiological responses to lysophosphatidic acid and related glycero-
phospholipids. Prostaglandins Other Lipid Mediat, 2001. 64(1-4): p. 47-62.
9. Tigyi, G., Preface to the special issue: Lysophospholipids in health and disease.
Biochim Biophys Acta, 2008. 1781(9): p. 423.
10. Panchatcharam, M., et al., Lysophosphatidic acid receptors 1 and 2 play roles in
regulation of vascular injury responses but not blood pressure. Circ Res, 2008.
103(6): p. 662-70.
11. Subramanian, P., et al., Lysophosphatidic Acid Receptors LPA1 and LPA3
Promote CXCL12-Mediated Smooth Muscle Progenitor Cell Recruitment in
Neointima Formation. Circulation Research, 2010. 107(1): p. 96-105.
12. Pamuklar, Z., et al., Individual heterogeneity in platelet response to
lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler
Thromb Vasc Biol, 2008. 28(3): p. 555-61.
13. Haseruck, N., et al., The plaque lipid lysophosphatidic acid stimulates platelet
activation and platelet-monocyte aggregate formation in whole blood: involvement
of P2Y1 and P2Y12 receptors. Blood, 2004. 103(7): p. 2585-92.
14. Zhou, Z., et al., Lipoprotein-derived lysophosphatidic acid promotes
atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab, 2011.
13(5): p. 592-600.
15. Mueller, P., et al., Lysophospholipid mediators in the vasculature. Exp Cell Res,
2015. 333(2): p. 190-4.
16. Sen, S., R.R. Smeby, and F.M. Bumpus, Antihypertensive effect of an isolated
phospholipid. Am J Physiol, 1968. 214(2): p. 337-41.
17. Vogt, W., Pharamacologically active acidic phospholipids and glycolipids. Biochem
Pharmacol, 1963. 12: p. 415-20.
123 
18. Aoki, J., A. Inoue, and S. Okudaira, Two pathways for lysophosphatidic acid
production. Biochim Biophys Acta, 2008. 1781(9): p. 513-8.
19. Contos, J.J., et al., Requirement for the lpA1 lysophosphatidic acid receptor gene
in normal suckling behavior. Proc Natl Acad Sci U S A, 2000. 97(24): p. 13384-9.
20. Althoff, T.F., et al., Procontractile G protein-mediated signaling pathways
antagonistically regulate smooth muscle differentiation in vascular remodeling. J
Exp Med, 2012. 209(12): p. 2277-90.
21. Tager, A.M., et al., The lysophosphatidic acid receptor LPA1 links pulmonary
fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat
Med, 2008. 14(1): p. 45-54.
22. Panchatcharam, M., et al., Mice with targeted inactivation of ppap2b in endothelial
and hematopoietic cells display enhanced vascular inflammation and permeability.
Arterioscler Thromb Vasc Biol, 2014. 34(4): p. 837-45.
23. Zhao, J., et al., Lysophosphatidic acid receptor 1 antagonist ki16425 blunts
abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
Transl Res, 2015. 166(1): p. 80-8.
24. Contos, J.J.A., et al., Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4)
Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without
Obvious Phenotypic Abnormality Attributable to lpa2. Molecular and Cellular
Biology, 2002. 22(19): p. 6921-6929.
25. Cheng, H.-Y., et al., Lysophosphatidic Acid Signaling Protects Pulmonary
Vasculature From Hypoxia-Induced Remodeling. Arteriosclerosis, Thrombosis,
and Vascular Biology, 2012. 32(1): p. 24-32.
26. Sumida, H., et al., LPA4 regulates blood and lymphatic vessel formation during
mouse embryogenesis. Blood, 2010. 116(23): p. 5060-5070.
27. Rai, V., et al., Lysophosphatidic acid targets vascular and oncogenic pathways via
RAGE signaling. The Journal of Experimental Medicine, 2012. 209(13): p. 2339-
2350. 
28. Albers, H.M.H.G., et al., Boronic acid-based inhibitor of autotaxin reveals rapid
turnover of LPA in the circulation. Proceedings of the National Academy of
Sciences, 2010. 107(16): p. 7257-7262.
29. Kurano, M., et al., Possible Involvement of Minor Lysophospholipids in the
Increase in Plasma Lysophosphatidic Acid in Acute Coronary Syndrome.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2015. 35(2): p. 463-470.
30. Dohi, T., et al., Increased lysophosphatidic acid levels in culprit coronary arteries
of&#xa0;patients with acute coronary syndrome. Atherosclerosis. 229(1): p. 192-
197. 
31. Watanabe, N., et al., Both plasma lysophosphatidic acid and serum autotaxin
levels are increased in chronic hepatitis C. J Clin Gastroenterol, 2007. 41(6): p.
616-23.
32. Moolenaar, W.H. and A. Perrakis, Insights into autotaxin: how to produce and
present a lipid mediator. Nat Rev Mol Cell Biol, 2011. 12(10): p. 674-679.
33. Hausmann, J., et al., Structural basis of substrate discrimination and integrin
binding by autotaxin. Nat Struct Mol Biol, 2011. 18(2): p. 198-204.
34. Pamuklar, Z., et al., Autotaxin/lysopholipase D and lysophosphatidic acid regulate
murine hemostasis and thrombosis. J Biol Chem, 2009. 284(11): p. 7385-94.
35. Dusaulcy, R., et al., Adipose-specific disruption of autotaxin enhances nutritional
fattening and reduces plasma lysophosphatidic acid. Journal of Lipid Research,
2011. 52(6): p. 1247-1255.
124 
36. Leblanc, R., et al., Interaction of platelet-derived autotaxin with tumor integrin αVβ3
controls metastasis of breast cancer cells to bone. Blood, 2014. 124(20): p. 3141-
3150. 
37. Jansen, S., et al., Rapid clearance of the circulating metastatic factor autotaxin by
the scavenger receptors of liver sinusoidal endothelial cells. Cancer Letters.
284(2): p. 216-221.
38. Gierse, J., et al., A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid
Levels in Plasma and the Site of Inflammation. Journal of Pharmacology and
Experimental Therapeutics, 2010. 334(1): p. 310-317.
39. Chen, X., et al., Serum lysophosphatidic acid concentrations measured by dot
immunogold filtration assay in patients with acute myocardial infarction. Scand J
Clin Lab Invest, 2003. 63(7-8): p. 497-503.
40. van Meeteren, L.A., et al., Autotaxin, a Secreted Lysophospholipase D, Is
Essential for Blood Vessel Formation during Development. Molecular and Cellular
Biology, 2006. 26(13): p. 5015-5022.
41. Tanaka, M., et al., Autotaxin Stabilizes Blood Vessels and Is Required for
Embryonic Vasculature by Producing Lysophosphatidic Acid. Journal of Biological
Chemistry, 2006. 281(35): p. 25822-25830.
42. Ferry, G., et al., Functional invalidation of the autotaxin gene by a single amino
acid mutation in mouse is lethal. FEBS Lett, 2007. 581(18): p. 3572-8.
43. Yukiura, H., et al., Autotaxin regulates vascular development via multiple
lysophosphatidic acid (LPA) receptors in zebrafish. J Biol Chem, 2011. 286(51): p.
43972-83.
44. Siess, W., et al., Lysophosphatidic acid mediates the rapid activation of platelets
and endothelial cells by mildly oxidized low density lipoprotein and accumulates in
human atherosclerotic lesions. Proceedings of the National Academy of Sciences,
1999. 96(12): p. 6931-6936.
45. Siess, W., Athero- and thrombogenic actions of lysophosphatidic acid and
sphingosine-1-phosphate. Biochim Biophys Acta, 2002. 1582(1-3): p. 204-15.
46. Bot, M., et al., Atherosclerotic Lesion Progression Changes Lysophosphatidic Acid
Homeostasis to Favor its Accumulation. The American Journal of Pathology.
176(6): p. 3073-3084.
47. Tokumura, A., et al., Increased formation of lysophosphatidic acids by
lysophospholipase D in serum of hypercholesterolemic rabbits. J Lipid Res, 2002.
43(2): p. 307-15.
48. Navab, M., et al., Transgenic 6F tomatoes act on the small intestine to prevent
systemic inflammation and dyslipidemia caused by Western diet and intestinally
derived lysophosphatidic acid. J Lipid Res, 2013. 54(12): p. 3403-18.
49. Dawber, T.R., F.E. Moore, and G.V. Mann, Coronary heart disease in the
Framingham study. Am J Public Health Nations Health, 1957. 47(4 Pt 2): p. 4-24.
50. Dawber, T.R., G.F. Meadors, and F.E. Moore, Jr., Epidemiological approaches to
heart disease: the Framingham Study. Am J Public Health Nations Health, 1951.
41(3): p. 279-81.
51. Stary, H.C., et al., A Definition of Advanced Types of Atherosclerotic Lesions and
a Histological Classification of Atherosclerosis: A Report From the Committee on
Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
Circulation, 1995. 92(5): p. 1355-1374.
52. Stary, H.C., et al., A definition of initial, fatty streak, and intermediate lesions of
atherosclerosis. A report from the Committee on Vascular Lesions of the Council
on Arteriosclerosis, American Heart Association. Arterioscler Thromb, 1994. 14(5):
p. 840-56.
  125 
53. Stary, H.C., et al., A definition of the intima of human arteries and of its 
atherosclerosis-prone regions. A report from the Committee on Vascular Lesions 
of the Council on Arteriosclerosis, American Heart Association. Circulation, 1992. 
85(1): p. 391-405. 
54. Orr, A.W., et al., The subendothelial extracellular matrix modulates NF-kappaB 
activation by flow: a potential role in atherosclerosis. J Cell Biol, 2005. 169(1): p. 
191-202. 
55. Libby, P., Inflammation in atherosclerosis. Nature, 2002. 420(6917): p. 868-74. 
56. Buja, L.M., and Jagdish Butany, Cardiovascular Pathology 4th Edition. 4 ed, ed. 
L.M.B.a.J. Butany. 2016, London, UK: Academic Press in an imprint of Elsevier. 
57. Kellner-Weibel, G., et al., Crystallization of free cholesterol in model macrophage 
foam cells. Arterioscler Thromb Vasc Biol, 1999. 19(8): p. 1891-8. 
58. Thorp, E., et al., Mertk receptor mutation reduces efferocytosis efficiency and 
promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic 
lesions of apoe-/- mice. Arterioscler Thromb Vasc Biol, 2008. 28(8): p. 1421-8. 
59. Orr, A.W., Yurdagul Jr A., Patel B., Pathogenesis of Atherosclerosis: From Cell 
Biology to Therapeutics. Integrated Systems Physiology: From Molecule to 
Function to Disease, ed. a.G.J. Granger D. 2014: Morgan & Claypool Life 
Sciences. 
60. Taubman, M.B., et al., Tissue factor in the pathogenesis of atherosclerosis. 
Thromb Haemost, 1997. 78(1): p. 200-4. 
61. Goncharov, N.V., et al., Reactive oxygen species in pathogenesis of 
atherosclerosis. Curr Pharm Des, 2015. 21(9): p. 1134-46. 
62. Maseri, A. and T. Sanna, The role of plaque fissures in unstable angina: fact or 
fiction? Eur Heart J, 1998. 19 Suppl K: p. K2-4. 
63. Li, Z.Y., et al., The mechanical triggers of plaque rupture: shear stress vs pressure 
gradient. Br J Radiol, 2009. 82 Spec No 1: p. S39-45. 
64. van Dijk, A.C., et al., Intraplaque Hemorrhage and the Plaque Surface in Carotid 
Atherosclerosis: The Plaque At RISK Study (PARISK). 2015. 36(11): p. 2127-33. 
65. Mayranpaa, M.I., et al., Improved identification of endothelial erosion by 
simultaneous detection of endothelial cells (CD31/CD34) and platelets (CD42b). 
Endothelium, 2007. 14(2): p. 81-7. 
66. Inaba, M. and M. Ueda, [Vascular Calcification - Pathological Mechanism and 
Clinical Application - . The significance of arterial calcification in unstable plaques]. 
Clin Calcium, 2015. 25(5): p. 679-86. 
67. Eisenmenger, L.B. and B.W. Aldred, Prediction of Carotid Intraplaque Hemorrhage 
Using Adventitial Calcification and Plaque Thickness on CTA. 2016. 
68. McNamara, D.J., et al., Heterogeneity of cholesterol homeostasis in man. 
Response to changes in dietary fat quality and cholesterol quantity. J Clin Invest, 
1987. 79(6): p. 1729-39. 
69. Carter, C.P., P.N. Howles, and D.Y. Hui, Genetic variation in cholesterol absorption 
efficiency among inbred strains of mice. J Nutr, 1997. 127(7): p. 1344-8. 
70. Zhang, S.H., et al., Spontaneous hypercholesterolemia and arterial lesions in mice 
lacking apolipoprotein E. Science, 1992. 258(5081): p. 468-71. 
71. Plump, A.S., et al., Severe hypercholesterolemia and atherosclerosis in 
apolipoprotein E-deficient mice created by homologous recombination in ES cells. 
Cell, 1992. 71(2): p. 343-53. 
72. Ishibashi, S., et al., Hypercholesterolemia in low density lipoprotein receptor 
knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin 
Invest, 1993. 92(2): p. 883-93. 
  126 
73. Maeda, N., History of Discovery: Development of Apolipoprotein E-Deficient Mice. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 2011. 31(9): p. 1957-1962. 
74. Chen, Y.C., et al., A novel mouse model of atherosclerotic plaque instability for 
drug testing and mechanistic/therapeutic discoveries using gene and microRNA 
expression profiling. Circ Res, 2013. 113(3): p. 252-65. 
75. von der Thusen, J.H., et al., Induction of atherosclerotic plaque rupture in 
apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation, 
2002. 105(17): p. 2064-70. 
76. Rosenfeld, M.E., et al., Advanced atherosclerotic lesions in the innominate artery 
of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol, 2000. 20(12): p. 
2587-92. 
77. Whitman, S.C., A Practical Approach to Using Mice in Atherosclerosis Research. 
Clin Biochem Rev, 2004. 25(1): p. 81-93. 
78. Raslan, Z., et al., Targeting of type I protein kinase A to lipid rafts is required for 
platelet inhibition by the 3',5'-cyclic adenosine monophosphate-signaling pathway. 
J Thromb Haemost, 2015. 13(9): p. 1721-34. 
79. Chan, M.V., et al., P2Y12 receptor blockade synergizes strongly with nitric oxide 
and prostacyclin to inhibit platelet activation. Br J Clin Pharmacol, 2016. 81(4): p. 
621-33. 
80. Macdonald, P.S., M.A. Read, and G.J. Dusting, Synergistic inhibition of platelet 
aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb Res, 
1988. 49(5): p. 437-49. 
81. Moncada, S., R.M. Palmer, and E.A. Higgs, The discovery of nitric oxide as the 
endogenous nitrovasodilator. Hypertension, 1988. 12(4): p. 365-72. 
82. Vanhoutte, P.M., et al., Endothelial Dysfunction and Vascular Disease - A 
Thirthieth Anniversary Update. Acta Physiol (Oxf), 2015. 
83. Wu, C., et al., Mechanosensitive PPAP2B Regulates Endothelial Responses to 
Atherorelevant Hemodynamic Forces. Circ Res, 2015. 117(4): p. e41-53. 
84. Yukiura, H., et al., LPP3 localizes LPA6 signalling to non-contact sites in 
endothelial cells. J Cell Sci, 2015. 128(21): p. 3871-7. 
85. Hahn, C. and M.A. Schwartz, Mechanotransduction in vascular physiology and 
atherogenesis. Nat Rev Mol Cell Biol, 2009. 10(1): p. 53-62. 
86. Orr, A.W., et al., p21-activated kinase signaling regulates oxidant-dependent NF-
kappa B activation by flow. Circ Res, 2008. 103(6): p. 671-9. 
87. Rampersad, S.N., et al., EPAC1 promotes adaptive responses in human arterial 
endothelial cells subjected to low levels of laminar fluid shear stress: Implications 
in flow-related endothelial dysfunction. Cell Signal, 2016. 28(6): p. 606-19. 
88. Tzima, E., et al., Localized cdc42 activation, detected using a novel assay, 
mediates microtubule organizing center positioning in endothelial cells in response 
to fluid shear stress. J Biol Chem, 2003. 278(33): p. 31020-3. 
89. Tzima, E., et al., Activation of Rac1 by shear stress in endothelial cells mediates 
both cytoskeletal reorganization and effects on gene expression. Embo j, 2002. 
21(24): p. 6791-800. 
90. Tzima, E., et al., Activation of integrins in endothelial cells by fluid shear stress 
mediates Rho-dependent cytoskeletal alignment. Embo j, 2001. 20(17): p. 4639-
47. 
91. Syvaranta, S., et al., Potential pathological roles for oxidized low-density 
lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve 
stenosis. Atherosclerosis, 2014. 235(2): p. 398-407. 
92. Stewart, B.W. and S. Nagarajan, Recombinant CD36 inhibits oxLDL-induced 
ICAM-1-dependent monocyte adhesion. Mol Immunol, 2006. 43(3): p. 255-67. 
  127 
93. Bourdillon, M.C., et al., ICAM-1 deficiency reduces atherosclerotic lesions in 
double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. Arterioscler 
Thromb Vasc Biol, 2000. 20(12): p. 2630-5. 
94. Zernecke, A., E. Shagdarsuren, and C. Weber, Chemokines in atherosclerosis: an 
update. Arterioscler Thromb Vasc Biol, 2008. 28(11): p. 1897-908. 
95. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage 
subsets. Nat Rev Immunol, 2011. 11(11): p. 723-37. 
96. Dunay, I.R., et al., Gr1(+) inflammatory monocytes are required for mucosal 
resistance to the pathogen Toxoplasma gondii. Immunity, 2008. 29(2): p. 306-17. 
97. Orihuela, R., C.A. McPherson, and G.J. Harry, Microglial M1/M2 polarization and 
metabolic states. Br J Pharmacol, 2016. 173(4): p. 649-65. 
98. Zhu, L., et al., Cellular metabolism and macrophage functional polarization. Int Rev 
Immunol, 2015. 34(1): p. 82-100. 
99. Colin, S., G. Chinetti-Gbaguidi, and B. Staels, Macrophage phenotypes in 
atherosclerosis. Immunol Rev, 2014. 262(1): p. 153-66. 
100. Chen, F.Y., et al., Curcumin retunes cholesterol transport homeostasis and 
inflammation response in M1 macrophage to prevent atherosclerosis. Biochem 
Biophys Res Commun, 2015. 467(4): p. 872-8. 
101. Oberoi, R., et al., Lipocalin (LCN) 2 Mediates Pro-Atherosclerotic Processes and 
Is Elevated in Patients with Coronary Artery Disease. PLoS One, 2015. 10(9): p. 
e0137924. 
102. Chistiakov, D.A., Y.V. Bobryshev, and A.N. Orekhov, Macrophage-mediated 
cholesterol handling in atherosclerosis. J Cell Mol Med, 2016. 20(1): p. 17-28. 
103. Horiuchi, S., Y. Sakamoto, and M. Sakai, Scavenger receptors for oxidized and 
glycated proteins. Amino Acids, 2003. 25(3-4): p. 283-92. 
104. Bishop-Bailey, D., Peroxisome proliferator-activated receptors in the 
cardiovascular system. Br J Pharmacol, 2000. 129(5): p. 823-34. 
105. Nicholson, A.C., et al., CD36 in atherosclerosis. The role of a class B macrophage 
scavenger receptor. Ann N Y Acad Sci, 2000. 902: p. 128-31; discussion 131-3. 
106. Wang, S., et al., Wnt1 positively regulates CD36 expression via TCF4 and PPAR-
gamma in macrophages. Cell Physiol Biochem, 2015. 35(4): p. 1289-302. 
107. Kotla, S. and G.N. Rao, Reactive Oxygen Species (ROS) Mediate p300-dependent 
STAT1 Protein Interaction with Peroxisome Proliferator-activated Receptor 
(PPAR)-gamma in CD36 Protein Expression and Foam Cell Formation. J Biol 
Chem, 2015. 290(51): p. 30306-20. 
108. Kuchibhotla, S., et al., Absence of CD36 protects against atherosclerosis in ApoE 
knock-out mice with no additional protection provided by absence of scavenger 
receptor A I/II. Cardiovascular research, 2008. 78(1): p. 185-196. 
109. Qu, S.L., et al., Mipu1 overexpression protects macrophages from oxLDL-induced 
foam cell formation and cell apoptosis. DNA Cell Biol, 2014. 33(12): p. 839-46. 
110. Thomsen, J.H., et al., The haptoglobin-CD163-heme oxygenase-1 pathway for 
hemoglobin scavenging. Oxid Med Cell Longev, 2013. 2013: p. 523652. 
111. Boyle, J.J., Heme and haemoglobin direct macrophage Mhem phenotype and 
counter foam cell formation in areas of intraplaque haemorrhage. Curr Opin 
Lipidol, 2012. 23(5): p. 453-61. 
112. Gomez, D. and G.K. Owens, Smooth muscle cell phenotypic switching in 
atherosclerosis. Cardiovasc Res, 2012. 95(2): p. 156-64. 
113. Moncada, S., et al., A lipid peroxide inhibits the enzyme in blood vessel 
microsomes that generates from prostaglandin endoperoxides the substance 
(prostaglandin X) which prevents platelet aggregation. Prostaglandins, 1976. 
12(5): p. 715-37. 
  128 
114. Palmer, R.M., A.G. Ferrige, and S. Moncada, Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature, 1987. 327(6122): 
p. 524-6. 
115. Schror, K., et al., Thrombin receptors in vascular smooth muscle cells - function 
and regulation by vasodilatory prostaglandins. Thromb Haemost, 2010. 103(5): p. 
884-90. 
116. Schror, K. and A.A. Weber, Roles of vasodilatory prostaglandins in mitogenesis of 
vascular smooth muscle cells. Agents Actions Suppl, 1997. 48: p. 63-91. 
117. Tousoulis, D., et al., The role of nitric oxide on endothelial function. Curr Vasc 
Pharmacol, 2012. 10(1): p. 4-18. 
118. Qiu, J., et al., Biomechanical regulation of vascular smooth muscle cell functions: 
from in vitro to in vivo understanding. J R Soc Interface, 2014. 11(90): p. 20130852. 
119. Owens, G.K., Regulation of differentiation of vascular smooth muscle cells. Physiol 
Rev, 1995. 75(3): p. 487-517. 
120. Allahverdian, S., et al., Contribution of intimal smooth muscle cells to cholesterol 
accumulation and macrophage-like cells in human atherosclerosis. Circulation, 
2014. 129(15): p. 1551-9. 
121. Cherepanova, O.A., et al., Oxidized phospholipids induce type VIII collagen 
expression and vascular smooth muscle cell migration. Circ Res, 2009. 104(5): p. 
609-18. 
122. Pidkovka, N.A., et al., Oxidized phospholipids induce phenotypic switching of 
vascular smooth muscle cells in vivo and in vitro. Circ Res, 2007. 101(8): p. 792-
801. 
123. Navab, M., et al., Source and role of intestinally derived lysophosphatidic acid in 
dyslipidemia and atherosclerosis. J Lipid Res, 2015. 56(4): p. 871-87. 
124. McIntyre, T.M., et al., Identification of an intracellular receptor for lysophosphatidic 
acid (LPA): LPA is a transcellular PPARγ agonist. Proceedings of the National 
Academy of Sciences, 2003. 100(1): p. 131-136. 
125. What are single nucleotide polymorphisms (SNPs)? 2016  March 15, 2016]; 
Available from: https://ghr.nlm.nih.gov/primer/genomicresearch/snp. 
126. Erbilgin, A., et al., Identification of CAD candidate genes in GWAS loci and their 
expression in vascular cells. Journal of Lipid Research, 2013. 54(7): p. 1894-1905. 
127. Sigal, Y.J., M.I. McDermott, and A.J. Morris, Integral membrane lipid 
phosphatases/phosphotransferases: common structure and diverse functions. 
Biochem J, 2005. 387(Pt 2): p. 281-93. 
128. Long, J.S., N.J. Pyne, and S. Pyne, Lipid phosphate phosphatases form homo- 
and hetero-oligomers: catalytic competency, subcellular distribution and function. 
Biochem J, 2008. 411(2): p. 371-7. 
129. Tomsig, J.L., et al., Lipid phosphate phosphohydrolase type 1 (LPP1) degrades 
extracellular lysophosphatidic acid in vivo. Biochem J, 2009. 419(3): p. 611-8. 
130. Morris, A.J., et al., Lipid phosphate phosphatases:  Recent progress and assay 
methods, in Lysophospholipid Receptors: Signaling and Biochemistry. 2012, John 
Wiley. 
131. Escalante-Alcalde, D., et al., The lipid phosphatase LPP3 regulates extra-
embryonic vasculogenesis and axis patterning. Development, 2003. 130(19): p. 
4623-37. 
132. Mukherjee, A., R.A. Neher, and A.D. Renault, Quantifying the range of a lipid 
phosphate signal in vivo. J Cell Sci, 2013. 126(Pt 23): p. 5453-64. 
133. Panchatcharam, M., et al., Lipid phosphate phosphatase 3 negatively regulates 
smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler 
Thromb Vasc Biol, 2013. 33(1): p. 52-9. 
  129 
134. The, C.D.C., Large-scale association analysis identifies new risk loci for coronary 
artery disease. Nature genetics, 2013. 45(1): p. 25-33. 
135. Reschen, M.E., et al., Lipid-induced epigenomic changes in human macrophages 
identify a coronary artery disease-associated variant that regulates PPAP2B 
Expression through Altered C/EBP-beta binding. PLoS Genet, 2015. 11(4): p. 
e1005061. 
136. Tang, X., M.G. Benesch, and D.N. Brindley, Lipid phosphate phosphatases and 
their roles in mammalian physiology and pathology. J Lipid Res, 2015. 56(11): p. 
2048-60. 
137. Escalante-Alcalde, D., R. Sanchez-Sanchez, and C.L. Stewart, Generation of a 
conditional Ppap2b/Lpp3 null allele. Genesis, 2007. 45(7): p. 465-9. 
138. Tomsig, J.L., et al., LIPID PHOSPHATE PHOSPHOHYDROLASE TYPE 1 (LPP1) 
DEGRADES EXTRACELLULAR LYSOPHOSPHATIDIC ACID IN VIVO. The 
Biochemical journal, 2009. 419(3): p. 611-618. 
139. Escalante-Alcalde, D., S.L. Morales, and C.L. Stewart, Generation of a reporter-
null allele of Ppap2b/Lpp3and its expression during embryogenesis. Int J Dev Biol, 
2009. 53(1): p. 139-47. 
140. Daugherty, A. and D.L. Rateri, Development of experimental designs for 
atherosclerosis studies in mice. Methods, 2005. 36(2): p. 129-38. 
141. Paigen, B., et al., Quantitative assessment of atherosclerotic lesions in mice. 
Atherosclerosis, 1987. 68(3): p. 231-40. 
142. Goldstein, D.G.D.B., SNPExpress. 
143. Albert, F.W. and L. Kruglyak, The role of regulatory variation in complex traits and 
disease. Nat Rev Genet, 2015. 16(4): p. 197-212. 
144. Lagace, T.A., PCSK9 and LDLR degradation: regulatory mechanisms in circulation 
and in cells. Curr Opin Lipidol, 2014. 25(5): p. 387-93. 
145. Mabuchi, H., et al., Genotypic and phenotypic features in homozygous familial 
hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 
(PCSK9) gain-of-function mutation. Atherosclerosis, 2014. 236(1): p. 54-61. 
146. Schneider, A., et al., Differential, inducible gene targeting in renal epithelia, 
vascular endothelium, and viscera of Mx1Cre mice. Am J Physiol Renal Physiol, 
2003. 284(2): p. F411-7. 
147. Alpert, J.S., The pathophysiology of acute myocardial infarction. Cardiology, 1989. 
76(2): p. 85-95. 
148. Heinzen, E.L., et al., Tissue-specific genetic control of splicing: implications for the 
study of complex traits. PLoS Biol, 2008. 6(12): p. e1. 
149. Bentzon, J.F., et al., Mechanisms of Plaque Formation and Rupture. Circulation 
Research, 2014. 114(12): p. 1852-1866. 
150. Mozaffarian, D., et al., Heart Disease and Stroke Statistics—2016 Update: A 
Report From the American Heart Association. Circulation, 2015. 
151. Hata, E., et al., Lysophosphatidic acid receptors LPA4 and LPA6 differentially 
promote lymphocyte transmigration across high endothelial venules in lymph 
nodes. Int Immunol, 2015. 
152. Igarashi, H., et al., The lysophosphatidic acid receptor LPA4 regulates 
hematopoiesis-supporting activity of bone marrow stromal cells. Sci Rep, 2015. 5: 
p. 11410. 
153. Knowlden, S.A., et al., Regulation of T cell motility in vitro and in vivo by LPA and 
LPA2. PLoS One, 2014. 9(7): p. e101655. 
154. Ponnuchamy, B. and R.A. Khalil, Role of ADAMs in Endothelial Cell Permeability. 
Cadherin Shedding and Leukocyte Rolling. Circulation research, 2008. 102(10): p. 
1139-1142. 
  130 
155. Nilsson, J., et al., Lipoprotein-like phospholipid particles inhibit the smooth muscle 
cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. 
Arterioscler Thromb Vasc Biol, 1998. 18(1): p. 13-9. 
156. Smyth, S.S., et al., Arguing the case for the autotaxin-lysophosphatidic acid-lipid 
phosphate phosphatase 3-signaling nexus in the development and complications 
of atherosclerosis. Arterioscler Thromb Vasc Biol, 2014. 34(3): p. 479-86. 
 
131 
 Vita 
PERSONAL 
Place of Birth: Lexington, KY 
Nationality: United States 
EDUCATION 
Institution Dates  Degree Subject 
University of Kentucky 2005 – 2009 B. Sc. Biology 
ACADEMIC AND PROFESSIONAL HONORS 
Certificates: 
Graduate Certificate in Clinical and Translational Science 2015 
Research Support: 
2009 – 2010 ARRA Award: Integrin Signaling in Vascular Cells (3048105950). 
2011 – 2013 NIH “Interdisciplinary Cardiovascular Training Grant” (T32 HL072743). 
2013 – 2015 NIH “Clinical and Translational Science Training Grant” (TL1RR033172). 
Invited Speaker Engagements: 
Mueller, P., Smyth, S. Functional Validation of Polymorphisms in PPAP2B that 
Associates with Coronary Artery Disease. T32 Scholar Presentation Gill Heart Institute 
Cardiovascular Research Day, Lexington KY – 2011 
Mueller, P., Smyth, S. Functional Validation of Polymorphisms in PPAP2B that 
Associates with Coronary Artery Disease T32 Scholar Presentation Gill Heart Institute 
Cardiovascular Research Day, Lexington KY – 2012 
Mueller, P., Smyth S. Functional Validation of Polymorphisms in PPAP2B that 
Associates with Coronary Artery Disease 48th Southeastern Regional Lipid Conference, 
Cashiers NC – 2013 
Mueller, P., Smyth S. Functional Validation of Polymorphisms in PPAP2B that 
Associates with Coronary Artery Disease. CCTS Spring Conference, Lexington KY – 
March 2014 
Mueller, P., Smyth S. PPAP2B Expression Regulates the Development of 
Atherosclerosis” Translational Science Conference 2015, Washington DC – April 2015 
Poster Presentations: 
132 
Mueller, P., Smyth S. “Functional Validation of Polymorphisms in PPAP2B that 
Associates with Coronary Artery Disease”. Translational Science Conference, 
Washington DC – 2014 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis”. Scientific Sessions, Chicago IL – 2014 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis”. 9th Platelet Colloquium, Lexington KY – 2015 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis”. CCTS Spring Conference, Lexington KY – 2015 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis” Translational Science Conference, Washington DC – 2015 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis” ATVB|PVD 2015 Scientific Sessions, San Francisco CA -- 2015 
Mueller, P., Smyth S. “PPAP2B Expression Regulates the Development of 
Atherosclerosis” AHA 2015 Scientific Sessions, Orlando FL – 2015 
*Invited to re-present the in the Best of AHA Specialty Conferences: ATVB 2015
AWARDS 
2014 – Travel Support, University of Kentucky Graduate School. Abstract: “Functional 
Validation of Polymorphisms in PPAP2B that Associates with Coronary Artery 
Disease”. Translational Science Conference 2014, Washington DC – April 2014 
2014 – ATVB Travel Award for Young Investigators. Abstract: “PPAP2B Expression 
Regulates the Development of Atherosclerosis” Scientific Sessions 2014 
2015 – ATVB Travel Award for Young Investigators. Abstract: “PPAP2B Expression 
Regulates the Development of Atherosclerosis” ATVB|PVD 2015 Scientific 
Sessions 
2015 – Invitation to re-present abstract: “PPAP2B Expression Regulates the 
Development of Atherosclerosis” in the Best of AHA Specialty Conferences: 
ATVB 2015 at AHA Scientific Sessions, Orlando FL. 
PUBLICATIONS 
Manuscripts: 
1. Dong A, Caicedo J, Han SG, Mueller P, Saha S, Smyth SS, Gairola CG.
Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette
smoke is attenuated by P2Y12 antagonism. Thromb Res. 2010 Oct;126(4): e312-
7. (PMID 2921009)
133 
2. Cheng HY, Dong A, Panchatcharam M, Mueller P, Yang F, Li Z, Mills G, Chun J,
Morris AJ, Smyth SS. Lysophosphatidic acid signaling protects pulmonary
vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol.
2012 Jan;32(1):24-32. (PMID 3241874)
3. Federico L, Ren H, Mueller PA, Wu T, Liu S, Popovic J, Blalock EM, Sunkara M,
Ovaa H, Albers HM, Mills GB, Morris AJ, Smyth SS. Autotaxin and its product
lysophosphatidic acid suppress brown adipose differentiation and promote diet-
induced obesity in mice. Mol Endocrinol. 2012 May;26(5):786-97. (PMID
3355557) 
4. Yang F, Dong A, Mueller P, Caicedo J, Sutton AM, Odetunde J, Barrick CJ,
Klyachkin YM, Abdel-Latif A, Smyth SS. Coronary artery remodeling in a model
of left ventricular pressure overload is influenced by platelets and inflammatory
cells. PLoS One. 2012 August;7(8):e40196. (PMID 3423413)
5. Panchatcharam M, Miriyala S, Salous A, Wheeler J, Dong A, Mueller P, Sunkara
M, Escalante-Alcalde D, Morris AJ, Smyth SS. Lipid phosphate phosphatase 3
negatively regulates smooth muscle cell phenotypic modulation to limit intimal
hyperplasia. Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):52-9. (PMID
3524385) 
6. Salous AK, Panchatcharam M, Sunkara M, Mueller P, Dong A, Wang Y, Graf
G, Smyth S, Morris A. Mechanism of rapid elimination of lysophosphatidic acid
and related lipids from the circulation of mice. J Lipid Res. 2013 Oct; 54(10):
2775 – 2784. PMC3770090.
Reviews: 
1. Ren H, Panchatcharam M, Mueller P, Escalante-Alcalde D, Morris AJ, Smyth
SS. Lipid phosphate phosphatase (LPP3) and vascular development. Biochim
Biophys Acta. 2013 Jan;1831(1):126-32. (PMID 3683602)
2. Smyth S, Mueller P, Yang F, Brandon JA, Morris A. The case for autotaxin –
lysophosphatidic acid – lipid phosphate phosphatase 3 (ATX/LPA/LPP3)
signaling nexus in the development and complications of atherosclerosis.
Arterioscler Thromb Vasc Bio. 2014 Mar;34(3): 479-486. PMC3944085.
3. Mueller P, Ye S, Morris A, Smyth S. Lysophospholipid mediators in the
vasculature. Experimental Cell Research. (Accepted March 2015 – PMC In
Process).
TEACHING EXPERIENCE 
Center for Academic Resources and Enrichment Services (CARES). University of 
Kentucky. Tutor in General Chemistry (CHE 105). Fall 2006. 
Case Studies in Physiology (PGY 207). Department of Physiology, University of 
Kentucky. Teaching Assistant. Spring 2012, Fall 2012, Spring 2014. 
134 
Human Anatomy and Physiology II (Bio 139). Department of Biological Sciences, 
Bluegrass Community and Technical College. Adjunct Faculty/Lecturer. Spring 2015. 
